UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 10, 2014

 

BIO-EN HOLDINGS CORP.  
(Exact name of registrant as specified in its charter)

 

Delaware   333-186629   990369776
(State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)

 

56 Main Street

Monsey, New York 10952

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (213) 947-1011

 

8605 Santa Monica Blvd #88454

Los Angeles, CA 90069-4109

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see  General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

 

 
 

 

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS

 

This Current Report on form 8-K (this “Report”) contains forward-looking statements. The forward-looking statements are contained principally in the sections entitled “Description of Business,” “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “seeks,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. These risks and uncertainties include, but are not limited to, the factors described in the section captioned “Risk Factors” below. Given these uncertainties, you should not place undue reliance on these forward-looking statements.  Such statements may include, but are not limited to, information related to: anticipated operating results; relationships with our customers; consumer demand; financial resources and condition; changes in revenues; cost of sales; selling, general and administrative expenses; interest expense; legal proceedings and claims.

 

Also, forward-looking statements represent our estimates and assumptions only as of the date of this Report. You should read this Report and the documents that we reference and filed as exhibits to this Report completely and with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update any forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, even if new information becomes available in the future.

 

Item 1.01 Entry Into A Material Definitive Agreement

 

Merger Agreement

 

On September 10, 2014 (the “Closing Date”), Bio-En Holdings Corp. (the “Company” or “BHC”) closed on a merger and share exchange agreement, dated August 21, 2014, (the “Merger Agreement”) by and among (i) the Company, (ii) Bio-En Corp., a Delaware corporation, (“Bio-En”), and (iii) Serena B. Potash, an officer and director of BHC and the majority shareholder of BHC. Pursuant to the terms of the Merger Agreement, Bio-En shall be merged with and into BHC, with BHC to continue as the surviving corporation (the “Surviving Corporation”) in the Merger, and BHC succeeding to and assuming all the rights, assets, liabilities, debts, and obligations of Bio-En (the “Merger”).

 

The foregoing descriptions of the terms of the Merger Agreement are qualified in their entirety by reference to the provisions of the Merger Agreement filed as Exhibit 2.1 to this Report, which is incorporated by reference herein.

 

Cancellation Agreement

 

In connection with the Merger, BHC entered into a cancellation agreement with Ms. Potash (the “Cancellation Agreement”) whereby Ms. Potash, owning an aggregate of 7,894,625 shares of the BHC’s common stock cancelled 6,024,625 of her BHC shares. 

 

The foregoing descriptions of the terms of the Cancellation Agreement are qualified in its entirety by reference to the provisions of the Cancellation Agreement filed as Exhibit 10.1 to this Report, which is incorporated by reference herein.

 

Increase in Authorized Shares and Preferred Shares

 

On August 5, 2014, the Company filed a Certificate of Amendment to its Certificate of Incorporation, pursuant to which: (1) the Company increased its authorized capital stock from 200,000,000 to 300,000,000; and (2) created 50,000,000 shares of blank check preferred stock, par value $0.0001 per share, with such preferred shares to be issued in one or more classes or series with such designations, powers, preferences and relative participation, optional and other special rights, if any, of each such class or series, and qualifications, limitations and restrictions thereof, to be stated by a resolution adopted by the Board. As a result, the Company’s capital stock is comprised of comprised of 250,000,000 shares of common stock, par value of $0.0001 per share (“Common Stock”), and 50,000,000 shares of preferred stock, par value $0.0001 per share (“Preferred Stock”).

 

Amended and Restated By-Laws

 

On April 20, 2014, prior to the Merger, the Board of Directors and majority shareholders of BHC adopted Amended and Restated By-Laws of the Company. The Amended and Restated Bylaws are filed as Exhibit 3.4 to this Report, which is incorporated by reference herein.

 

 
 

 

Item 2.01 Completion Of Acquisition Or Disposition Of Assets

 

Reference is made to the disclosure set forth under Item 1.01 of this Report, which disclosure is incorporated herein by reference.

 

On September 10, 2014, we acquired Bio-En Corp. upon closing of the Merger. The assets and liabilities of the acquired entity have been brought forward at their book value and no goodwill has been recognized.

  

FORM 10 DISCLOSURE

 

As disclosed elsewhere in this Report, on September 10, 2014, the Company acquired Bio-En in a merger transaction. Item 2.01(f) of Form 8-K provides that if the registrant was a shell company, other than a business combination related shell company, as those terms are defined in Rule 12b-2 under the Exchange Act, immediately before the reverse acquisition transaction, then the registrant must disclose the information that would be required if the registrant were filing a general form for registration of securities on Form 10 under the Exchange Act reflecting all classes of the registrant’s securities subject to the reporting requirements of Section 13 of the such Exchange Act upon consummation of the transaction.

 

Since we were a shell company immediately before the reverse acquisition transaction disclosed under Item 2.01, we are providing below the information that we would be required to disclose on Form 10 under the Exchange Act if we were to file such form. Please note that the information provided below relates to the combined enterprises after the acquisition of Bio-En, except that information relating to periods prior to the date of the reverse acquisition only relate to Bio-En unless otherwise specifically indicated.

 

Information in response to this Item 2.01 below is keyed to the items numbers of Form 10.

 

Item 1. Description Of Business

 

Business Overview

 

The Company intends to enter into an agreement with Applied Biofuels (Malta) Limited whereby all assets of Applied Buiels (Malta) Limited shall be transferred to a new subsidiary (“Newco”), to be incorporated in Malta, which will be a wholly owned subsidiary of the Company. The Company is a project and plant development company in the business of producing and selling ethanol and butanol made from municipal solid waste and other cellulosic fiber. Bio-En and BHC are referred to in this section collectively as “we,” “us” and the “Company” unless the context indicates otherwise, in which case such terms refer just to Bio-En or BHC.

 

We have planned, designed, engineered and prepared agreements to build and operate a facility using Gravity Pressure Vessel Technology in Weak Acid Hydrolysis to convert Biomass to Ethanol (the “Facility”). The Facility will be built on the Island of Malta and is anticipated to be fully operational by the end of the 4th quarter of 2016.

 

The Facility will combine technologies from the waste management industry and integrate the recycling of waste, control of carbon dioxide and other emissions, with the profitable production of fuel grade Ethanol.

 

Our Corporate History and Background

 

Bio-En Corp. was incorporated under the laws of the State of Delaware on January 6, 2014. The Company, through its merger with Bio-En, is in the development stage and is devoting substantially all of its efforts to the development of its business plan. The Company intends to be a world leader of setting the standard for waste to bio-fuel technologies. The Company intends to plan, design, and execute agreements to build, operate and maintain a bio-mass to energy facility on the island of Malta, which is contingent on sufficient capital funding.  The Company’s fiscal year-end is March 31.

 

 
 

  

Industry

 

The Company is a renewable energy company which intends to offer profitable solutions to environmental problems by the integration and application of proven technologies and methods that deal with waste materials and the processing of biomass to fuel grade ethanol or other biofuels. The Company is focused on the up-to-date use of established process engineering principles joined with specific patented technology available to it through a license agreement entered into on March 23, 2014 between Bio-En Corp. and GeneSyst International, Inc. a Delaware corporation.

 

The Company has received correspondence from Malta Enterprise, the governing body in Malta overseeing projects for the government indicating the Company has been given a green light to design, build and operate a facility to convert municipal solid waste and other forms of cellulosic biomass to ethanol subject to requirements established by Malta Enterprises and the government of Malta. The Malta Facility should be fully operational within 18/24 months of full funding.

 

The planned Facility is designed to be a major GREEN project. The Facility will combine technologies from the waste management industry which will be integrated into the Facility’s overall waste recycling program, control of carbon dioxide and other emissions and the profitable production of fuel grade ethanol and other Biofuels.

 

The Company plans to derive its revenue from gate fees for MSW (as defined below) brought to the plant, the sale of ethanol or other biofuels, sale of carbon dioxide and sale of excess electricity to Malta. No off-take contracts have been entered into as of this time.

 

In addition to these traditional sources of revenue, the Company expects to derive additional revenue from biofuels production subsidies. The European Union (“EU”) recognizes that producing Biofuel food crops on crop land has considerable cost implications since they are staple foods and need significant subsidies to be converted to biofuels. The price and demand for fuel has contributed to escalating food price inflation over recent years causing serious hardship for poorer populations. The EU is expected to implement a major overhaul of biofuels production subsidies that favor the Company.

 

Green Business Opportunity and Cellulosic Feedstock

 

The past decade has seen soaring oil prices, Middle East turmoil, government Biofuel incentives, clean-tech venture investments and maturing technologies, all these factors contributing to the critical mass necessary to launch the Biofuel market in a meaningful way.

 

Ethanol is a significant source of liquid fuel and its production from food grains is widespread. However, the use of the food grains in the production of ethanol along with the cost for fuel is causing widespread increases in food prices and governments are now seeking alternative feedstock and fuel sources to accommodate the increasing demand for clean fuels from sustainable sources other than food grains or fossil fuels.

 

The global market for ethanol will be open to enormous opportunities and transitional challenges over the next ten years. A few issues hold the key to these growth opportunities. If the promises of competitive, large-scale cellulosic ethanol production is realized, and if national import/export policies for Biofuels are further liberalized, then the possibilities for ethanol to replace 20% of gasoline consumption in the USA, Europe, China and India may be actualized by the year 2020.

 

Business Strategy

 

The Green Business Opportunity is not about green sentiment, anymore. It is about building national energy security and being part of a huge emerging market of a kind that may come once in a century. Global Biofuel production is estimated to reach 1,900 million barrels in 2020, at a compound annual growth rate (CAGR) of 10% over the forecast period 2015 – 2020.

 

The Company intends to take advantage of the worldwide burgeoning demand for Biofuels thus adding value to the Company and high returns for the Company’s investors by integrating world-class technology matched to a project for the conversion of solid waste feedstock (“MSW”) and other cellulosic feedstock into fuel grade ethanol and other Biofuel.

 

 
 

 

The Company’s use of patented Gravity Pressure Vessel (“GPV”) technology will demonstrate its leadership in setting the standard for best practicable waste conversion to fungible Ethanol and other Biofuels for the world market in an environmentally friendly manner.

 

The Company believes that its Malta project will be the future standard that will be used to measure all projects of this type and will lead to additional projects across the EU, Asia and the Middle East.

 

Intellectual Property

 

Bio-En, as a first step in achieving its business plan has entered into a license agreement (the “License Agreement”) with GeneSyst International, Inc., the exclusive licensing agent for a portfolio of patents including the Gravity Pressure Vessels and supporting appurtenances. The license and patents are issued by political boundary, with exclusive rights defined by the physical location of the Facility. There are no restrictions on source of materials or marketing of products. Pursuant to the Merger, the Company has assumed the rights and responsibilities under the License Agreement.

 

The License Agreement calls for a fee of 3% of income, but not less than $330,000 per year. After the initial payment, alternate one-time payment plans are available. Supporting services are available by separate arrangement coincident with the License Agreement. As new patents are developed they are automatically added to the patent portfolio without additional charge.

 

The License Agreement runs for the life of the most recently issued patent - which is twenty years from the original filing date. Quality control matters are built into the License Agreement.

 

A list of granted patents pertaining to the Company’s business is included in the License Agreement. The most applicable and flexible patent being US 8496754 which patent has been approved in the EU awaiting publishing. Another which has several advantages has been disclosed to the patent attorneys and in the application process.  For further patent detail please see United States Patent No. US 8,496,754 B2 Titmas Date of Patent: Jul.30, 2013

 

The foregoing descriptions of the terms of the License Agreement are qualified in their entirety by reference to the provisions of the License Agreement filed as Exhibit 10.2 to this Report, which is incorporated by reference herein.

 

Patent Technical Field and Description

 

The present invention is generally directed toward a process whereby woody cellulosic material is converted to ethanol via acid hydrolysis of cellulosic material to sugars that are subsequently fermented. The acid hydrolysis takes place in a gravity pressure vessel. In particular, the present invention is directed to apparatus and methods for impregnating woody cellulosic material with an alkali to make it more amiable to treatment in the gravity pressure vessel. In more particular embodiments, this invention is also directed toward employing ultrasound in a gravity pressure vessel to aid in the processing of woody cellulosic material.

 

Production and Facility

 

The Company plans to produce 88.5 million liters (23.3 million gallons) of fuel grade Ethanol each year which it would sell under contract to offshore users and spot purchasers. The production volume can be adjusted to accommodate short-term increases in overall capacity.

 

The Company plans to build a Biofuels and Ethanol production facility that will have an initial capacity to take in a mixture of raw materials amounting to 370,000 wet metric tons of Biomass per year. In addition, the Company has reached a preliminary understanding with the Maltese Government to take into the planned Malta facility a major portion of the MSW that is generated by Malta and Gozo. The gross annual amount is approximately 250,000 metric tons and the Company will become the only Government contractor employed to receive this MSW supply for processing and treatment. The plant is designed to meet the requirements for Zero Waste Back to Landfill.

 

The planned facility anticipates using MSW and various forms of Biomass as the raw feedstock in the production process. The GenySyst process is a wet-based procedure and requires a supply of water to initiate the operation of the process. This water supply can come from any non-salt water source, direct potable water, rain water, final effluent from a sewage works, or from recovered process water from businesses or from sewage sludge. Once initiated, the internal process water is continuously recycled. This water supply will be supplemented with make-up water contained within new supplies of Biomass and sources of non-potable water.

 

 
 

 

All residual products and excess water produced from the plant will be treated in a small waste water treatment processing plant located on or adjacent to the site. The waste water treatment plant will be designed to produce water that is suitable for discharge into inland watercourses or for irrigation purposes, as well as make-up water or used in the production of electricity from the Combined Heat and Power (“CHP”) plant. Excess power not used at the facility will be sold to the Malta grid.

 

An Electrical Generation set will be installed on site as part of the Facility. This will allow the facility to operate independently of the Malta Electrical Grid. The Facility may use residual heat and by-products, such as Methane and a CHP (Combined Heat and Power) plant to provide the power needed for the plant to operate. The facility will be a net producer of heat energy that can be converted to electricity and sold to local users.

 

All the Biomass contained within the process facility, or any further materials produced during the production process would be non-toxic, and can be reused or incorporated into construction materials and pavement foundations for roads.

 

Production

 

The quantity of Bio-fuel or Ethanol produced will vary according to the type and source of Biomass. The estimated range is from 550 liters per dry metric ton from pure cotton, 400 to 450 liters per dry metric ton of recovered paper and wood, 300 to 350 liters per dry metric ton from green waste in parks & gardens and food waste, to around 200 to 250 liters per metric ton from MSW.

 

The sources of Biomass proposed for the facility include recovered paper, green waste from parks and gardens, MSW, as well as coastal sea weed and shore debris.

 

There appears to be ample supply of various sources of Biomass obtained within Malta or imported from the EU or to meet the feedstock needs of the facility. The company plans to develop its first facility based on MSW and recovered paper, augmenting the feedstock with a blend of additional raw materials to increase bottom line revenues. Malta prohibits the importation of raw trash and garbage, but does allow pre-processed materials.

 

Integration of Technologies for Mitigation and Production

 

The Bio-En facility is designed to integrate existing proven technologies with GeneSyst’s GPV technology to convert the cellulose content in Biomass into fuel grade Ethanol, Biofuel and other byproducts that can be sold in the open market.

 

Proven Technologies and Key Components

 

The key components of a Mild Acid Hydrolysis Facility needed to convert municipal and agricultural wastes to Ethanol and Biofuel have been in use and functioning for many years. Two decades ago a breakthrough occurred in the creation of a “continuous pressure cooker” that operated with extremely high thermal and mechanical efficiency coupled with industry setting records for on-line availability, which is now known as the GPV.

 

The key element in this technology is how the GPV accepts and processes solid wastes in water. When the GPV technology was coupled with wastewater treatment technology, the joining of these technologies supported a process that achieved rapid, high volume processing of waste products and various other environmentally unfriendly raw materials into environmentally safe Biofuel at a low sustainable cost.

 

The incorporation of municipal waste and other waste streams into the process economics results in a negative cost for feedstock. Bio-En’s robust returns are a result of the low cost of its feedstock, which in fact is not a cost (liability) but a source of revenue (asset), since Malta pays a tipping fee to get rid of its MSW. The use of MSW and other waste feedstock ensures economically viable operations with or without tax incentives and meets the sustainability requirements which have been written into EU laws pertaining to the sustainability of Biofuel production. The use of grains and other foodstuffs to make Biofuel has caused widespread increases in the cost of food in Europe and is affecting the economics of everyday life.

 

 
 

 

Extrapolation of Known Procedures

 

Throughout this business summary predictions have been made based upon generally accepted engineering procedures to predict performance of the facility as well as the economic expectations to be derived from these practices. In order to be successful, it is necessary to build a facility that is more efficient and more effective than previous technologies employed by others. To accomplish this with minimal risk, certain protocols have been established by the Company’s engineers to insure that the plant to be designed and built will meet all requisite standards discussed throughout the body of this plan. The Company’s engineers believe these extrapolations are limited, conservative and reasonable in nature so as to result in a financially viable facility. However, some actual results may differ from projections due to unforeseen developments.

 

Basis of the Technology

 

The process of turning Biomass (Celluloses) to the Saccharides by Weak Acid Hydrolysis prior to making Ethanol has been used in the United States in the Pulp and Paper industry for over 30 years, using small scale plants with heating under pressure in multiple batch tanks above ground. The GPV has been used for twenty years to oxidize wet waste materials. During this time GPVs were also used for the conversion of waste streams to commercial commodities, thus proving their viability and profitability.

 

Drivers Promoting Processing MSW to Ethanol

 

a. Need for a clean, non-polluting process for the manufacture of fuel grade Ethanol
b. The absolute amount of waste produced is rising
c. Unchecked emission of greenhouse gases may lead to a rise in global temperature
d. In less developed countries, waste production per capita is rising, probably at an even faster rate than the EU, as per-capita GNP and living standards increase
e. Developed countries are banning/limiting landfill and dumping of waste leading to an increased demand for waste processing and waste mitigation
f. Less developed countries have acknowledged the need for waste management
g. Release of toxic materials into water and air is prohibited in many countries
h. More countries are banning or limiting landfill and dumping of waste to protect the environment
i. Governments are increasingly enacting environmental taxation
j. Recycling of materials is fundamental in modern waste treatment and disposal
k. Oil, electricity and other energy prices are all rising
l. Population is rising and land is getting increasingly expensive particularly land used for growing feedstock for fuel
m. Transportation costs are increasing - reflecting rising oil, land and labor prices
n. Increasing demand for waste treatment in urban areas, coupled with ongoing health concerns requires innovative application of proven technologies/methods to treat waste economically
o. The cost of food grain is rising due to their diversion to Biofuel production thus causing higher food prices and starvation
p. Liquid energy in the form of Ethanol may have higher market value than other forms of energy conversion

 

Background of the GPV Technology

 

The GPV was invented and developed by James Titmas a professional engineer with 54 years of experience in water and waste treatment and the founder of GeneSyst International Inc.

 

The process of using the GPV in Weak Acid Hydrolysis to convert celluloses to saccharides was discovered in the 1820’s and used by Henry Ford in the 1920-30’s to provide the feed stock for producing fuel grade Ethanol.

 

 
 

 

The use of a GPV increases the efficiency of converting celluloses to high value saccharides, and thus increases the resulting yield of Ethanol from Biomass and waste materials.

 

The GeneSyst system updates this conversion process by using a shallow commercial water well chamber modified to be a sealed vacuum chamber in which hangs the GPV. After receipt and initial shredding of cellulosic materials, the Biomass is mixed with water and impregnated with a mild alkali solution. The processed Biomass then enters the outer annulus of the GPV passing downwards, pre-heating and accumulating pressure. In the reaction chamber at the bottom of the GPV, Oxygen is used to destroy tramp organics that inhibit fermentation followed by the introduction of a catalyst (dilute carbonic acid) to instigate the disassociation of the celluloses to saccharides (sugars). This oxidation step is exothermic and after pre-heating, the temperature is trimmed to 455ºF (235 o Celsius). With a small portion of un-reacted nitrogen and thermal expansion, the density of the mixture is lowered to allow natural convection to move the fluids through the GPV without pumping. The mixture, which is now sugar based, rises up the inner pipe after neutralization of its acid in the reaction chambers. The mixture continues to rise driven upwards past the downward flowing colder feed mix, and as it does, it allows its heat to pass through the wall of the inner heat exchanging pipe to the descending raw materials in the outer annulus of the GPV. At the surface the sugar mixture is then cleaned using conventional water processing equipment and forwarded for conversion to Ethanol or Biofuel ready for sale. All tanks and processing vessels are enclosed. The system is completely sealed to prevent loss of product, odors and environmental contamination. Ethanol produced from Biomass waste eliminates the production of new Green House Gases (GHG) arising from the waste. Ethanol is used up to an 85% concentration as a substitute for the refined fossil fuels as an additive to gasoline. It offers a further reduction in the emission of GHG giving additional benefits to the environment. The GHG emissions of landfill gasses are also dramatically reduced.

 

The Process Advantage

 

The process to extract the saccharides from cellulosic material uses a combination of higher temperatures with acid conditions. The higher the temperature, the lesser the amount of acid needed. This hydrolysis reaction process is nearly instantaneous and must be arrested before the acids decompose the saccharides created from de-polymerization of the cellulosic materials. In the case of the GPV the acidic conditions are neutralized to arrest the reaction and the heat energy is recovered.

 

The process described above is the specific advantage made available by using a continuous plug flow GPV reaction chamber, combined with the advantages of no moving parts, a tolerance for large size pieces and use of many types of raw materials, the internal recycling of pressure and heat energy all combine to create high availability.

The process is continuous and not batching which leads to increased productivity at lower costs.

 

Gravity Pressure Vessel © (GPV) Visual

 

 

 
 

 

Recap of the Gravity Pressure Vessel and How It Works

 

a. The GPV hangs freely in a 700 meter deep shaft
b. The containment shaft consists of a steel tube fixed in a grout jacket
c. The shaft is brought under vacuum pressure, like a vacuum flask
d. The GPV is a closed outer tube with an open inner tube
e. Celluloses waste in water is pumped through the outer pipe down and through the inner pipe up
f. At the bottom of the pipe, celluloses converts to sugars in a low pH environment
g. The acid is neutralized with alkaline to retain the sugars
h. The up going stream heats the down going stream
i. It is an energy efficient sterile chemical flow process without moving parts and gas emissions
j. After the celluloses are cracked in the “reactor” chamber, the sugar dissolves and rises through the inner pipe to the closed sedimentation tanks on ground level
k. Here the remaining inorganic dense and lightweight particles are removed for beneficial reuse.
l. The Saccharides are then stripped of other valuable organic byproducts and passed forward for fermentation to ethanol

 

GeneSyst Schematic for Conversion of Biomass to Ethanol

 

 

Project Description

 

The Malta Facility is intended to be a Finance, Design, Construct and Operate Facility and will cost approximately $150 million to complete and to put into full operation.

 

This facility will be located on designated land allocated by the Government of Malta at the eastern end of the Hal Far Industrial Area. The site has an area of 55,000 square meters (13.25 acres) and is fully accessible being bounded on three sides by major roads suitable for HGV Class III vehicles. The site is in the south east of the island of Malta within 6 kilometers of Malta’s main airport (Luqa) and more importantly 3 kilometers of the Malta Free Port.

 

The Bio-En Malta Biomass to Ethanol Facilities targeted to make upwards of 88 Million liters per year of the Bio-Ethanol. The source material to make this will be 270,000 dry metric tons equivalent per year of the Raw Material Biomass. It is anticipated that 80% of the feedstock come from sources on Malta and Gozo. The target date to begin commercial production of ethanol is estimated to be the last quarter of 2016.

 

 
 

 

The ethanol produced at the facility will be made using the process known as Dilute-Acid Hydrolysis in conjunction with GeneSyst’s patented Gravity Pressure Vessel ™ along with remainder of plant engineering and design obtained from the waste water (sewage) treatment industry and traditional fermentation and distillation plant technology used in the Ethanol Industry.

 

The issue of using non-invasive enzymes or GMO (genetically-modified-organisms) in the conversion process was a major point of discussion with the Advisory Board of Assessors and Engineers for the Government of Malta. Once it was proven that the plant did not pose a risk to humans, animals and the flora and fauna on the Island, the project was given an immediate go-ahead by the Malta Authorities.

 

The Company has been in discussions with an EPC contractor to design, construct and operate the facility and to oversee local sub-contractors such as the civil engineering construction company Attard Construction supported by Panta Lesco who specializes in mechanical, electrical and ICA/SCADA (Instrumentation Control and Automation/System Collection and Data Acquisition). Both of these local sub-contractors have worked on projects in the Water and Waste Water (Sewage) Treatment and the Food and Chemical Process Industry.

 

As soon as the project financing is in place, the Company’s in house engineers along with the EPC contractor and the sub-contractors will finalize the various protocols and strategies for the design and construction for the facility, and establish the parameters for the facility to be completed. During this period, the target dates for overall completion of the project will be set along with the purchase of Owners Protective Professional Indemnity Insurance to cover any risks concerning the design and operations of the project.

 

The Company anticipates starting delivery of Ethanol or Biofuel as soon as the first phase of the plant is completed. The Company’s business implementation strategy has been to assemble a first class team to design and construct and operate the plant at the earliest possible time. Bio-En will be using the appropriate FIDIC (Fédération International Des Ingénieurs-Conseils) Conditions of Contract to ensure that any issues are normalized under traditional working practices as used in the EU.

 

This Biomass to Ethanol Facility will be developed according to a Design and Construct contract where a portion of the design may not be fully developed until construction is about to start. However as soon as the financing is in place and mobilization of the designers and construction companies has occurred, this process will be started. This whole procedure will be nurtured through a VM/VE (Value Management/Value Engineering) audit trail which will be under constant review by the in-house staff and consultants for the Company.

 

All the confirmatory site investigations and the residual planning assays with MEPA (Malta Environment and Planning Authority) need to be finalized before the actual construction begins. These investigations may be carried out simultaneously with the need to assess and confirm the supply of the raw materials used to make the Biofuels and should be confirmed by the necessary laboratory testing which will be carried out in the local testing centers and University. At the same time, pre-orders should be lodged with the longest lead time items including that for the drilling company that will be needed to drill the bore-holes for the installation of the three gravity pressure vessels. All boreholes should be drilled to the common depth of 610 meters (2000 feet) needed for the process. The drilling of these boreholes and the installation of the steel-work will take approximately 6 weeks. Two major drilling companies have been asked for quotes for this part of the operation and early indications suggest that one will be the most acceptable in terms of practice, record and price for this part of the work. Again the lead time to obtain the fermentation and concentration plant for the production of the Ethanol will also be required to be ordered early on and this should be organized at the same time.

 

As soon as the first gravity pressure vessel is installed and operational, the sections making up the overall plant needed for full commercial operation, complete with its pre-treatment settlement tanks needed to prepare the Biomass, and its subsequent post gravity pressure vessel cleaning mechanical elements for cleaning the saccharides/sugars and treatment plant items may be put on-line making the plant ready for full service and for training personnel in operations and maintenance.

 

This first train (unit) will also include the final waste water (or residual effluent) treatment process plant, the anaerobic digestion facility, its CHP (Combined Heat and Power) plant for creating electrical generation capacity and the residual water treatment component for discharging water for irrigation purposes.

 

 
 

 

At the same time as this first unit is being installed, the construction and fitting out of the additional gravity pressure vessels that form the main service units of the overall plant will be carried to completion. Simultaneously with the development of the service units, the facilities for the processing and preparation of the Biomass will be ongoing along with the facilities for post gravity pressure vessel cleaning of the saccharides/sugars) and treatment items for fermentation and concentration of Biofuels and/or Ethanol.

 

Once the Ethanol has been prepared it can be moved to its own on-site storage tanks so the Malta and the EU Customs and Excise Authority can inspect and confirm the amount and specifications of the fuel prior to its release and collection by Bio-En Holdings, Inc.’s own transportation fleet of HGV Class III articulated tankers to ship the fuel to the storage depot in the Malta Free Port for export. Within the Malta Free Port an additional storage tank for the Ethanol can be built to accommodate this need.

 

Overall, the Malta Biomass to Ethanol Facility should take around 22 months to construct but because of the phased nature of construction and commissioning it will start delivering Ethanol well within this period – at around 12 to 15 months. It is anticipated that upon establishment of the full operating protocols the facility may become fully operational within 22 months of commissioning.

 

Key Contractors

 

Currently, the Company is in discussions with the following contractors:

 

Design and Engineering

 

a. David Xuereb & Associates is anticipated to be the local firm of Architects and Engineers. The Maltese authorities approved the employment of David Xuereb & Associates at an early stage in negotiations and the firm will be the single point of contact for the full design and all attendant issues of the facility. The design role should include the direct design input from GeneSyst International Incorporated - as part of the licensing arrangements with GeneSyst.

 

b. Kevin H Ramsey Consulting may provide additional design work relating to the Civil and Process Engineering, which includes Chemical, Hydraulics, Thermodynamics etc. with Mechanical and Electrical, HV/LV and Power, and ICA/SCADA works.

 

c. The Malta College of Arts Science and Technology and the University of Malta, together with Queen's University in Belfast and the Carbolea Institute at the University of Limerick may also be providing services to assist in verifying the input materials through testing and analytical work.

 

 
 

 

Operations and Maintenance Contractor

 

a. The Facility Operations and Maintenance (O & M) is currently integrated into the OPEX budget projections. However, it is envisioned that the O & M function will be organized as a separate Company Contractor under a separate contract expected with an EPC contractor.

 

b. The Biomass to Ethanol Facility is not a complex type of plant and uses traditional and standard equipment that is generally used across a wide selection of water, waste water, chemical and food process industries. The O &M Contractor personnel will be trained people with experience from Malta based chemical and waste water and process industries.

 

c. Selected personnel will be trained on site and through coordinated courses at the Malta College of Arts Science and Technology.

 

Plant Performance

 

The estimated quantity of Ethanol produced from different sources of Biomass ranges from 132 liters of Ethanol per metric ton, to over 340liters per metric ton from raw materials rich in fiber such as wood, low lignin pulp and sugar beet residues. It is estimated, over 40 different kinds of fiber sources may be available from population centers, many associated with negative cost sourcing, all of which are usable in GPV processing.

 

The overall process has the potential to use a majority of the total volume of organic wastes from human activity. The process is believed to meet and exceed all public mandates to recycle. The conversion process has no air emissions. The separation, fermentation and distillation processes are well known and widely used.

 

Feedstock Compatible with the GeneSyst Technology

 

A blending of the waste streams in the processing would allow for significant efficiencies along with administrative, environmental and social advantages.

 

Food Waste Sewer Screenings
Septic Tank Waste Restaurant waste
Magazine Paper Dilute WWTP Sludge
Crop Processing Garden Waste
Pulp and Paper Waste Office paper
News Print Cardboard
Crop Chaff Scrap Wood
Landscaping Debris Road Sweepings
Hospital Waste Cotton Cloth
Tree clearing waste Biofuel MFG waste
Feed lot Manure Expired food and Drink

 

Project and Plant Strengths

 

a. Dedicated municipal solid waste supply from Government of Malta
b. Agreement with Malta on building site (No competition)
c. Gate fee for selected waste materials already established with Malta
d. The plant system is a closed loop and emits no harmful gases or odors
e. Ethanol produced from will create a significant reduction in greenhouse gases
f. The Facility will be self-sufficient by generating its own power and surplus of clean water
g. Carbon Credits and Emissions Trading Credits for each metric ton of waste used and for each liter of Ethanol produced
h. Generates excess energy that can be sold into the Malta market
i. Continuous production rather than batching leading to lower production costs
j. Production residue can be sold to construction industry as filler material and road paving material

 

 
 

  

Competing Technologies

 

Gasification: The GPV or “Titmas Process” grew out of the need to meet the inherent failures of incineration and gasification processes. The problems arose from complications in recovery of first stage combustion energy (complex heat exchanger failures) incidence of toxic emissions from chlorinated and toxic inclusions in the feed stocks, char and clinker interference with continuance ash extraction, low “on line availability (less than 75%) failure to meet permit standards during start up and shut down protocols and an overall failure to “scale up” beyond weekly batch operations larger than 100 tons per day. Despite the known technical failings of gasification, promoters continue to garner investment of significant funds which will fail on observing the traditional problems have not been resolved. Examples of these failures include Brightstar, Thermoselect, Siemens-Fürth, Range Fuel and others to name just a few. The losses to investors ranged from $200 million to $500 million US.

 

Mechanical Heat and Pressure: The generic family of processing materials, known as the “pump and tank” mechanical means of inducing higher temperatures in fluids via pumping and heat exchangers includes: wet oxidation (Zimproet. Al.) pyrolysis, acid hydrolysis (both concentrated and dilute). All have in common the use of heat to crack, decompose or make digestible complex organic debris – basically similar to cooking foods for the same reasons. The most common practitioner of these arts was the Zimpro process which built over 200 commercial plants between 1960 and 1990. Of these only 5 are still in operation by virtue of cannibalization of parts from other units. Again, the problems revolve around “on line availability,” mechanical complexity, moving parts, operator challenges and low yields. Attempts at strong acid hydrolysis in lieu of wet oxidation had the added complication of acid destruction of containment vessels. Yields in all cases were low due to the time period to manipulate the combination of the cellulose to sugar reaction (the combination of higher temperatures and acidic conditions) and complex mixtures of thick cellulosic semi-solid pastes obligated by the costs of pumping and containment. The longer the reaction, the more sugars were destroyed before extraction.

 

Enzymatic Conversions: Rather than solve the problems of acid hydrolysis researchers moved to the more academic fields of enzyme enhancements which to date have turned out to require the use of expendable proteins for the saccharides conversion. Enzymes also held the promise of continuous academic study which also had a peculiar advantage in the research fields. Lignin remains problematic and some attempts are at hand to separate cellulose, hemi cellulose and lignin prior to further processing. Most of these are pursuing agricultural raw materials. The same problems of the processing of incoming MSW remain the same, noting that many components of agri-wastes and MSW share many characteristics and processing challenges in common. The real shortfall occurs from the seasonality of agricultural cellulose sources and the costs to collect and transport adequate quantities of agricultural chaff.

 

Customers

 

At the present time the Company has not sought out any customers because the Facility has yet to be built. Prior to the completion of the first phase of plant construction the Company intends to make its first entry onto the Biofuel Marketplace seeking a long-term contract for 80% of its production. The Company plans to sell 20% of its total production on the spot market or under short term contracts to take advantage of what it believes to be a rising market demand and subsequent increase in ethanol prices.

 

Government Regulation

 

European Union :  The EU maintains two complementary pieces of legislation relating to renewable fuels: the Renewable Energy Directive (RED) and the Fuel Quality Directive (FQD). Together, these directives establish targets for the adoption of renewable fuels in EU member states by 2020. Transportation fuels are one category of fuels covered by these directives, and the targeted goals cover all renewable fuels – that is, they are not limited to ethanol. The FQD is relevant to the present discussion in that it establishes a limit of 10% for ethanol blending within EU member states, which are obligated to adopt national laws in conformance with the requirements of the directive.

 

The European Commission’s Renewable Energy Directive (RED) requires that by 2020 all transportation fuels in the EU must contain 10% Biofuel. Individual EU states are free to incrementally build up to this target as they see fit, meaning that current mandated levels vary. Nevertheless, the fines incurred by fuel producers for not meeting local requirements offer some measure of demand stability. Of course, given that the mandates are dictated as percentages, declines in the consumption of the primary fuel for example, gasoline or diesel – will also affect Biofuel demand.

 

 
 

  

The mandated requirements apply to Biofuels across the board, but there are numerous other legislative changes that are set to affect specific products in different ways. Biofuels produced from a raw material that is not part of the food chain, known as second-generation Biofuels, are set to count double when tallying up the bio-content of a fuel blend. This will include Biodiesel, which is made from used cooking oil and Ethanol produced from crude glycerin, which is itself a by-product of Biodiesel production. These changes add up to a positive future for the product, which has yet to enjoy widespread usage.

 

Marketing Strategy and Sources of Revenue

 

The Company’s business model is based on management’s belief that there is a significant market demand for fuel grade Ethanol and other Biofuels derived from sources other than agricultural feedstock and which are fully sustainable without impacting the food supply chain. The Company believes that its revenue model has the capability to provide substantial and predictable recurring revenue because it uses waste materials, MSW and agricultural waste at no feedstock costs to the enterprise. In addition to the negative feedstock costs, the Company will be receiving substantial gate fees for taking in the waste as well as other environmental cash credits from the EU. The Company has developed a multi-faceted revenue model that is expected, over time, to provide recurring revenue from the following sources:

 

a. Sales of Ethanol and other Biofuels
b. Sales of byproducts
c. Gate fees
d. EU Environmental subsidies

 

Markets

 

Biofuels have seen a spurt in the United States and the EU, with the latter planning to increase its annual production to about 10% of its liquid fuels by 2020. The United States has set up an ambitious target to produce about 8 billion gallons annually by 2012 and about 40 billion gallons by 2022. Though the energy companies are widening their portfolios to include Biofuels, the move is fraught by significant challenges such as types of fuels to be used, regulations and regulatory approvals, increased usage of land for cultivating Biofuel crops and diversion of food crops for fuel production which is resulting in the increase of food prices.

 

The global market for Biofuels is projected to grow by a CAGR of 12.9% during the period 2006-2015 to reach US$ 61.5 billion by 2015. Focusing on the key challenges that still impede the realization of the billion-metric ton renewable fuels vision, this Memorandum integrates technological development and business development rationales to highlight the key technological developments that are necessary to industrialize Biofuels on a global scale. Technological issues addressed in this work include fermentation and downstream processing technologies, as compared to current industrial practice and process economics. Business issues that provide the lens through which the technological review is performed span the entire Biofuel value chain, from financial mechanisms to fund biotechnology start-ups in the Biofuel arena up to large green field manufacturing projects, to raw material farming, collection and transport to the bioconversion plant, manufacturing, product recovery, storage, and transport to the point of sale. Emphasis has been placed throughout the book on providing a global view that takes into account the intrinsic characteristics of various Biofuels markets from Brazil, the EU, the US, or Japan, to emerging economies as agricultural development and Biofuel development appear undissociably linked. Biofuels have emerged as a widely used renewable source of energy in the recent years. However, the rising demand for Biofuels in developed as well as developing countries has put a lot of pressure on - such as corn, sorghum, and soy, which are food crops. To ease off this pressure on food crops, scientists around the world are working on methods to convert lignocelluloses from plant waste material into Biofuels, instead of utilizing more food crops.

 

Any types of Biomass derived from plant such as cellulose, hemicellulose, and lignin are known as lingo-cellulosic Biomass. It is possible to categorize lignocellulosic Biomass into four categories: energy crops, wood residues, agricultural residues and municipal paper waste.

 

 
 

  

Lignocellulosic Biofuels have the potential to provide a large portion of cheap fuel for transportation especially if the available conversion processes are made cost effective. If technological hurdles are overcome, then a wide variety of lingocellulosic Biomass can be converted into Biofuels.

 

Global cellulosic ethanol is expected to increase from 14.25m gallons in 2012 to 412.25m gallons in 2020, with commercial production anticipated to take off on a large scale in late 2013 and 2014, thanks to major players adding substantial production capacity and new companies joining the market. The US is expected to retain its market dominance until 2020.

 

Ethanol is the most widely acclaimed alternative or additive for gasoline used for running vehicles, and the US ranked as number one producer of this biofuel using natural waste feedstock, states new analysis.

 

According to the latest report “Cellulosic Ethanol - Global Production, Major Trends, Regulations, and Key Country Analysis to 2020 the US is the global leader in cellulosic ethanol production, manufacturing 5.42m gallons in 2012 –

http://www.reportsnreports.com/reports/232712-cellulosic-ethanol-global-production-major-trends-regulations-and-key-country-analysis-to-2020.html”

 

Some EU countries such as France and Italy have cellulosic ethanol production infrastructure, but a limited supply of biomass feedstock. Growth of commercial production in these countries may fuel the need to import feedstock from nearby countries or expand production to other countries with ample feedstock availability. A few producers with upcoming commercial scale plants in the US have already started signing agreements to procure agricultural residue and other kinds of cellulosic feedstock.

 

Employees

 

As of the date of this Report, the Company has no employees.

 

Item 1a. Risk Factors

 

An investment in our common stock involves a high degree of risk. You should carefully consider the risks described below, together with all of the other information included in this Report, before making an investment decision. If any of the following risks actually occurs, our business, financial condition or results of operations could suffer. In that case, the trading price of our shares of common stock could decline, and you may lose all or part of your investment. You should read the section entitled “Special Note Regarding Forward Looking Statements” above for a discussion of what types of statements are forward-looking statements, as well as the significance of such statements in the context of this Report.

 

Risks Related to Our Company and the Biofuel Industry

 

We have no trading history and may never achieve profitability and the failure to raise additional capital could place our continued viability in question.

 

In particular we must raise additional capital from external sources to carry out our business plan, develop the Malta facility and develop markets for the sale of our products. If we are unable to generate the required additional capital, our ability to meet our financial obligations and to implement our business plan may be adversely affected.  We currently have no commitments to obtain additional capital, and there can be no assurance that financing will be available in amounts or on terms acceptable to us, if at all.  If we are not successful in raising additional working capital to support our operations and implement our business plan, we may be forced to curtail our operations, take additional measures to reduce costs, modify our business plan, and consider strategic alternatives that could include a sale of our business or filing for bankruptcy protection.

 

 
 

 

We are a development stage green field company with a limited history and a small employee base, which makes an investment in us highly speculative.

 

Our business plan for the production and marketing of fuel grade ethanol, carbon dioxide, electricity and other associated products is primarily based upon the construction and operation of a future facility in Malta. We have not produced or sold any products to date. Accordingly, we have a limited operating history from which you can evaluate our business and prospects.   In addition, our prospects must be considered in light of the inherent risks, expenses and difficulties encountered by companies in the early stages of development, particularly companies in rapidly evolving markets, such as the bioenergy market, where supply and demand may change significantly in a short amount of time.  Some of these risks relate to our potential inability to:

 

Effectively manage our business and operations;
Recruit and retain key personnel;
Manage rapid growth in personnel and operations;
Raise capital to implement our business plan or address unforeseen capital requirements;
Overcome competitive disadvantages against larger and more established companies; and
Successfully address the other risks described throughout this prospectus.

 

If we cannot successfully address these risks, our business and our results of operations and financial position would suffer.

  

We may not be able to secure additional necessary funding on favorable terms, or at all, in order to sustain our current operations, execute on our business plan and market our products.

 

We must seek additional capital to support our ongoing operations and complete construction of our Malta facility. We may raise these additional funds from public and private debt or equity offerings, borrowings under bank or lease lines of credit, or other sources. Any additional financing may not be available on a timely basis, on terms acceptable to us, or at all. Such financing may be dilutive to shareholders or may require us to grant a lender a security interest in our assets, which could be detrimental to our shareholders if we are unable to repay our obligations. The amount of money we will need may depend on many factors, including:

 

An increase in the cost of constructing or commencing operation at our Malta facility;
A material increase in the cost of the biomass and other materials we need for our operations;
A decrease in the price we receive as gate fees for the intake of waste materials;
A decrease in the price we receive for our fuel grade ethanol and other products, which would  reduce our revenues; and
An increase in the cost of operating our Malta facility.

 

If adequate funds are not available, we may incur further delays in completing our Malta facility or be required to curtail or cease our operations altogether. Any of these results would materially harm our business, financial condition and results of operations.

 

Additional delays due to, among other things, labor or material shortages, permitting or zoning issues, or opposition from local groups may hinder our ability to commence operations at the Malta facility, which would harm our business, financial condition and results of operations.

 

We may experience delays in the construction of the Malta facility for any number of reasons, including compliance with permitting and zoning requirements, opposition from local groups, shortages of labor or material, defects in materials or workmanship, changes in interest rates or the credit market, or policy changes at the Malta Government or European Community level.   There can be no assurance that we will be able to raise the additional required capital, complete construction and operate the Malta facility at full design capacity.   If our timetable for construction and the commencement of operations at the Malta facility is delayed, this will impact our ability to generate revenue and achieve profitability, which would have an adverse material effect on our business, our financial condition and our results of operations.

 

 
 

 

Significant increases in the cost of constructing the Malta facility may further delay or cause us to abandon construction of the Malta facility, which would materially impact our ability to achieve profitability and the value of your shares.

 

There can be no assurance that the final cost of constructing the Malta facility and commencing operations will not be significantly higher than budgeted.   Many events and conditions, including economic factors, site conditions, design modifications and set-up delays or overruns, could also lead to significant increases in project costs.   Furthermore, we need to obtain and comply with a number of permitting requirements, many of which can be costly and time consuming.   As a condition to granting necessary permits, regulators may make additional demands that increase the costs of constructing and operating the plant.   If any of these events occurs, we could be forced to seek additional debt or equity financing beyond what we currently expect to need, which may not be immediately available, may not be available on favorable terms, or may not be available at all.   If additional capital is required, we may experience additional significant construction delays, or fail to achieve profitability, any of which would have a material adverse effect on our business, our financial condition and our results of operations, and significantly diminish or eliminate the value of your shares.

 

We may materially modify our business plan for any number of reasons, which may cause us to incur additional costs or further delay the expansion of our production capacity, which would harm our business, financial condition and results of operations.

 

We may modify our business plan in any number of ways, including decreasing the design capacity of the Malta facility or abandoning the Hal Far Estate site for an alternative location. Any material modification to our business plan may result in higher than anticipated construction and start-up costs at the Malta facility, require us to abandon the Malta facility with or without the ability to recoup acquisition, design and construction costs incurred to date; may cause significant delays before we are able to increase our current production capacity, cause our planned production to be significantly below our current estimates, or result in higher than anticipated operating costs, any of which could have an adverse material effect on our business, our financial condition and our results of operations.

 

We operate in an intensely competitive industry and we may not be able to compete effectively.

 

The market for the manufacture, marketing and sale of alternative fuels is highly competitive. Competition could be intense and result in increases in the costs of raw materials, plant construction and operating expenses, as well as make it more difficult to attract and retain qualified engineers, chemists and other employees whose services could be key to our operations as they develop. Larger companies that are already engaged in this business may have access to greater financial and other resources, making it difficult to compete with them in recruiting and retaining qualified employees, in acquiring attractive locations for the construction and operation of future production facilities, and selling our products at competitive prices.

 

New plants under construction or decreases in the demand for biofuels may result in excess production capacity in our industry.

 

We expect that the number of biofuel producers and the amount of biofuels produced will likely continue to increase in the near future, which may lead to excess biofuel production capacity.   In a manufacturing industry with excess capacity, producers have an incentive to manufacture additional products for so long as the price exceeds the marginal cost of production (i.e., the cost of producing only the next unit, without regard for interest, overhead or fixed costs). This incentive can result in the reduction of the market price of biofuel to a level that is inadequate to generate sufficient cash flow to cover costs.   Excess capacity may also result from decreases in the demand for biofuel, which could result from a number of factors, including increased governmental regulation, the elimination or modification of governmental incentives, the development of other technologies or products that compete with biofuel, or reduced fuel consumption generally. Excess capacity in the biofuel industry or the reduction of the market price for biofuel could have an adverse effect on our results of operations, cash flows and financial position.

 

The production of biofuel requires that we purchase significant amounts of raw materials, such as biomass waste, paper waste and other materials that we may be unable to procure.

 

Our biofuel production requires significant amounts of biomass waste. We will be required to purchase purchase significant amounts of raw materials, such as biomass waste, paper waste and other materials. Such raw materials may be unavailable which could significantly reduce our ability to produce biofuels.

 

Our business is highly sensitive to the gate fees we receive and the prices we pay for biomass waste, and any future price adjustments could increase our operating costs and may adversely affect our operating results.

 

 
 

 

Negative consumer perceptions of biofuel may impair or prevent the acceptance of biofuel in the marketplace, which could harm our business.

 

The biofuel industry is relatively new and general public acceptance of biofuel is uncertain. Public acceptance of biofuel as a reliable, high-quality alternative transport fuel may be limited or slower than anticipated. Even if our production processes consistently produce biofuel that complies with applicable standards, actual or perceived problems with quality control in the industry generally may lead to a lack of consumer confidence in biofuel and harm our ability to successfully market biofuel. Quality control issues in biofuel that is produced by other industry participants could result in a decrease in demand or mandates for biofuel, with a resulting decrease in our revenue. Furthermore, any negative media reports, whether substantiated or not, may adversely affect the demand for our biofuel, which in turn could decrease our sales, harm our business and adversely affect our financial condition.

 

Deterioration in European, United States and global credit and financial markets may have a material adverse impact on our liquidity, financial position and ability to operate our business.

 

The recent unprecedented deterioration in the European, United States and global credit and financial markets could negatively impact our ability to obtain financing to construct and operate our Malta facility.

 

We may be adversely affected by environmental, health and safety laws, regulations and liabilities.

 

Our Malta facility production business is subject to various environmental laws and regulations, including those relating to the discharge of materials into the air, water and ground, the generation, storage, handling, use, transportation and disposal of hazardous materials, and the health and safety of our employees. In addition, some of these laws and regulations require our facilities to operate under permits that are subject to renewal or modification. These laws, regulations and permits can often require expensive pollution control equipment or operational changes to limit actual or potential impacts to the environment. A violation of these laws and regulations or permit conditions can result in substantial fines, natural resource damages, criminal sanctions, permit revocations and/or facility shutdowns. In addition, we have made, and expect to make, significant capital expenditures on an ongoing basis to comply with increasingly stringent environmental laws, regulations and permits.

 

In addition, new laws, new interpretations of existing laws, increased governmental enforcement of environmental laws or other developments could require us to make additional significant expenditures. Continued government and public emphasis on environmental issues can be expected to result in increased future investments for environmental controls at our production facilities. Present and future environmental laws and regulations (and interpretations thereof) applicable to our operations, more vigorous enforcement policies and discovery of currently unknown conditions may require substantial expenditures that could have a material adverse effect on our results of operations and financial position.

 

European biofuel industries are highly dependent upon a myriad of legislation and regulation and any changes in legislation or regulation could materially and adversely affect our results of operations and financial position.

 

There are a number of European and Maltese laws, regulations and programs that have led to an increase in the supply and demand for biofuels, some of which provide significant economic incentives to biofuel producers and users.   These laws, regulations and programs are constantly changing.   The passage of new European and Maltese energy legislation, or the revocation or amendment of existing laws, regulations or programs related to biofuel and renewable fuels, could have a significant adverse effect on the biofuel industry in general and our business specifically. We cannot assure you that any of the laws, regulations or programs from which our business benefits will continue in the future or that these laws, regulations or programs will benefit us or benefit us more than our competitors.   The elimination or reduction of government subsidies and tax incentives could cause the cost of biofuel to increase to the point where it is not feasible to economically produce and market biofuel, which could require us to abandon our business plan and cease operations. 

 

 
 

 

Our competitive position, financial position and results of operations may be adversely affected by technological advances.

 

The development and implementation of new technologies could result in the processes and procedures that we intend to use at our Malta facility becoming less efficient or obsolete, allow our competitors to produce biofuel at a lower cost than us, or cause the biofuel we produce to be of a lesser quality than the biofuel produced by our competitors.   Also, any advance in biofuel process technology could make our Malta facility less competitive, less efficient or obsolete, any of which could lower the revenue we would otherwise earn from our product sales.   We do not predict when new technologies may become available, the rate of acceptance of new technologies by our competitors or the costs associated with new technologies.   In addition, advances in the development of alternatives to biofuel could significantly reduce demand or eliminate the need for biofuel.  Any advances in technology which require significant capital expenditures to remain competitive or which reduce demand or prices for biofuel would have a material adverse effect on our results of operations and financial position.

 

Defects in the construction or performance of the Malta facility could result in a reduction in our revenues and profitability and in the value of your shares.

 

Although we intend to engage third party companies to construct our Malta facility, we do not believe we will receive any warranties with respect to materials and workmanship or assurances that the project will be capable of operating at its full design capacity. Defects in the construction or performance of the plant could occur and there is no assurance that we, our sub-contractors or anyone else that we contract with to construct the project would be able to correct all problems that arise.   If defects delay the construction or hinder the continued operation of the Malta facility, our business, financial condition and results of operations could be adversely affected.

 

Our directors and officers have limited experience in the construction and operation of a waste biomass to biofuel facility.

 

Our directors and officers have limited experience in raising large amounts of project finance related equity and debt capital, or building and operating the proposed Malta waste biomass to biofuel facility.   Although we expect to hire additional personnel and enter into agreements with contractors and consultants to assist us in constructing and operating the facility, there is no assurance that we will be able to hire employees or sign agreements satisfactory to us.   If our directors and officers are unable or find it difficult to manage our development and operations successfully, our ability to succeed as a business and the value of your shares will be adversely affected.

 

Our management will be subject to greater demands and we will incur increased costs as a result of being a public company, which could affect our profitability and operating results.  Our accounting, internal audit and other management systems and resources may not be adequately prepared for these demands.

 

We have not been responsible for the corporate governance and financial reporting practices and policies required of a public company.   Following the effectiveness of the registration statement of which this prospectus is a part, we will be a public reporting company in the United States subject to the information and reporting requirements of the Securities Exchange Act of 1934 and the compliance obligations of the Sarbanes-Oxley Act of 2002. As a public reporting company, we will incur significant legal, accounting, investor relations and other expenses. These significant expenses could affect our profitability and our results of operations.

 

Section 404 of the Sarbanes-Oxley Act requires annual management assessment of the effectiveness of our internal controls over financial reporting and a report by our independent auditors addressing these assessments. These reporting and other obligations will place significant demands on our management, administrative, operational, internal audit and accounting resources. We anticipate that we will need to upgrade our systems; implement additional financial and management controls, reporting systems and procedures; implement an internal audit function; and hire additional accounting, internal audit and finance staff. If we are unable to accomplish these objectives in a timely and effective fashion, our ability to comply with our financial reporting requirements and other rules that apply to reporting companies could be impaired. Any failure to maintain effective internal controls could have a material adverse effect on our business, operating results and stock price.

 

 
 

 

We are dependent upon our officers for management and direction, and the loss of any of these persons could adversely affect our operations and results.

 

We are dependent upon our officers for the successful management of our operations and execution of our business plan. We do not have employment agreements with our officers or other key personnel.   The loss of any of our officers could delay or prevent the achievement of our business objectives, which could have a material adverse effect upon our results of operations and financial position.  

 

Competition for qualified personnel in the biofuel industry is intense and we may be unable to hire and retain qualified managers and other key personnel.

 

Prior to commencement of commercial operations at our Malta facility, we will need to hire additional employees to manage and operate the plant.   Competition to attract and retain qualified employees is intense in the biofuel industry, and we expect that competition will continue or increase as a result of significant growth in the number of companies producing biofuel and other alternative fuels.   If we are unable to attract and retain key personnel, we may be unable to successfully execute our business plan and our financial condition and results of operation may be adversely affected.

 

It may be more difficult for us to retain or attract officers and directors due to the Sarbanes-Oxley Act of 2002.

 

The Sarbanes-Oxley Act of 2002 was enacted in response to public concerns regarding corporate accountability in connection with recent accounting scandals. The stated goals of the Sarbanes-Oxley Act are to increase corporate responsibility, to provide for enhanced penalties for accounting and auditing improprieties at publicly traded companies, and to protect investors by improving the accuracy and reliability of corporate disclosures pursuant to the securities laws. The Sarbanes-Oxley Act generally applies to all companies that file or are required to file periodic reports with the SEC under the Securities Exchange Act of 1934.  The enactment of the Sarbanes-Oxley Act of 2002 has led to a series of rules and regulations by the SEC that significantly increases the responsibilities and potential liabilities of directors and executive officers.   Because of the perceived increased personal risk associated with acting as an executive officer or director of a public company, we may be unable, or it may be significantly more expensive, to attract and retain qualified executive officers and directors.

 

Our directors and officers devote time to other ventures, which may adversely impact the time they can devote to our company and its operations.

 

Some of our officers and directors also serve as officers and/or directors of other companies, and they devote only that portion of their time, which, in their judgment and experience, is reasonably required for the management and operation of our company and our business.   Executive management may have conflicts of interest in allocating management time, services and functions among our company and any current and future ventures in which they are engaged.  If our officers and directors are unable to devote adequate time to manage our operations successfully, our potential to succeed as a business and the value of your shares may be adversely affected.

 

Our ability to operate depends on obtaining adequate financing to build and operate the Facility, and our ability to grow and compete in the future will be adversely affected if adequate capital is not available to us or not available on terms favorable to us.

 

The success of our business plan depends on our ability to build and operate the Facility in Malta. The ability of our business to grow and compete depends on the availability of adequate capital, which in turn depends in large part on our cash flow from operations and the availability of equity and debt financing. We cannot assure you that our cash flow from operations will be sufficient or that we will be able to obtain equity or debt financing on acceptable terms or at all to implement our growth strategy. We estimate that we will need a minimum of $80-90 million to successfully implement our business plans. As a result, we cannot assure you that adequate capital will be available to finance the building and operation of the Facility, take advantage of business opportunities or respond to competitive pressures, any of which could harm our business.

 

Our future success is dependent, in part, on the performance and continued service of our Chief Executive Officer.

 

We are presently dependent to a great extent upon the experience, abilities and continued services of Serena B. Potash, our Chief Executive Officer. The loss of services of any of the management staff could have a material adverse effect on our business, financial condition or results of operation. We do not intend on taking out key man insurance on Ms. Potash after the Closing Date.

 

 
 

 

Risks Related to Ownership of Our Common Stock

 

There is no public trading market for our Common Stock and you may not be able to resell your Common Stock.

 

There is no established public trading market for our securities. Although we intend to be quoted on the OTC Markets in the United States, our shares are not and have not been quoted on any exchange or quotation system. We cannot assure you that a market maker will agree to file the necessary documents with the FINRA, nor can there be any assurance that such an application for quotation will be approved or that a regular trading market will develop or that if developed, will be sustained. In the absence of a trading market, an investor may be unable to liquidate its investment, which will result in the loss of your investment.

 

If our shares are quoted on the over-the-counter bulletin board, we will be required to remain current in our filings with the SEC and our securities will not be eligible for quotation if we are not current in our filings with the SEC.

 

In the event that our shares are quoted on the over-the-counter bulletin board, we will be required to remain current in our filings with the SEC in order for shares of our common stock to be eligible for quotation on the over-the-counter bulletin board.   In the event that we become delinquent in our required filings with the SEC, quotation of our common stock will be terminated following a 30 or 60 day grace period if we do not make our required filing during that time.   If our shares are not eligible for quotation on the over-the-counter bulletin board, investors in our common stock may find it difficult to sell their shares.

 

If a public market develops for our common stock, the market price may be particularly volatile and you may be unable to sell your common stock at or above your purchase price, which may result in substantial losses to you.

 

If a public market for our common stock develops, it is likely to be characterized by significant price volatility when compared to seasoned issuers, and we expect that our share price will continue to be more volatile than a seasoned issuer for the indefinite future.   Fluctuations in share price could be based on various factors in addition to those otherwise described in this prospectus, including:

 

Our operating performance and the performance of our competitors;
The public’s reaction to our press releases, our other public announcements and our filings with the Securities and Exchange Commission;
Changes in earnings estimates or recommendations by research analysts who follow us or other companies in our industry;
Variations in general economic conditions;
The number of shares to be publicly traded after this offering;
Actions of our existing shareholders, including sales of common stock by our directors and executive officers;
The arrival or departure of key personnel; and
Other developments affecting us, our industry or our competitors.

 

Many of these factors are beyond our control and may decrease the market price of our common stock, regardless of our operating performance and financial condition.

 

The market price of our common stock may decline if a substantial number of shares of our common stock are sold at once or in large blocks.

 

There is presently no public market for our common stock.   If a public market for our shares develops in the future, many of our shareholders may, subject only to the volume, manner of sale and notice requirements of Rule 144 of the Securities Act of 1933 in the case of some shareholders, desire to sell their shares. Sales of a substantial number of these shares in the public market, or the perception that these sales could occur, could cause the market price of our common stock to decline. In addition, the sale of these shares could impair our ability to raise capital through the sale of additional equity securities.

 

 
 

 

Future issuance of our Common Stock could dilute the interests of existing shareholders.

 

We may issue additional shares of our Common Stock in the future. The issuance of a substantial amount of Common Stock could have the effect of substantially diluting the interests of our shareholders. In addition, the sale of a substantial amount of Common Stock in the public market, either in the initial issuance or in a subsequent resale by the target company in an acquisition which received such Common Stock as consideration or by investors who acquired such Common Stock in a private placement could have an adverse affect on the market price of our Common Stock.

 

We have no plans to pay dividends.

 

To date, we have paid no cash dividends on our common shares. For the foreseeable future, earnings generated from our operations will be retained for use in our business and not to pay dividends.

   

The application of the Securities and Exchange Commission’s “penny stock” rules to our Common Stock could limit trading activity in the market, and our shareholders may find it more difficult to sell their stock.

 

It is expected our Common Stock will be trading at less than $5.00 per share and is therefore subject to the SEC penny stock rules. Penny stocks generally are equity securities with a price of less than $5.00. Penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer’s account. The broker-dealer must also make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. These requirements may have the effect of reducing the level of trading activity, if any, in the secondary market for a security that becomes subject to the penny stock rules. The additional burdens imposed upon broker-dealers by such requirements may discourage broker-dealers from effecting transactions in our securities, which could severely limit their market price and liquidity of our securities. These requirements may restrict the ability of broker-dealers to sell our Common Stock and may affect your ability to resell our Common Stock.

 

We will have broad discretion over the use of the net proceeds to the company and may not use them effectively.

 

Our management will have broad discretion to use the net proceeds to the company for a variety of purposes, including, further development of our products and operations, working capital and general corporate purposes. We may spend or invest these proceeds in a way with which our shareholders disagree. Failure by our management to effectively use these funds could harm our business and financial condition. Until the net proceeds are used, they may be placed in investments that do not yield a favorable return to our investors, do not produce significant income or lose value.

 

If we are unable to establish appropriate internal financial reporting controls and procedures, it could cause us to fail to meet our reporting obligations, result in the restatement of our financial statements, harm our operating results, subject us to regulatory scrutiny and sanction, cause investors to lose confidence in our reported financial information and have a negative effect on the market price for shares of our Common Stock.

 

Effective internal controls are necessary for us to provide reliable financial reports and to effectively prevent fraud. We maintain a system of internal control over financial reporting, which is defined as a process designed by, or under the supervision of, our principal executive officer and principal financial officer, or persons performing similar functions, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

 

 
 

 

As a public company, we will have significant additional requirements for enhanced financial reporting and internal controls. We will be required to document and test our internal control procedures in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act of 2002, which requires annual management assessments of the effectiveness of our internal controls over financial reporting. The process of designing and implementing effective internal controls is a continuous effort that requires us to anticipate and react to changes in our business and the economic and regulatory environments and to expend significant resources to maintain a system of internal controls that is adequate to satisfy our reporting obligations as a public company.

 

We cannot assure you that we will not, in the future, identify areas requiring improvement in our internal control over financial reporting. We cannot assure you that the measures we will take to remediate any areas in need of improvement will be successful or that we will implement and maintain adequate controls over our financial processes and reporting in the future as we continue our growth. If we are unable to establish appropriate internal financial reporting controls and procedures, it could cause us to fail to meet our reporting obligations, result in the restatement of our financial statements, harm our operating results, subject us to regulatory scrutiny and sanction, cause investors to lose confidence in our reported financial information and have a negative effect on the market price for shares of our Common Stock.

  

Lack of experience as officers of publicly-traded companies of our management team may hinder our ability to comply with Sarbanes-Oxley Act.

 

It may be time consuming, difficult and costly for us to develop and implement the internal controls and reporting procedures required by the Sarbanes-Oxley Act. We may need to hire additional financial reporting, internal controls and other finance staff or consultants in order to develop and implement appropriate internal controls and reporting procedures.

 

We will incur increased costs as a public company which may affect our profitability.

 

Bio-En previously operated as a private company in Delaware. As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. We are subject to the SEC’s rules and regulations relating to public disclosure. SEC disclosures generally involve a substantial expenditure of financial resources. Compliance with these rules and regulations will significantly increase our legal and financial compliance costs and some activities will become more time-consuming and costly.  Management may need to increase compensation for senior executive officers, engage additional senior financial officers who are able to adopt financial reporting and control procedures, allocate a budget for an investor and public relations program, and increase our financial and accounting staff in order to meet the demands and financial reporting requirements as a public reporting company. Such additional personnel, public relations, reporting and compliance costs may negatively impact our financial results.

 

In the event a market develops for our Common Stock, the market price of our Common Stock may be volatile.

 

In the event a market develops for our Common Stock, the market price of our Common Stock may be highly volatile, as is the stock market in general, and the market for OTC Market quoted stocks in particular. Some of the factors that may materially affect the market price of our Common Stock are beyond our control, such as changes in financial estimates by industry and securities analysts, conditions or trends in the industry in which we operate or sales of our Common Stock. These factors may materially adversely affect the market price of our Common Stock, regardless of our performance. In addition, the public stock markets have experienced extreme price and trading volume volatility. This volatility has significantly affected the market prices of securities of many companies for reasons frequently unrelated to the operating performance of the specific companies. These broad market fluctuations may adversely affect the market price of our Common Stock.

 

Public company compliance may make it more difficult to attract and retain officers and directors.

  

The Sarbanes-Oxley Act and rules subsequently implemented by the SEC have required changes in corporate governance practices of public companies. As a public company, we expect these rules and regulations to increase our compliance costs and to make certain activities more time consuming and costly. As a public company, we also expect that these rules and regulations may make it more difficult and expensive for us to obtain director and officer liability insurance in the future and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified persons to serve on our board of directors or as executive officers.

 

 
 

   

Because our directors and executive officers are among our largest shareholders, they can exert significant control over our business and affairs and have actual or potential interests that may depart from those of subscribers in the Offering.

 

Our directors and executive officers collectively and beneficially own 52.5% of outstanding common stock. Serena B. Potash, our Chief Executive Officer and Director, beneficially owns 19.46% of our outstanding common stock. Additionally, the holdings of our directors and executive officers may increase in the future upon vesting or other maturation of exercise rights under any of the options or warrants they may hold or in the future be granted or if they otherwise acquire additional shares of our Common Stock. The interests of such persons may differ from the interests of our other shareholders, including purchasers of Units in the Offering. As a result, in addition to their board seats and offices, such persons will have significant influence over and control all corporate actions requiring shareholder approval, irrespective of how the Company’s other shareholders, including purchasers in the Offering, may vote, including the following actions:

 

  ¨ to elect or defeat the election of our directors;

 

  ¨ to amend or prevent amendment of our Certificate of Incorporation or By-laws;

 

  ¨ to effect or prevent a merger, sale of assets or other corporate transaction; and

 

  ¨ to control the outcome of any other matter submitted to our shareholders for vote.

 

Such persons’ stock ownership may discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of the Company, which in turn could reduce our stock price or prevent our shareholders from realizing a premium over our stock price.

 

Item 2. Financial Information

 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF OPERATIONS

 

The following discussion and analysis of the results of operations and financial condition for   the year ended March 31, 2014, should be read in conjunction with our financial statements and the notes to those financial statements that are attached as Exhibit A to this Report. The Financial Statements should not be relied on for an understanding of the current financial status of the Company.

 

Overview

 

The Company was incorporated under the laws of the State of Delaware on August 2, 2011 as Olivia, Inc. On March 27, 2014, the Company filed with the State of Delaware a Certificate of Amendment to the Articles of Incorporation changing the Company’s name from Olivia, Inc. to Bio-En Holdings Corp.

 

Bio-En Corp. was incorporated under the laws of the State of Delaware on January 6, 2014. The Company is in the development stage and is devoting substantially all of its efforts to the development of its business plan. The Company intends to be a world leader of setting the standard for waste to bio-fuel technologies. The Company intends to plan, design, and execute agreements to build, operate and maintain a bio-mass to energy facility on the island of Malta, which is contingent on sufficient capital funding of at least $80-90 million.  The Company’s fiscal year-end is March 31.

 

The Company intends to enter into an agreement with Applied Biofuels (Malta) Limited whereby all assets of Applied Buiels (Malta) Limited shall be transferred to a new subsidiary (“Newco”), to be incorporated in Malta, which will be a wholly owned subsidiary of the Company. Company, is a project and plant development company in the business of producing and selling ethanol and butanol made from municipal solid waste and other cellulosic fiber.

 

 
 

  

We have planned, designed, engineered and signed agreements to build and operate a facility using Gravity Pressure Vessel Technology in Weak Acid Hydrolysis to convert Biomass to Ethanol (“Facility”). The Facility will be built on the Island of Malta and is anticipated be fully operational by the end of the 4th quarter of 2015.

 

The Facility will combine technologies from the waste management industry and integrate the recycling of waste, control of carbon dioxide and other emissions, with the profitable production of fuel grade Ethanol.

 

Results of Operations

 

For the three months ended June 30, 2014

 

Bio-En has generated no revenues from January 6, 2014 (Inception) through June 30, 2014.

 

Our operating expenses from for the three months ended June 30, 2014 were $46,546, resulting in a net loss of $46,545 for the same period. Our operating expenses consist primarily of general and administrative expenses.

 

For the year ended March 31, 2014

 

Bio-En has generated no revenues from January 6, 2014 (Inception) through March 31, 2014.

 

Our operating expenses from January 6, 2014 (Inception) through March 31, 2014 were $66,982, resulting in a net loss of $66,982. Our operating expenses consist primarily of general and administrative expenses.

 

Liquidity and Capital Resources

 

As reflected in the accompanying financial statements, the Company had a net loss of $46,545 and net cash used in operations of $60 as of June 30, 2014, and a working capital deficit and stockholders’ deficit of $6,736 at June 30, 2014. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

The ability of the Company to continue its operations is dependent on Management's plans, which may include the raising of capital through debt and/or equity markets with some additional funding from other traditional financing sources, which may include term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The Company may need to incur liabilities with certain related parties to sustain the Company’s existence.

 

The Company will require additional funding to finance the growth of its current and expected future operations as well as to achieve its strategic objectives. There can be no assurance that financing will be available in amounts or terms acceptable to the Company, if at all.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements.

 

Inflation

 

We do not believe that inflation has had a material effect on our results of operations.

 

Critical Accounting Policies

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to select appropriate accounting policies and to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses.

 

Recently Issued Accounting Pronouncements

 

There are no recently issued accounting pronouncements that are expected to have a material impact on the consolidated financial statements or notes thereto.

 

Item 3. Properties

 

Our executive offices are located at 56 Main Street, Monsey NY 10952.

 

 
 

  

Item 4. Security Ownership Of Certain Beneficial Owners And Management

 

The following table sets forth certain information as of September 10, 2014 with respect to the holdings of: (1) each person known to us to be the beneficial owner of more than 5% of our Common Stock; (2) each of our directors, nominees for director and named executive officers; and (3) all directors and executive officers as a group. To the best of our knowledge, each of the persons named in the table below as beneficially owning the shares set forth therein has sole voting power and sole investment power with respect to such shares, unless otherwise indicated.

 

Name of Beneficial Owner and Address (1)   Amount and Nature of
Beneficial Ownership of
Common Stock
    Percent of Common
Stock (2)
 
5% Shareholders                
Applied Bio-Fuels Limited (3)     4,424,118       13.68 %
Genesyst International Inc.     2,548,853       7.88 %
Directors and Executive Officers                
Serena B. Potash (5)     6,294,118       19.46 %
Bruce Minsky     0       0 %
Peter Hurrell     3,563,740       11.02 %
Geoffrey Maclaran     3,563,740       11.02 %
Joseph Micallef     3,563,740       11.02
                 
All directors and officers as a group (5 people)             52.5 %

 

(1) Unless otherwise noted, the address of each beneficial owner is c/o 56 Main Street, Monsey NY 10952.
(2) Based on 32,350,003 shares of Common Stock issued and outstanding as of September 10, 2014.
(3) Serena B. Potash is the beneficial owner of all shares held by Applied Bio-Fuels Limited.
(4) Genesyst International Inc. has 2,262,657 shares outstanding. Of these, 727,040 are held by Eau-Viron, Inc., 474,541 shares are held by James A. Titmas, 149,504 shares are held by Susan Tomchi, and 106,386 are held by David Shriber.
(5) Includes: (1) 1,870,000 shares of Common Stock held by Serena B. Potash; and (2) 4,424,118 shares held by Applied Bio-Fuels Limited.

 

Changes in Control

 

We are not aware of any person who owns of record, or is known to own beneficially, five percent or more of our outstanding securities of any class, other than as set forth above.   Reference is made to Item 2.01 and Item 5.01 for a description of the change in control of the Company as a result of the transactions disclosed herein.

 

Item 5. Directors And Executive Officers

 

The following table sets forth the names and ages of all of our directors, executive officers and key employees; and all positions and offices held as of the date of this Report. The directors will hold such office until the next annual meeting of shareholders and until his or her successor has been elected and qualified.

 

Name   Age   Position
Serena B. Potash   58   President, Chairman of the Board of Directors
Bruce Minsky   50   Corporate Secretary
Peter Hurrell   65   Vice President
Geoffrey Maclaran   64   Director
Joseph Micallef   59   Director

 

 
 

 

Business Experience

 

The following summarizes the occupation and business experience during the past five years for our officers, directors and key employees as of the date of this Report:

 

Officers

 

Serena B. Potash, 58, President and Chairman of the Board of Directors

 

Serena B. Potash is the President and member of the Board of Directors of the Company. She has over 25 years experience as a business consultant. She was cofounder of JIF, an investment/development advisory service with links to venture capitalist groups, investment bankers, underwriters and other business service providers. Ms. Potash focuses on existing and new Bio-tech companies, assisting them with commercialization issues, business and marketing strategies, company structuring and management staffing.

 

Bruce Minsky, 50, Corporate Secretary

 

Bruce W. Minsky, Company’s Corporate Secretary, is a graduate of Boston University (B.A., 1985), Southwestern University School of Law (J.D., 1988), and Boston University – Morin Center for Banking Law Studies (LLM in American Banking, 1989). Mr. Minsky is the managing partner of Law Offices of Bruce W. Minsky, P.C., a private law firm specializing in individual business/in-house legal counselings. Prior to the Law Offices of Bruce W. Minsky, P.C., Mr. Minsky was Vice-President/House Counsel for Banco Popular North America, a multi-billion dollar domestic bank, from 1991 to 2004, and a trial/litigation/appellate associate of business matters at Quirk & Bakalor, P.C. from 1989 to 2001. Mr. Minsky has years of experience in the gamut of legal services ranging from Consumer/Commercial finance products/services, Corporate Governance, Real Estate, Business/Portfolio transactions, as well as acquisitions matters, to Advertising, Technology, Marketing, Labor, SEC, Finance and Tax scenarios, along with an array of Operational, Compliance and Regulatory oversights. Mr. Minsky is currently a Trustee of the Village of New Hempstead, a board member of Kehillat New Hempstead, board member of ASHAR, and a board member of VGTel, Inc. 

 

Peter Hurrell, 65, Vice President

 

Peter Hurrell is a member of the Board of Directors of the Company. He has profound Civil Engineering and Construction experience devoted to Waste Water Treatment, Sewage Sludge Treatment Design and Construction works. Over the last five years, Mr. Hurrel has been employed by Genesis International. He has worked in Bahrain, Dubai, UK, Ireland and Malta and is technical Advisor in the Far East on proposals for treating sludge and municipal wastes for Pacific Rim countries. As the Technical Director Peter brings the skills and experience from working in a similar process facility for Sludge Treatment in Apeldoorn in the Netherlands. He has developed major interests in Non-Adversarial Contractual Relationships and Value Management and Engineering and Sustainable Construction.

 

Geoffrey Maclaran, 64, Director

 

Geoffrey Maclaran is a member of the Board of Directors of the Company. Mr. Maclaran worked as a Senior Engineer for Monk & Company and a Project Manager for Daniel Pipelines. He was Project Manager OBG Limited as a Contracts Director and Managing Director for Maclaran Construction and Maclaran Services. He is Managing Director of ReUse Limited and a Director for Peel Facilities. Peel with ReUse, offers to share with Developers or Commercial Businesses, from onsite effluent treatment for the reuse of grey water to sourcing alternative “environmentally friendly” energy from waste to power or BioEthanol to maximize on site services assets that are non-carbon emitting. Mr. McLaren has helped the company redefine its approach to the European Union and its Programmes and Procedures for development in Converting Biomass derived from Wastes and Non-Food sources to Ethanol. Mr. McLaren has been employed by Genesis UK for the past five years.

 

Joseph Micallef, 59, Director

 

Joseph Micallef, a member of the Board of Directors of the Company, is based in Malta and has over 25 years of Senior Projects Management experience including Chairman of Research & Business with a major construction company. He has also served a term as President of the Federation of Building Contractors. Apart from local contracts, Mr. Micallef has worked overseas on major projects from Libya to Saudi Arabia and Iraq. For the past five years, he has been the general manager of ATTRD Construction Company.

 

 
 

  

Committees

 

The board of directors has no standing committees. However, the Company intends to implement a comprehensive corporate governance program, including establishing various board committees and adopting a Code of Ethics in the future. In addition, the Company will secure Directors and Officers insurance consistent with the Company’s and Board of Director’s mandates.

 

Family Relationships

 

No family relationship has ever existed between any director, executive officer of the Company, and any person contemplated to become such.

 

Item 6. Executive Compensation

 

The following table shows for the period ended March 31, 2014, the compensation awarded (earned) or paid by the Company to its named executive officers or acting in a similar capacity as that term is defined in Item 402(a)(2) of Regulation S-K. There are no understandings or agreements regarding compensation that our management will receive after a business combination that is required to be included in this table, or otherwise.

 

Name and Principal Position   Fiscal
Year (1)
    Salary ($)     Bonus     Option
Awards
    All Other
Compensation
    Total ($)  
                                                 
Serena B. Potash, President     2014     $ 0     $ 0     $ 0     $ 0     $ 0  
                                                 
      2013     $ -     $ -     $ -     $ -     $ -  
                                                 
Bruce Minsky, Secretary     2014     $ 0     $ 0     $ 0     $ 0     $ 0  
                                                 
      2013     $ -     $ -     $ -     $ -     $ -  
                                                 
Peter Hurrell, Vice President     2014     $ 0     $ 0     $ 0     $ 0     $ 0  
                                                 
      2013     $ -     $ -     $ -     $ -     $ -  

 

(1) Bio-En has was incorporated on January 6, 2014.

 

Employment Agreements

 

As of the date of this Report, there has not been any material plan, contract or arrangement (whether or not written) to which any of our officers or directors are a party in connection with their appointments as officers or directors of the Company. The Company intends to enter into employment and director agreements with its officers and directors.

  

Option Plan

 

There are no stock option plans or common shares set aside for any stock option plan.

 

Item 7. Certain Relationships And Related Transactions

 

Except as disclosed below, none of the following persons has any direct or indirect material interest in any transaction to which we are a party since our incorporation or in any proposed transaction to which we are proposed to be a party:

 

 
 

  

(A) Any of our directors or officers;
(B) Any proposed nominee for election as our director;
(C) Any person who beneficially owns, directly or indirectly, shares carrying more than 10% of the voting rights attached to our Common Stock; or
(D) Any relative or spouse of any of the foregoing persons, or any relative of such spouse, who has the same house as such person or who is a director or officer of any parent or subsidiary of our company.

 

For the three months ended June 30, 2104, an officer of the Company paid operating expenses on behalf of the Company totaling $62,809, which was treated as contributed capital.

 

Director Independence

 

Because our common stock is not currently listed on a national securities exchange, we have used the definition of “independence” of The NASDAQ Stock Market to make this determination. NASDAQ Listing Rule 5605(a)(2) provides that an “independent director” is a person other than an officer or employee of the Company or any other individual having a relationship which, in the opinion of the Company’s board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The NASDAQ listing rules provide that a director cannot be considered independent if:

 

¨ the director is, or at any time during the past three years was, an employee of the company;
¨ the director or a family member of the director accepted any compensation from the company in excess of $120,000 during any period of 12 consecutive months within the three years preceding the independence determination (subject to certain exclusions, including, among other things, compensation for board or board committee service);
¨ a family member of the director is, or at any time during the past three years was, an executive officer of the company;
¨ the director or a family member of the director is a partner in, controlling stockholder of, or an executive officer of an entity to which the company made, or from which the company received, payments in the current or any of the past three fiscal years that exceed 5% of the recipient’s consolidated gross revenue for that year or $200,000, whichever is greater (subject to certain exclusions);
¨ the director or a family member of the director is employed as an executive officer of an entity where, at any time during the past three years, any of the executive officers of the company served on the compensation committee of such other entity; or the director or a family member of the director is a current partner of the company’s outside auditor, or at any time during the past three years was a partner or employee of the company’s outside auditor, and who worked on the company’s audit.

  

We do not have any independent directors. We do not have an audit committee, compensation committee or nominating committee. We currently do not have a code of ethics that applies to our officers, employees and director.

 

Item 8. Legal Proceedings

 

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse affect on our business, financial condition or operating results.

 

Item 9. Market Price And Dividends On The Registrant’s Common Equity And Related Shareholder Matters

 

There is no established public trading market for our Common Stock. As of the date of this Report, there are no outstanding options and warrants to purchase shares of Common Stock of the Registrant.

 

Record Holders

 

As of September 10, 2014, there were approximately 60 shareholders of record holding a total of 32,350,003 shares of Common Stock. The holders of the Common Stock are entitled to one vote for each share held of record on all matters submitted to a vote of shareholders. Holders of the Common Stock have no preemptive rights and no right to convert their Common Stock into any other securities. There are no redemption or sinking fund provisions applicable to the Common Stock.

 

 
 

  

Dividends

 

The Registrant has not declared any cash dividends since inception and does not anticipate paying any dividends in the foreseeable future. The payment of dividends is within the discretion of the Board of Directors and will depend on the Company’s earnings, capital requirements, financial condition and other relevant factors. There are no restrictions that currently limit the Registrant’s ability to pay dividends on its Common Stock other than those generally imposed by applicable state law.

 

Item 10. Recent Sales Of Unregistered Securities

 

Reference is made to the disclosure set forth under Item 3.02 of this Report, which disclosure is incorporated by reference into this section.

   

Item 11. Description Of Securities

 

Authorized Capital Stock

 

Our authorized capital stock consists of 300,000,000 shares of capital stock, comprised of 250,000,000 shares of common stock, par value of $0.0001 per share, and 50,000,000 shares of preferred stock, par value $0.0001 per share. As of September 10, 2014, 32,350,003 shares of our Common Stock and no shares of preferred stock were issued and outstanding.

 

Common Stock

 

All outstanding shares of Common Stock are of the same class and have equal rights and attributes. The holders of Common Stock are entitled to one vote per share on all matters submitted to a vote of shareholders of the Company. All shareholders are entitled to share equally in dividends, if any, as may be declared from time to time by the Board of Directors out of funds legally available. In the event of liquidation, the holders of Common Stock are entitled to share ratably in all assets remaining after payment of all liabilities. The shareholders do not have cumulative or preemptive rights.

 

Preferred Stock

 

Our Amended Certificate of Incorporation provides that we are authorized to issue up to 50,000,000 shares of preferred stock with a par value of $0.0001 per share. Our Board of Directors has the authority, without further action by the shareholders, to issue from time to time the preferred stock in one or more series for such consideration and with such relative rights, privileges, preferences and restrictions that the board may determine. The preferences, powers, rights and restrictions of different series of preferred stock may differ with respect to dividend rates, amounts payable on liquidation, voting rights, conversion rights, redemption provisions, sinking fund provisions and purchase funds and other matters. The issuance of preferred stock could adversely affect the voting power or other rights of the holders of Common Stock.

 

Item 12. Indemnification Of Directors And Officers

 

(a)           The Company shall indemnify and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may hereafter be amended, any person who was or is made or is threatened to be made a party or is otherwise involved in any claim, action, suit, or proceeding, whether civil, criminal, administrative or investigative (a “proceeding”) by reason of the fact that the person, or a person for whom he or she is the legal representative, is or was a Director or officer of the Company or is or was serving at the request of the Company as a director, officer or fiduciary of another corporation or of a partnership, joint venture, trust, non-profit entity, or other enterprise, including service with respect to employee benefit plans, against all expense, liability and loss (including attorneys’ fees, judgments, fines, ERISA excise taxes or penalties and amounts paid or to be paid in settlement) reasonably incurred or suffered by such person. The right to indemnification conferred in the Company’s Bylaw (“Bylaws”) shall be a contract right. Except as provided in paragraph (c) of this Bylaw with respect to proceedings seeking to enforce rights to indemnification, the Company shall indemnify a person in connection with a proceeding initiated by such person or a claim made by such person against the Company only if such proceeding or claim was authorized in the specific case by the Board of Directors of the Company.

 

 
 

 

(b)           Subject to applicable law, the Company shall pay the expenses incurred in defending any proceeding in advance of its final disposition, provided, however, that if and to the extent required by law the payment of expenses incurred by any person covered hereunder in advance of the final disposition of the proceeding shall be made only upon receipt of an undertaking by or on behalf of the affected person to repay all amounts advanced if it should ultimately be determined that such person is not entitled to be indemnified under the Company’s Bylaw or otherwise.

 

(c)           If a claim for indemnification (following the final disposition of such proceeding) or advancement of expenses under the Bylaws is not paid in full within thirty days, or such other period as might be provided pursuant to contract, after a written claim therefor has been received by the Company, the claimant may file suit to recover the unpaid amount of such claim or may seek whatever other remedy might be provided pursuant to contract. In any such action the Company shall have the burden of proving that the claimant was not entitled to the requested indemnification or advancement of expenses under applicable law. If successful in whole or in part, claimant shall be entitled to be paid the expense of prosecuting such claim to the fullest extent permitted by law. Neither the failure of the Company (including its Directors, independent legal counsel or shareowners) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because the claimant has met the applicable standard of conduct set forth in the General Corporation Law of Delaware, nor an actual determination by the Company (including its Directors, independent legal counsel or shareowners) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that the claimant has not met the applicable standard of conduct.

 

(d)           Any determination regarding whether indemnification of any person is proper in the circumstances because such person has met the applicable standard of conduct set forth in the General Corporation Law of Delaware shall be made in accordance with the applicable provisions of Section 145 of the General Corporation Law of Delaware.

 

(e)           The Company may, but shall not be required to, indemnify and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may hereafter be amended, any person who was or is made or is threatened to be made a party or is otherwise involved in any claim, action, suit, or proceeding, whether civil, criminal, administrative or investigative (a “proceeding”) by reason of the fact that the person, or a person for whom he or she is the legal representative, is or was an employee or agent of the Company or is or was serving at the request of the Company as an employee or agent of another corporation or of a partnership, joint venture, trust, non-profit entity, or other enterprise, including service with respect to employee benefit plans, against all expense, liability and loss (including attorneys’ fees, judgments, fines, ERISA excise taxes or penalties and amounts paid or to be paid in settlement) reasonably incurred or suffered by such person.

 

(f)            The rights conferred on any person by the Bylaws shall not be exclusive of any other rights which such person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, the Bylaws, agreement, vote of shareowners or disinterested Directors or otherwise.

 

(g)            Any repeal or modification of the foregoing provisions of the Bylaws shall not adversely affect any right or protection hereunder of any person with respect to any act or omission occurring prior to or at the time of such repeal or modification for which indemnification or advancement of expenses is sought.

 

(h)           The Company’s obligation, if any, to indemnify or to advance expenses to any person who was or is serving at its request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, enterprise or nonprofit entity shall be reduced by any amount such person may collect as indemnification or advancement of expenses from such other corporation, partnership, joint venture, trust, enterprise or non-profit enterprise.

 

 
 

  

 

Item 13. Financial Statements And Supplementary Data

 

Information concerning the financial information of the Registrant set forth under Item 9.01 of this Report is incorporated by reference.

 

Item 14. Changes In And Disagreements With Accountants On Accounting And Financial Disclosure

 

None.

 

Item 3.02 Unregistered Sales of Equity Securities.

 

The information contained in Item 1.01 above is incorporated herein by reference in response to this Item 3.02.

 

Pursuant to the Merger Agreement, we issued 28,980,000 shares of our common stock to the shareholders of Bio-En Corp . The above issuance is exempt from registration, pursuant to Section 4(2) of the Securities Act.  These securities qualified for exemption under Section 4(2) of the Securities Act since the issuance securities by us did not involve a public offering. The offering was not a “public offering” as defined in Section 4(2) due to the insubstantial number of persons involved in the deal, size of the offering, manner of the offering and number of securities offered. We did not undertake an offering in which we sold a high number of securities to a high number of investors. In addition, these stockholders had the necessary investment intent as required by Section 4(2) since they agreed to and received share certificates bearing a legend stating that such securities are restricted pursuant to Rule 144 of the Securities Act. This restriction ensures that these securities would not be immediately redistributed into the market and therefore not be part of a “public offering.” Based on an analysis of the above factors, we have met the requirements to qualify for exemption under Section 4(2) of the Securities Act for this transaction.

  

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
2.1  

Merger Agreement, dated August 21, 2014 by and among Bio-En Holdings, Corp., Bio-En Corp., and Serena B. Potash

3.1   Certificate of Incorporation of Bio-En Holdings, Corp. (f/k/a Olivia, Inc.) (1)
3.2   Certificate of Amendment of the Certificate of Incorporation of Bio-En Holdings, Corp., filed April 1, 2014
3.3   Certificate of Amendment of the Certificate of Incorporation of Bio-En Holdings, Corp., filed August 5, 2014
3.4   Amended and Restated Bylaws of Bio-En Holdings, Corp.
10.1   Cancellation Agreement, dated August 20, 2014, by and between Bio-En Holdings, Corp. and Serena B. Potash
10.2   License Agreement, dated March 23, 2014, by and between Bio En Corp. and GeneSyst International, Inc.
99.1  

Consolidated Financial Statements for the year ended March 31, 2014 and the quarter ended June 30, 2014

99.2   Pro Forma Financial Information (2)

 

(1) Incorporated by reference to exhibit to our Registration Statement on Form S-1 filed with the SEC on February 13, 2013.
(2) To be filed by amendment.

 

 
 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  BIO-EN HOLDINGS CORP.

Date: September 11, 2014

   
  By: /s/ Serena B. Potash
    Serena B. Potash
    President
    (Duly Authorized, Principal Executive Officer and Principal Financial Officer)

 

 

 

 

Exhibit 2.1

 

Execution Copy

 

SHARE EXCHANGE/MERGER AGREEMENT

 

This SHARE EXCHANGE/MERGER AGREEMENT (this “Agreement”) , dated as of August 21, 2014 (the “ Effective Date ”), by and among BIO-EN HOLDINGS CORP. f/k/a Olivia, Inc. , a Delaware corporation (“ BHC ”), SERENA B. POTASH (the “ BCH Principal Shareholder ”); and BIO-EN CORP. , a Delaware corporation (“ Bio-En ”). Each of BHC, BCH Principal Shareholder, and Bio-En is sometimes referred to herein as a “ Party ,” and together they are sometimes referred to herein as the “ Parties .”

 

WITNESSETH:

 

WHEREAS , the respective Boards of Directors of BHC and Bio-En have determined that it is advisable and in the best interests of the respective corporations and their shareholders to be merged (the “ Merger ”); and

 

WHEREAS , pursuant to the Merger and, in connection therewith, each issued and outstanding share of common stock, par value $0.0001 per share, of Bio-En (“ Bio-En Common Stock ” or “ Bio-En Shares ”), will be converted into one share of BHC common stock, $0.0001 par value per share (“ BHC Common Stock ” or “ BHC Shares ”), in accordance with the provisions of Article II of this Agreement; and

 

WHEREAS , for federal income tax purposes, the Merger is intended to qualify as a tax-free reorganization under the provisions of Section 368 of the United States Internal Revenue Code of 1986, as amended (the “ Code ”); and

 

WHEREAS , BHC and Bio-En desire to make certain representations, warranties, covenants and agreements in connection with the Merger and also to prescribe certain conditions to the Merger; and

 

WHEREAS , the respective Boards of Directors of each of BHC and Bio-En have approved this Agreement and the merger on the terms and conditions contained in this Agreement;

 

WHEREAS , simultaneously, the BHC Principal Shareholder owning an aggregate of 7,894,625 shares of BHC’s common stock agrees to cancel 6,024,625 of its shares pursuant to a cancellation agreement dated of the date of this Agreement, in substantially the form attached hereto as Exhibit A (the “ Cancellation Agreement ”).

 

NOW, THEREFORE , in consideration of the foregoing and the mutual covenants and agreements contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged and accepted, the Parties, intending to be legally bound hereby, hereby agree as follows:

 

 
 

 

ARTICLE I

THE MERGER

 

Section 1.1             Cancellation and Merger. At the ‘Effective Time,’ as hereinafter defined, subject to the terms and on the conditions of this Agreement, Bio-En shall be merged with and into BHC, with BHC to continue as the surviving corporation (the “ Surviving Corporation ”) in the Merger, and BHC succeeding to and assuming all the rights, assets, liabilities, debts, and obligations of Bio-En in accordance with the Delaware General Corporation Law (the “ DGCL ”). Simultaneously, at the Effective Time, the BHC Principal Shareholder owning an aggregate of 7,894,625 shares of the BHC’s common stock shall cancel 6,024,625 of its shares pursuant to the Cancellation Agreement.

 

Section 1.2             The Closing: Effective Time. The consummation of the Merger shall be effected as promptly as practicable, but in no event more than three business days after the satisfaction or waiver of the conditions set forth in Article VII of this Agreement, and the parties hereto will cause a copy of the Certificate of Merger, to be properly completed consistent with the terms hereof (the “ Certificate of Merger ”), and to be executed, delivered and filed with the Secretary of State of the State of Delaware (the “ Closing Date ”). The Merger shall become effective immediately upon the filing of such Certificate of Merger with the Delaware Secretary of State in substantially the form attached hereto as Exhibit B. The date and time on which the Merger shall become effective is referred to herein as the “ Effective Time ” or “ Effective Date ”.

 

Section 1.3           Subsequent Actions . If, at any time after the Effective Time, the Surviving Corporation shall consider or be advised that any deeds, bills of sale, assignments, assurances or any other actions or things are necessary or desirable to vest, perfect or confirm the Surviving Corporation’s right, title or interest in, to or under any of the rights, properties, privileges, franchises or assets of either of its constituent corporations acquired or to be acquired by the Surviving Corporation as a result of, or in connection with the Merger, or otherwise to carry out the intent of this Agreement, the officers and directors of the Surviving Corporation shall be authorized to execute and deliver, in the name and on behalf of the Surviving Corporation, all such deeds, bills of sale, assignments and assurances and to take and do in the name and on behalf of each such corporation, all such other actions and things as may be necessary or desirable to vest, perfect or confirm any and all right, title and interest in, to and under such rights, properties, privileges, franchises or assets in the Surviving Corporation or otherwise to carry out the intent of this Agreement.

 

Section 1.4             Surviving Corporation; Articles of Incorporation; By-Laws; Officers; and Directors . Unless otherwise agreed to by BHC and Bio-En prior to the Closing, at the Effective Time:

(a) the Articles of Incorporation of BHC as in effect immediately prior to the Effective Time with such changes as shall be acceptable to Bio-En shall be, at and after the Effective Time, the Articles of Incorporation of the Surviving Corporation (the “ Articles of Incorporation ”) until further altered, amended or repealed in accordance with the Articles of Incorporation or applicable law;

(b) the by-laws of BHC as in effect immediately prior to the Effective Time with such changes as shall be acceptable to Bio-En shall be, at and after the Effective Time, the by-laws of the Surviving Corporation until further altered, amended or repealed in accordance with the Articles of Incorporation, such by-laws or applicable law; and

(c) the officers and directors of the Surviving Corporation from and after the Effective Time shall be the officers and directors of BHC immediately prior to the Effective Time.

 

BHC/Bio-En - Merger Agreement – Execution Copy 2
 

 

ARTICLE II

CAPITAL STOCK

 

Section 2.1             Treatment of Capital Stock . The manner and basis of converting shares of Bio-En Common Stock by virtue of the Merger and without any action on the part of Bio-En and BHC or any holder thereof, shall be as set forth in this Article II.

 

Section 2.2             Conversion of Bio-En Common Stock .

(a) At the Effective Time, each share of Bio-En Common Stock issued and outstanding immediately prior to the Effective Time, the same as delineated on the attached Schedule 2.2, and all rights in respect thereof, shall forthwith cease to exist and shall be converted into the right to receive one share of validly issued, fully paid and non-assessable shares of BHC Common Stock (the “ Issuable Shares ”). Each holder of a certificate representing any such shares of Bio-En Common Stock shall, to the extent such certificate represents such shares, cease to have any rights with respect to such shares, except the right to receive the Issuable Shares allocable to the shares represented by such certificate upon surrender of such certificate in accordance with Section 2.3. Such Issuable Shares shall be held in escrow by BHC until the Closing Date (defined below) pending the completion of all conditions of closing set forth in Article V;

(b) Except as otherwise provided herein, commencing immediately after the Effective Time, each certificate (a “ Certificate ”) which, immediately prior to the Effective Time, represents issued and outstanding shares of Bio-En Common Stock, shall evidence the right to receive shares of BHC Common Stock on the basis set forth in Section 2.2(a). No fractional shares shall be issued and all fractional shares shall be rounded up to the next whole share.

 

Section 2.3               Exchange Procedures. If applicable, as soon as reasonably practicable after the Effective Time, BHC shall implement a process to mail to each record holder a certificate representing shares of BHC Common Stock as provided in this Article II.

 

Section 2.4             Transfer Books . The stock transfer books of Bio-En shall be closed at the Effective Time and no transfer of any Bio-En Shares will thereafter be recorded on any of such stock transfer books.

 

Section 2.5            Restricted Securities . The parties acknowledge and agree that there is only a limited market through the facilities of the National Quotation Bureau for the BHC Common Stock, that the offers and issuance of shares of BHC Common Stock under this Agreement has not been and will not be registered under the Securities Act of 1933, as amended (the " Securities Act ") or any state securities laws and that such offer and issuance are being made in reliance upon exemptions from the registration all shares of BHC Common Stock issued in connection with the Merger will be "restricted securities," as that term is defined in Rule 144 promulgated under the Securities Act, and all certificates representing shares of BHC Common Stock will bear the following legend or other legend substantially similar:

 

“THESE SECUTRITIES REPRESENTED BY THIS INSTRUMENT OR DOCUMENT HAVE BEEN ACQUIRED FOR INVESTMENT, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED (THE “ACT”), HAVE BEEN OFFERED AND SOLD IN RELIANCE UPON THE EXEMPTION SET FORTH IN SECTION 4(2) OF THE ACT AND UPON REGULATION D PROMULGATED THEREUNDER AND HAVE BEEN SOLD AS “RESTRICTED SECURITIES” AS SUCH ARE DEFINED UNDER THE ACT. WITHOUT SUCH REGISTRATION, SUCH SECURITIES MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF, EXCEPT UPON DELIVERY TO THE CORPORATION ON THE OPINION OF COUNSEL SATISFACTORY TO THE CORPORATION TO THE EFFECT THAT ANY SUCH TRANSFER WOULD NOT BE IN VIOLATION OF THE ACT, APPLICABLE STATE SECURITIES LAWS OR ANY RULE OR REGULATION PROMULGATED THEREUNDER.”

 

BHC/Bio-En - Merger Agreement – Execution Copy 3
 

 

ARTICLE III

REPRESENTATIONS AND WARRANTIES OF BHC

 

BHC hereby represents and warrants, as of the date hereof and as of the Closing Date, to Bio-En as follows:

 

Section 3.1             Organization and Standing of BHC . BHC is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has the corporate power to carry on its business as now conducted and to own its assets and is duly qualified to transact business as a foreign corporation in each state where such qualification is necessary. BHC has no Subsidiaries and no interest in any other corporation, partnership, joint venture or other entity.

 

Section 3.2             Capitalization . The authorized capital stock of BHC consists of 300,000,000 shares of capital stock, consisting of 250,000,000 shares of common stock, par value $0.0001 per share, and 50,000,000 shares of preferred stock, par value $0.0001. As of the Effective Date , there are 9,394,609 shares of common stock and no shares of preferred stock issued and outstanding. All issued and outstanding shares of common stock are duly authorized, validly issued, fully paid, and non-assessable, and were not issued in violation of any “Laws”, as hereinafter defined, or the pre-emptive rights of any Person. The BHC Shares to be issued pursuant to this Agreement when issued in accordance with the terms of this Agreement, will be duly authorized, validly issued, fully paid and non-assessable, and will not be issued in violation of any Laws or the pre-emptive rights of any Person. There are no outstanding rights, subscriptions, warrants, puts, calls, unsatisfied preemptive rights, options or other agreements (including shareholder agreements), of any kind relating to shares of BHC Common Stock, or any other security of BHC and there are no authorized or outstanding securities convertible into or exchangeable for any such BHC Common Stock or other security of BHC.

 

Section 3.3             Non-Reporting Company . BHC is not a reporting company under the rules and regulations of the Securities Exchange Act of 1934, as amended (the " Exchange Act ").

 

Section 3.4             Authorization: Validity . BHC has the necessary corporate power to execute and deliver this Agreement, to perform its obligations hereunder and to consummate the transactions contemplated hereby. The execution and delivery by BHC of this Agreement, the performance by BHC of its obligations hereunder and the consummation by BHC of the transactions contemplated hereby have been duly authorized by all necessary corporate action on the part of BHC. This Agreement has been duly executed and delivered by BHC constitutes a valid and binding obligation of BHC enforceable against each in accordance with the terms hereof, subject to the “Enforceability Exceptions”, as hereinafter defined.

 

BHC/Bio-En - Merger Agreement – Execution Copy 4
 

 

Section 3.5             No Conflict: Required Filings and Consents . (a) The execution and delivery by BHC of this Agreement does not, and the performance by BHC of its respective obligations hereunder and the consummation by BHC of the transactions contemplated hereby, will not: (i) violate or conflict with the certificate of incorporation or by-laws of BHC; (ii) subject to obtaining or making the notices, reports, filings, waivers, consents, approvals or authorizations referred to in Section 3.5(b), conflict with or violate any law, regulation, court order, judgment or decree applicable to BHC or any of its ‘Subsidiaries’, as hereinafter defined, or by which any of their respective assets or property is bound or subject; and/or (iii) result in any breach of or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, cancellation, vesting, modification, alteration or acceleration of any obligation under, or result in the creation of a lien, claim or encumbrance on any of the properties or assets of BHC pursuant to, or result in the loss of any benefit under (including an increase in the price paid by, or cost to, BHC), or require the consent of any other party to, or result in any obligation on the part of BHC to repurchase (with respect to a bond or a note), any agreement, contract, instrument, bond, note, indenture, permit, license or franchise to which BHC is a party or by which BHC, any of its Subsidiaries or any of their respective assets or properties are bound or subject.

(b) BHC is not required to submit any notice, report or other filing with any governmental entity in connection with the execution, delivery, performance or consummation of this Agreement or the Merger. Except as set forth in the immediately preceding sentence, no waiver, consent, approval or authorization of any governmental entity is required to be obtained by BHC in connection with the execution, delivery, performance or consummation by it of this Agreement or any agreement or instrument or other document contemplated hereby or the transactions contemplated hereby or thereby.

 

Section 3.6             Full Disclosure . None of representations and warranties made by BHC contains any untrue statement of a material fact, or omits any material fact the omission of which would be misleading under the circumstances by which it was made.

 

Section 3.7             Contract and Leases; Liabilities; Properties; Employees . Except as previously disclosed, BHC (i) has no assets; (ii) conducts no business; (iii) is not a party to any contract, agreement or lease; (iv) has no liabilities (absolute, accrued, contingent or otherwise); or (v) owns no property (real, personal or otherwise). No Person holds a power of attorney from BHC.

 

Section 3.8              Compliance with Laws. To the best of its knowledge, BHC has substantially complied with, and is not in material violation of any federal, state, or local statute, law, rule and/or regulation.

 

Section 3.9             Litigation. BHC is not a party to any suit, action, arbitration, or legal, administrative, or other proceeding, or pending governmental investigation. To the best knowledge of BHC, there is no basis for any such action or proceeding and no such action or proceeding is threatened against BHC. BHC is not subject to or in default with respect to any order, writ, injunction, or decree of any federal, state, local, or foreign court, department, agency or instrumentality.

 

BHC/Bio-En - Merger Agreement – Execution Copy 5
 

 

Section 3.10             Delivery of Documents; Corporate Records . Bio-En has heretofore received true, correct and complete copies of all documents, instruments, agreements and records referred to in Article 3 of this Agreement and copies of the minute and stock record books of BHC. The minute and stock record books of BHC, in all material respects, contain true, correct and complete copies of the records of all meetings and consents in lieu of meetings of BHC’s Board of Directors (and all committees thereof) and the shareholders since date of incorporation.

 

Section 3.11             Validity of Documents. All minutes, consents or other documents pertaining to BHC to be delivered at or prior to closing shall be valid and in accordance with the applicable state law.

 

Section 3.12             Title to Shares. Except to any transferability restriction as required as under this Agreement and/or imposed under applicable securities laws, the BHC Shares to be issued pursuant to this Agreement will be, at closing, free and clear of all liens, security interests, pledges, charges, claims, encumbrances and restrictions of any kind.

 

Section 3.13             Board Action: Required Vote .

(a) BHC’s Board of Directors has unanimously adopted (and not withdrawn) a resolution approving this Agreement, and the transactions contemplated hereby.

(b)          The votes taken by BHC referred to in paragraph (a) are the only votes required by holders of any class or series of BHC capital stock required to approve this Agreement and the transactions contemplated hereby.

 

Section 3.14             Brokers. There is no broker, finder or investment banker or other Person entitled to any brokerage, finder’s, investment banking or other similar fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of BHC.

 

Section 3.15             Taxes . (a) All Tax Returns, as hereinafter defined, required to be filed by BHC on or prior to the Effective Time or with respect to taxable periods ending on or prior to the Effective Time have been or will be prepared in good faith and timely filed with the appropriate Governmental Entity on or prior to the Effective Time or by the due date thereof including extensions.

(b)          All “Taxes”, as hereinafter defined, that are required to be paid have been or will be fully paid.

(c)          BHC has not waived any statute of limitations with respect to federal and state income Taxes or agreed to any extension of time with respect to federal income or state Tax assessment or deficiency.

(d)          As of the date hereof, there are not pending or, to the knowledge of BHC, threatened any audits, examinations, investigations or other proceedings in respect of matters of Tax that (i) were raised by any taxing authority in a written communication to BHC or any thereof; and (ii) would, if determined adversely to BHC, individually or in the aggregate, reasonably be expected to have an BHC Material Adverse Effect.

(e)          BHC has made available to Bio-En true and correct copies of the United States federal income and all material state income or franchise Tax Returns filed by BHC and its Subsidiaries for each of its fiscal years ended 2011, 2012 and 2013.

 

Section 3.16             No Other Agreements to Sell . BHC has no obligation, absolute or contingent, legally binding or otherwise to any other ‘Person’, as hereinafter defined, to sell any portion of its assets, to sell any portion of its capital stock or other ownership interests or to effect any merger, consolidation or other reorganization of itself or to enter into any agreement with respect thereto.

 

BHC/Bio-En - Merger Agreement – Execution Copy 6
 

 

Section 3.18             BHC Shareholders . BHC has delivered to Bio-En a shareholder list prepared by its transfer agent, which, to BHC’s knowledge, is a complete and accurate undated list setting forth the following information with respect to each Person who is a record holder of any BHC Shares: (a) such Person’s name; and (b) the number of BHC Shares held by such Person.

 

Section 3.19             Government Consent . No consent, waiver, approval, order or authorization of, or registration, declaration or filing with, any court, administrative agency or commission or other federal, state, county, local or other foreign governmental authority, instrumentality, agency or commission or any third party, including a party to any agreement with BHC, is required by or with respect to BHC in connection with the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby, except for (i) such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable securities laws thereby, and (ii) the filing of the Certificate of Merger with the Secretary of State of the State of Delaware.

 

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF BIO-EN

 

Bio-En hereby represents and warrants, as of the date hereof and as of the Closing Date, to BHC as follows:

 

Section 4.1             Organization . Bio-En is a corporation or other business entity duly organized, validly existing and in good standing under the laws of its jurisdiction of incorporation or organization, with all requisite corporate or other organizational power to own, operate or lease its properties and to carry on its business as it is now being conducted, and is duly qualified and in good standing as a foreign corporation authorized to do business in each jurisdiction where the character of its properties owned, operated or leased or the nature of its business or activities makes such qualification necessary, in each case, except as would not, individually or in the aggregate, reasonably be expected to have a ‘Bio-En Material Adverse Effect’, as hereinafter defined.

 

Section 4.2             Authorization: Validity . The Board of Directors of Bio-En has determined that the Merger is advisable and in the best interests of the stockholders of Bio-En and, shall recommend that Bio-En’s stockholders vote to approve and adopt this Agreement. Bio-En has the necessary corporate power to execute and deliver this Agreement and to perform its obligations hereunder and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement by Bio-En, the performance by Bio-En of its obligations hereunder and the consummation by Bio-En of the transactions contemplated hereby, have been duly authorized by all necessary corporate action on the part of Bio-En. This Agreement has been duly executed and delivered by Bio-En and, assuming the due authorization, execution and delivery by BHC hereof, constitutes a valid and binding obligation of Bio-En enforceable against it in accordance with the terms hereof, subject to the Enforceability Exceptions.

 

BHC/Bio-En - Merger Agreement – Execution Copy 7
 

 

Section 4.3             Capitalization . The authorized capital stock of Bio-En consists of 200,000,000 shares of common stock, par value $0.0001. As of the Effective Date , there are 30,600,000 shares of common issued and outstanding. All issued and outstanding shares of common stock are duly authorized, validly issued, fully paid, and non-assessable, and were not issued in violation of any Law, or the pre-emptive rights of any Person. There are no outstanding rights, subscriptions, warrants, puts, calls, unsatisfied preemptive rights, options or other agreements (including shareholder agreements), of any kind relating to shares of Bio-En Common Stock, or any other security of Bio-En and there are no authorized or outstanding securities convertible into or exchangeable for any such Bio En Common Stock or other security of Bio-En.

 

Section 4.4             No Conflict: Required Filings and Consents . (a) The execution and delivery by Bio-En of this Agreement does not, and the performance by Bio-En of its obligations hereunder and the consummation by Bio-En of the transactions contemplated hereby will not: (i) subject to the adoption of this Agreement by Bio-En’s stockholders, violate or conflict with the Articles of Incorporation or by-laws of Bio-En; (ii) subject to obtaining or making the notices, reports, filings, waivers, consents, approvals or authorizations referred to in Section 4.4(b) below, conflict with or violate any law, regulation, court order, judgment or decree applicable to Bio-En or by which any of its assets or property is bound or subject; (iii) result in any breach of or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, cancellation, vesting, modification, alteration or acceleration of any obligation under, or result in the creation of a lien, claim or encumbrance on any of the properties or assets of Bio-En pursuant to, or result in the loss of any benefit under (including an increase in the price paid by, or cost to, Bio-En), or require the consent of any other party to, or result in any obligation on the part of Bio-En to repurchase (with respect to a bond or a note), any agreement, contract, instrument, bond, note, indenture, permit, license or franchise to which Bio-En is a party or by which Bio-En or any of its respective assets or properties are bound or subject.

 

Section 4.5             Full Disclosure . None of representations and warranties made by Bio-En contains any untrue statement of a material fact, or omits any material fact the omission of which would be misleading under the circumstances by which it was made.

 

Section 4.6             Brokers . There is no broker, finder or investment banker or other Person entitled to any brokerage, finder’s, investment banking or other similar fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Bio-En.

 

Section 4.7             Compliance With Law . Bio-En materially complies with material Laws applicable to it.

 

Section 4.8             Litigation . Bio-En is not a party to any suit, action, arbitration, or legal, administrative, or other proceeding, or pending governmental investigation. To the best knowledge of Bio-En, there is no basis for any such action or proceeding and no such action or proceeding is threatened against Bio-En. Bio-En is not subject to or in default with respect to any order, writ, injunction, or decree of any federal, state, local, or foreign court, department, agency or instrumentality.

 

Section 4.9              Bio-En Shareholders . Bio-En on or before the Effective Date shall deliver to BHC a complete and accurate list setting forth the following information with respect to each Person who is a holder of any Bio-En Shares: (a) such Person’s name; and (b) the number of Bio-En Shares held by such Person

 

BHC/Bio-En - Merger Agreement – Execution Copy 8
 

 

Section 4.10    Government Consent . No consent, waiver, approval, order or authorization of, or registration, declaration or filing with, any court, administrative agency or commission or other federal, state, county, local or other foreign governmental authority, instrumentality, agency or commission or any third party, including a party to any agreement with Bio-En, is required by or with respect to Bio-En in connection with the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby, except for (i) such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable securities laws thereby, and (ii) the filing of the Certificate of Merger with the Secretary of State of the State of Delaware.

 

Section 4.11    Restrictions on Business Activities . There is no agreement (non-compete or otherwise), commitment, judgment, injunction, order or decree to which Bio-En is a party or otherwise binding upon Bio-En which has or may have the effect of prohibiting or impairing any business practice of Bio-En, any acquisition of property (tangible or intangible) by Bio-En or the conduct of business by Bio-En. Without limiting the foregoing, Bio-En has not entered into any agreement under which Bio-En is restricted from selling, licensing or otherwise distributing any of its technology or products to or providing services to, customers or potential customers or any class of customers, in any geographic area, during any period of time or in any segment of the market.

 

Section 4.12   No Undisclosed Liabilities . Except as previously disclosed, there are no liabilities or debts of Bio-En of any kind whatsoever, whether accrued, contingent, absolute, determined, determinable or otherwise, and there is no existing condition, situation or set of circumstances which could reasonably be expected to result in such a liability or debt.

 

Section 4.13   Material Contracts . Except as a previously disclosed, Bio-En’s Material Contracts are enforceable in accordance with their respective terms, and to the knowledge of Bio-En, Bio-En is not in violation of, and has received no notice of being in violation of such Material Contracts.

 

Section 4.14.  Taxes. (a) All Tax Returns required to be filed by Bio-En on or prior to the Effective Time or with respect to taxable periods ending on or prior to the Effective Time have been or will be prepared in good faith and timely filed with the appropriate Governmental Entity on or prior to the Effective Time or by the due date thereof including extensions.

(b)          All “Taxes”, as hereinafter defined, that are required to be paid have been or will be fully paid.

(c)          Bio-En has not waived any statute of limitations with respect to federal and state income Taxes or agreed to any extension of time with respect to federal income or state Tax assessment or deficiency.

(d)          As of the date hereof, there are not pending or, to the knowledge of BHC, threatened any audits, examinations, investigations or other proceedings in respect of matters of Tax that (i) were raised by any taxing authority in a written communication to Bio-En or any thereof; and (ii) would, if determined adversely to BHC, individually or in the aggregate, reasonably be expected to have an Bio-En Material Adverse Effect.

(e)          Bio-En has made available to BHC true and correct copies of the United States federal income and all material state income or franchise Tax Returns filed by Bio-En and its Subsidiaries for each of its fiscal year ended 2013.

 

BHC/Bio-En - Merger Agreement – Execution Copy 9
 

 

ARTICLE V

CONDITIONS TO CLOSING

 

Section 5.1    Financial Statements . This Agreement shall become effective as of such date and time as when BHC shall have received copies of (i) audited financial statements for Bio-En for its most recently ended fiscal year, or such shorter period if agreed by the parties, and (ii) unaudited quarterly financial statements for Bio-En for the quarter ended following the completion of its most recent fiscal year, the same to be included with BHC's expected Current Report Form 8-K to be filed with the Securities and Exchange Commission. .

 

ARTICLE VI

CONDUCT PENDING THE MERGER

 

Section 6.1    Stockholder Approval . Bio-En and BHC shall seek to secure from their stockholders approval pursuant to the written consent of the holders of such number of shares as may be permitted for the approval of a transaction of the type provided for herein, and shall further promptly comply with such notice requirements to the remaining shareholders.

 

Section 6.2     Operations of BHC . (a) BHC covenants for itself that, after the date hereof and prior to the Effective Time (unless Bio-En shall otherwise approve in writing or required by applicable law) BHC shall not:

(i) conduct any business;

(ii) (A) except as previously disclosed, amend its certificate of incorporation or by-laws, or adopt any stockholders’ rights plan or enter into any agreement with any of its stockholders in their capacity as such, (B) split, combine, subdivide or reclassify its outstanding shares of its capital, (C) declare, set aside, make or pay any dividend or distribution payable in cash, stock or property in respect of any of its capital stock, or, (D) repurchase, redeem or otherwise acquire to purchase, redeem or otherwise acquire, any shares of its capital stock;

(iii) take or fail to take any action that would (A) prevent the Merger from qualifying as a “reorganization” within the meaning of Section 368 of the Code, or (B) cause any of its representations and warranties herein to become inaccurate or misleading in any material respect;

(iv) except as expressly contemplated by this Agreement issue, deliver, sell or encumber shares of any class of its capital stock or any securities convertible into, or any rights, warrants or options to acquire, any such shares;

(v) acquire or make any investment in any business or other Person, whether by merger, consolidation, purchase of property or assets or otherwise; and/or,

(vi) enter into any commitments or agreements to do any business or other Person, whether by merger, consolidation, purchase of property or assets or otherwise;

(b) From the date hereof through the Closing Date, BHC shall promptly notify Bio-En of any investigations of which BHC has knowledge or any claims which, after the date hereof, are commenced or threatened against BHC, thereof or any of the properties or assets of BHC, or any officer, director or employee of BHC arising out of or relating to the affairs or conduct of the business of BHC.

(c) Bio-En and its employees, independent accountants, attorneys, agents and authorized representatives shall have reasonable opportunity and access during normal business hours to the plants, properties, documents, files, books and records of BHC, and shall be provided with such information as to the business, properties and assets of BHC as Bio-En may from time to time reasonably request to update Bio-En with respect to events occurring after the date hereof.

 

BHC/Bio-En - Merger Agreement – Execution Copy 10
 

 

ARTICLE VII

ADDITIONAL AGREEMENTS

 

Section 7.1             Publicity . No Party shall issue any press release or otherwise make any public statements with respect to the Merger without the prior consent of the other Party.

 

Section 7.2             Further Actions . Each of the Parties shall, subject to the fulfillment at or before the Effective Time of each of the conditions of performance set forth herein or the waiver thereof, use its reasonable best efforts: (a) to perform such further acts and execute such documents as may be reasonably required to: (i) effect the transactions contemplated hereby, (ii) obtain in a timely manner all necessary waivers, consents and approvals, and (iii) effect all necessary registrations and filings; and, (b) to take, or cause to be taken, all other actions and to do, or cause to be done, all other things necessary, proper or advisable to consummate and make effective as promptly as practicable the Merger.

 

Section 7.3             Expenses . Whether or not the Merger is consummated, all costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby, shall be paid by the Party incurring such expenses.

 

Section 7.4             Notification of Certain Matters . Each Party shall give prompt notice to the other Party(ies) of the following:

  (a) the occurrence or nonoccurrence of any event whose occurrence or non-occurrence is reasonably expected to cause not to be satisfied any of the conditions precedent set forth in Article VII; and,

  (b) the status of matters relating to the completion of the Merger, including promptly furnishing the other Party with copies of notices or other communications received by such notifying Party from any third party and/or Governmental Entity with respect to this Agreement or the transactions contemplated hereby, including the Merger.

 

Section 7.5             Review of Information . Subject to applicable laws relating to the exchange of information, each Party shall have the right to review in advance, and to the extent practicable, each will consult with the other about all information relating to that appears in any filing made with, or written materials submitted to, any third party and/or any Governmental Entity in connection with the Merger. In exercising the foregoing right, each of the Parties shall act reasonably and as promptly as practicable.

 

Section 7.6             Indemnification . From and after the Effective Time, BHC shall, or shall cause the Surviving Corporation to, defend, indemnify and hold harmless each present and former director and officer of Bio-En (to the extent such Person is or was acting in such capacity) (the “ Indemnified Parties ”), against any costs or expenses (including reasonable attorneys’ fees), judgments, fines, losses, claims, damages or liabilities incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, for acts or omissions existing or occurring at or prior to the Effective Time, whether asserted or claimed prior to, at or after the Effective Time, to the fullest extent permitted under applicable law. The provisions of this Section 6.6 are intended to be for the benefit of, and shall be enforceable by, each of the Indemnified Parties, their heirs and their representatives.

 

BHC/Bio-En - Merger Agreement – Execution Copy 11
 

 

Section 7.7             Tax-Free Reorganization . Each of the Parties will use its reasonable best efforts to cause the Merger to qualify as a tax-free “reorganization” under Section 368 of the Code.

 

Section 7.9             Regulation D . From and after the Effective Time, BHC shall comply with the requirements of Regulation D under the Securities Act and state securities laws.

  

ARTICLE VIII

CONDITIONS TO THE MERGER

 

Section 8.1           Conditions to the Obligations of the Parties to Consummate the Merger . The respective obligation of each Party to consummate the Merger shall be subject to the satisfaction of each of the following conditions:

(a)          No order, decree or injunction shall have been entered or issued by any Governmental Entity which shall be in effect and shall have the effect of making the Merger illegal or otherwise prohibiting consummation of the Merger. Each Party agrees that, in the event that any such order, decree or injunction shall be entered or issued, it shall use its reasonable best efforts to cause the same to be lifted or vacated.

 

Section 8.2           Additional Conditions to the Obligations of BHC . The obligations of BHC to consummate the Merger shall also be subject to the satisfaction or waiver of each of the following conditions:

(a) Representations and Warranties . The representations and warranties of Bio-En contained in this Agreement (without giving effect in any such representation or warranty to any materiality or the Bio-En Material Adverse Effect standard, qualification or exception contained therein) shall be true at and as of the Closing Date with the same effect as though made at and as of such time (except for representations and warranties which speak as of a different date, which shall be true as of such date).

(b) Agreements and Covenants . Bio-En shall have performed or complied in all material respects with all agreements and covenants required by this Agreement to be performed or complied with by it on or before the Effective Time.

(c) Consents . Bio-En shall have obtained all consents, approvals, releases or authorizations from, and Bio-En shall have made all filings and registrations to or with, any Person, including without limitation any Governmental Entity, necessary to be obtained or made by Bio-En in order for Bio-En to consummate the Merger, unless the failure to obtain any of such consents, approvals, releases or authorizations or make any such filings or registrations would not, individually or in the aggregate, reasonably be expected to have a Bio-En Material Adverse Effect.

(d) No Material Adverse Change . Since the date of this Agreement, no change or circumstance resulting in a Bio-E Material Adverse Effect shall have occurred.

(e) Stockholder Adoption/Approval . The requisite holders of the stock of Bio-En shall have voted to adopt this Agreement in accordance and such adoption shall have been certified by the Secretary or Assistant Secretary of Bio-En.

(f) Certificate of Good Standing. Bio-En shall have delivered to BHC a certificate as to the good standing of Bio-En in the State of Delaware certified by the Secretary of State of the State of Delaware on or within 20 calendar days of the Closing Date.

 

BHC/Bio-En - Merger Agreement – Execution Copy 12
 

 

Section 8.3            Additional Conditions to the Obligations of Bio-En . The obligations of Bio-En to consummate the Merger shall also be subject to the satisfaction or waiver of each of the following conditions:

(a) Representations and Warranties . The representations and warranties of BHC contained in this Agreement shall be true at and as of the Closing Date with the same effect as though made at and as of such time.

(b) Agreements and Covenants . BHC shall have performed or complied in all material respects with all agreements and covenants required by this Agreement to be performed or complied with by it on or before the Closing Date.

(c) Consents . BHC shall have obtained all consents, approvals, releases or authorizations from, and BHC shall have made all filings and registrations to or with, any Person, including without limitation any Governmental Entity, necessary to be obtained or made by BHC in order for BHC to consummate the Merger, unless the failure to obtain any such consents, approvals, releases or authorizations or make any such filings or registrations would not, individually or in the aggregate, be reasonably expected to have a BHC Material Adverse Effect.

(d) No Material Adverse Change . Since the date of this Agreement, no change or circumstance resulting in BHC Material Adverse Effect shall have occurred.

(e) Certificate of Good Standing. BHC shall have delivered to Bio-En a certificate as to the good standing of BHC in the State of Delaware certified by the Secretary of State of the State of Delaware on or within 20 calendar days of the Closing Date.

 

ARTICLE IX

TERMINATION AND AMENDMENT

 

Section 9.1           Termination . This Agreement may be terminated at any time before the Effective Time (except as otherwise provided) as follows:

(a) by mutual written consent of the Parties;

(b) by either Party, if the Effective Time shall not have occurred on or before August 31, 2014 (the “ Termination Date ”); provided, however , that the right to terminate this Agreement under this Section 8.1(b) shall not be available to any Party whose failure to fulfill any obligation under this Agreement has been the cause of, or resulted in, the failure of the Effective Time to occur on or before the Termination Date:

(c) by either Party, if a Governmental Entity shall have issued an order, decree or injunction having the effect of making the Merger illegal or permanently prohibiting the consummation of the Merger, and such order, decree or injunction shall have become final and non-appealable (but only if such Party shall have used its reasonable best efforts to cause such order, decree or injunction to be lifted or vacated); and

(d) by either Party, if (x) there shall have been a material breach by the other Party of any of its representations, warranties, covenants or agreements contained in this Agreement, which breach would result in the failure to satisfy one or more of the conditions set forth in Section 7.2(a) or (b) (in the case of a breach by Bio-En) or Section 7.3(a) or (b) (in the case of a breach by BHC), and (y) such breach shall be incapable of being cured or, if capable of being cured, shall not have been cured immediately upon the receipt by the Party alleged to be in breach of written notice thereof.

 

BHC/Bio-En - Merger Agreement – Execution Copy 13
 

 

Section 9.2             Effect of Termination and Abandonment . In the event of the termination of this Agreement pursuant to this Article VIII, this Agreement shall become void and of no effect with no liability on the part of any Party (or of any of its Representatives); provided, however , that (i) no such termination shall relieve any Party from any liability for damages resulting from any willful and intentional breach of this Agreement, and (ii) this Article VIII, Sections shall survive such termination.

 

Section 9.3               Amendment . This Agreement may be amended at any time before the Effective Time, but only pursuant to a writing executed and delivered by all Parties.

 

ARTICLE X

GENERAL PROVISIONS

 

Section 10.1             Survival of Representations, Warranties and Agreements . The representations, warranties, covenants and agreements shall survive the Effective Date.

 

Section 10.2             Notices . All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed to have been duly given or made as of the date of receipt and shall be delivered personally, mailed by registered or certified mail (postage prepaid, return receipt requested), sent by overnight courier, sent by email, or sent by telecopy, to the applicable Party at the following addresses or telecopy numbers (or at such other address or telecopy number for a Party as shall be specified by like notice):

 

  (a) if to BHC: Bio-En Holdings Corp. .
      c/o Szaferman Lakind Blumstein & Blader, PC
      101 Grovers Mill Road, Second Floor
      Lawrenceville, NJ 08648
      Fax: 609-557-0969;
      Email: gjaclin@szaferman.com
      Attn.:  Gregg Jaclin, Esq.
       
  (b) if to Bio-En: Bio-En, Corp.
      c/o Law Offices of Bruce W. Minsky, P.C.
      112 Brick Church Road
      New Hempstead, New York 10977
      Fax:  (702) 973-6607
      Email: bwminsky@gmail.com
      Attn.:  Bruce W. Minsky, Esq.

 

Section 10.3             Certain Definitions: Interpretation . (a) For purposes of this Agreement, the following terms shall have the following meanings:

 

Bio-en Material Adverse Effect ” means any material adverse change in or material adverse effect (x) on the business, results of operations, financial condition or prospects of Bio-En (or its successor), or (y) that will prevent or materially impair Bio-En’s ability to consummate the Merger.

 

BHC/Bio-En - Merger Agreement – Execution Copy 14
 

 

" BHC Material Adverse Effect ” means (x) a material change in liability or (y) that will prevent or materially impair BHC’s ability to consummate the Merger or the issuance by BHC of shares of BHC Common Stock in accordance with the terms hereof.

 

C(c)ontract shall mean any agreement, contract, license, indenture, lease, mortgage, license, plan, arrangement, commitment or instrument including any note or other debt instrument (whether written or oral).

 

C(c)onsents shall refer to the consents or approval of any third party including any governmental agency or registered securities association required in connection with the Merger.

 

Enforceability Exceptions shall mean the extent to which enforceability of an obligation may be limited by applicable bankruptcy, insolvency, re-organization or other similar laws affecting the enforcement of creditors’ rights generally and by principles of equity regarding the availability of remedies.

 

GAAP shall refer to generally accepted accounting principles as applicable in the United States.

 

Governmental Entity ” shall mean braches, departments and agencies (and subunits theref) of the federal, state and local government created by federal or state statutes, federal or state executive orders, or local ordinances or resolutions.

 

K(k)nowledge shall mean with respect to a party's awareness of the presence or absence of a fact, event or condition (a) actual knowledge plus, if different, (b) the knowledge that would be obtained if such party conducted itself faithfully and exercised a sound discretion in the management of his own affairs.

 

L(l)aws shall mean all laws, common laws, rules, regulations, ordinances, codes, judgments, injunctions, orders, decrees, permits, policies and other requirements of the United States and other jurisdictions to which a party, is subject, including all foreign and local governments and all agencies and instrumentalities thereof, including any administrative agencies or administrative body created by any such government.

 

L(l)iabilities” shall mean any indebtedness, liability, claim, loss, damage, deficiency, obligation or responsibility, fixed or unfixed, choate or inchoate, liquidated or unliquidated, secured or unsecured, accrued, absolute, contingent or otherwise, whether or not of a kind required by generally accepted accounting principles to be set forth on a financial statement including the notes thereto.

 

L(l)ien means any mortgage, pledge, lien, encumbrance, charge, adverse claim or restriction of any kind affecting title or resulting in an encumbrance against property, real or personal, tangible or intangible, or a security interest of any kind (including any conditional sale or other title retention agreement, any lease in the nature thereof, any third party option or other agreement to sell and any filing of or agreement to give, any financing statement under the Uniform Commercial Code (or equivalent statute) of any jurisdiction).

 

BHC/Bio-En - Merger Agreement – Execution Copy 15
 

 

P(p)erson(s) ” means an individual, corporation, partnership, joint venture, limited liability company, association, trust, unincorporated organization, entity or group (as defined in the Securities Exchange Act of 1934, as amended).

 

Subsidiary(ies) ” of a Person means any corporation or other legal entity (A) which is directly or indirectly owned or controlled by such Person (either alone or through or together with any other Subsidiary or Subsidiaries), and (B) of which such Person (either alone or through or together with any other Subsidiary or Subsidiaries) (x) is the general partner or managing entity or (y) controls, directly or indirectly, at least a majority of the stock or other equity interests which are generally entitled to be voted by the holders thereof for the election of the board of directors (or others performing similar functions of such corporation or other legal entity).

 

Taxes shall mean any income, alternative or add-on minimum, business, employment, franchise, occupancy, payroll, property, sales, transfer, use, value added, withholding or other tax, levy, impost, fee, imposition, assessment or similar charge together with any related addition to tax, interest, penalty or fine thereon.

 

Tax Returns ” means any and all reports, returns, declarations, claims for refund, elections, disclosures, estimates, information reports or returns or statements required to be supplied to a governmental authority in connection with Taxes, including any schedule or attachment thereto or amendment thereof.

 

(b)               When a reference is made in this Agreement to Articles, Sections, or Exhibits, such reference is to an Article or a Section of, or an Exhibit to, this Agreement, unless otherwise indicated. The table of contents and headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the words “ include ,” “ includes ” or “ including ” are used in this Agreement, they shall be understood to be followed by the words “ without limitation .”

 

Section 10.4             Headings . The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.

 

Section 10.5             Severability . If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any Party. Upon a determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to affect the original intent of the Parties as closely as possible such that the transactions contemplated hereby are fulfilled to the maximum extent possible.

 

Section 10.6             Entire Agreement: No Third-Party Beneficiaries . This Agreement, together with the Exhibits and Schedules, constitutes the entire agreement and supersedes any and all other prior agreements and undertakings, both written and oral, among the Parties, or any of them, with respect to the subject matter hereof and, except for Section 6.6 (Indemnification) does not, and is not intended to, confer upon any Person other than the parties hereto any rights of remedies hereunder.

 

BHC/Bio-En - Merger Agreement – Execution Copy 16
 

 

Section 10.7        Assignment . This Agreement shall not be assigned by any Party by operation of law or otherwise without the express written consent of each of the other Parties. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of and be enforceable by the parties and their respective permitted successors and assigns.

 

Section 10.8         Governing Law . (a) THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, INCLUDING LAWS RELATING TO THE VALIDITY, INTERPRETATION AND EFFECT OF THIS AGREEMENT, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW, EXCEPT TO THE EXTENT THAT THE LAWS OF THE STATE OF DELAWARE AND/OR THE STATE OF NEW YORK SHALL SPECIFICALLY AND MANDATORILY APPLY TO THE MERGER AND THE RIGHTS OF STOCKHOLDERS INCIDENTAL THERETO.

(b) EACH OF THE PARTIES HEREBY IRREVOCABLY AND UNCONDITIONALLY CONSENTS TO SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE COURTS OF THE STATES OF NEW YORK AND THE COURTS OF THE UNITED STATES OF AMERICA LOCATED IN THE STATE OF NEW YORK, SUCH EITHER IN THE COUNTY OF NEW YORK OR ROCKLAND, AND/OR THE SOUTHERN DISTRICT OF THE STATE OF NEW YORK, RESPECTIVELY, FOR ANY LITIGATION ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE MERGER OR ANY OF THE OTHER TRANSACTION CONTEMPLATED HEREBY. EACH PARTY AGREES NOT TO COMMENCE ANY LITIGATION RELATING HERETO EXCEPT IN SUCH COURTS REFERENCED ABOVE, AND FURTHER AGREES THAT SERVICE OF ANY PROCESS, SUMMONS, NOTICE OR DOCUMENT BY U.S. REGISTERED MAIL TO ITS RESPECTIVE ADDRESS SET FORTH IN SECTION 10.2 SHALL BE EFFECTIVE SERVICE OF PROCESS FOR ANY LITIGATION BROUGHT AGAINST IT IN ANY SUCH COURT. EACH OF THE PARTIES HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY OBJECTION TO THE LAYING OF VENUE IN THE ABOVE REFERENCED COURTS.

 

(c) EACH OF THE PARTIES HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY IN CONNECTION WITH ANY LITIGATION ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE MERGER OR ANY OF THE OTHER TRANSACTIONS CONTEMPLATED HEREBY.

 

Section 10.10      Counterparts . This Agreement may be executed in one or more counterparts, and by the different Parties in separate counterparts, each of which when executed shall be deemed to be an original, but all of which shall constitute one and the same agreement.

 

Section 10.11     Exclusivity . Except for the transactions contemplated by this Agreement, none of the Parties shall (i) solicit, initiate, or encourage the submission of any proposal or offer relating to the acquisition of any capital stock or other voting securities or any substantial portion of the assets of such or any other Party hereto (including any acquisition structured as a merger, consolidation, or share exchange) or (ii) participate in any discussions or negotiations regarding, furnish any information with respect to, assist or participate in, or facilitate in any other manner any effort or attempt by any Person to do or seek any of the foregoing. The Parties shall notify each other Party immediately if any Person makes any proposal, offer, inquiry, or contact with respect to any of the foregoing.

 

BHC/Bio-En - Merger Agreement – Execution Copy 17
 

 

Section 10.12   Bio-En Operations .

 

(a) Bio-En is pursuing the planning, design, along with being the intended builder/operator, of a certain facility using ‘Gravity Pressure Vessel Technology in Weak Acid Hydrolysis’ to convert biomass to ethanol (“ Facility ”), the Facility, being built on the Island of Malta, to combine technologies from the waste management industry and integrating the recycling of waste, control of carbon dioxide and other emissions, with the profitable production of fuel grade ethanol (the " Bio-En Business(es) ");

 

  (b) As part of the Business, Bio-En is the holder of a licensee from GeneSyst International, Inc. (“ GeneSyst ”), the licensing agreement/arrangement, dated March 23, 2013 (“ License Agreement ”), affording Bio-En a portfolio of patents including, but not limited to, several specialty Gravity Pressure Vessels and supporting appurtenances;

 

(c) As part of the transaction herein. BHC shall assume from Bio-En the following assets, which shall hereinafter collectively be designated the "Assets":

(i) the License Agreement; and,

 

(ii) Proprietary Rights - Any and all of the following used by Bio-En in connection with Bio-En’s Business, including:

(A) production operations and processes, trade secrets, know-how and confidential, information, customer lists and information;

 

(B) logos, trade dress (including, without limitation, configuration, design and packaging), goodwill, rights of publicity and privacy (including, without limitation, photographic and other releases, whether published or unpublished), marketing rights, and any similar rights, together with the goodwill of the Bio-En Business associated therewith and/or symbolized thereby;

 

(C) other intellectual property, intangible industrial property and proprietary rights, titles, interests and privileges, however designated, that are similar or analogous to any of the foregoing including, without limitation any and all rights in and to product configurations and designs, label, designs, graphic and artistic designs; artwork; dyes; character; rights; and UPC bar codes;

 

(D) registrations, applications, renewals, and extensions with respect to each of the foregoing now or hereafter in force, in whole and/or in part;

 

(E) rights of possession, ownership, use and enjoyment with respect to each of the foregoing, including, without limitation, the right to license, sublicense, assign, pledge sell, transfer, convey, grant, gift over, divide, partition or use (or not use) in any way any of the foregoing now or hereafter (including without limitation any claims, demands or causes of action of any kind with respect thereto);

 

(F) Bio-En’s customers, and their related information;

BHC/Bio-En - Merger Agreement – Execution Copy 18
 

 

(G) all books and records relating to the Assets; and

 

(H) claims, demands and causes of action of any kind with respect to, and any and all other rights relating to the enforcement of, any of the foregoing, including, without limitation, any claims, demands or causes of action for any infringement, conversion, misappropriation, dilution or other violation of or injury to any of them.

Each and all of the foregoing being hereinafter referred to collectively as the "Proprietary Rights." To the extent, if any, that any rights of Bio-En or of the author of any work encompassed by the Proprietary Rights cannot be legally transferred by Bio-En, they shall be waived in a signed writing providing for same.

 

(d) Bio-En shall execute and deliver to BHC such other documents as may be reasonably required by BHC to evidence BHC’s assumption of the Assets.

 

109.13                  Share Cancellation . On the Closing Date, BHC and the BHC Principal Shareholder, the current Chief Executive Officer of BHC and owner of 7,894,625 shares of BHC (“ Potash Shares ”), will execute the Cancellation Agreement, requiring the BHC Principal Shareholder, contemporaneous with the effectiveness of the closing of the transaction(s) herein, to cancel 6,024,625 of the Potash Shares, with Potash, subsequent the Closing Date, retaining 1,870,000 of the Potash Shares.

 

[SIGNATURE PAGE TO FOLLOW IMMEDIATELY]

 

BHC/Bio-En - Merger Agreement – Execution Copy 19
 

 

IN WITNESS WHEREOF , the Parties hereto have executed this instrument the date first above written.

 

  BIO-EN HOLDINGS CORP.  
       
  By: /s/ Serena B. Potash  
  Name: Serena B. Potash  
  Title: President  
       
  BIO-EN CORP.  
       
  By: /s/ Serena B. Potash  
  Name: Serena B. Potash  
  Title: President  
       
  By: /s/ Serena B. Potash  
  SERENA B. POTASH , Individually  

 

The rest of this page is left intentionally blank.

 

BHC/Bio-En - Merger Agreement – Execution Copy 20
 

 

SCHEDULES

 

Schedule 2.2                    Bio-En Common Stock Shareholders

 

BHC/Bio-En - Merger Agreement – Execution Copy 21
 

 

EXHIBIT A

 

CANCELLATION AGREEMENT

 

This CANCELLATION AGREEMENT (this “ Agreemen t”), dated August 21, 2014 ( the “ Effective Date ”), by and among, BIO-EN HOLDINGS CORP. (the “ Company ”) a Delaware corporation, and SERENA B. POTASH (the “ Canceling Party ”). Company and Cancelling Party are also hereinafter individually and jointly referred to as “ P(p)arty ” and/or “ P(p)arties ”.

 

RECITALS

 

WHEREAS , as of the date hereof, the Canceling Party is the owner of 7,894,625 shares of the Company’s commons stock, par value $0.0001 per share (“ Potash Shares ”); and

 

WHEREAS , concurrently herewith, Company and the Canceling Party are entering into an ‘Share Exchange/Merger Agreement’ (“ Exchange Agreement ”) with Bio-En Corp., a Delaware corporation (“ Bio-En ”), pursuant to which Company and the Canceling Party will cancel 6,024,625 shares of the Potash Shares (“ Subject Shares ”) in exchange for the consummation of the Exchange Agreement (“ Cancellation Payment ”); and

 

WHEREAS , after the cancellation of the Subject Shares, the Canceling Party will own 1,870,000 Potash Shares (“ Remaining Shares ”); and

 

WHEREAS , it is a condition precedent to the consummation of the Exchange Agreement that the Canceling Party will enter into this Agreement, which will effectuate the cancellation of the Subject Shares; and

 

WHEREAS , the Canceling Party is entering into this Agreement to, amongst other things, induce Bio-En to enter into the Exchange Agreement and the Canceling Party acknowledges that Bio-En would not consummate the transactions contemplated by the Exchange Agreement unless the transactions contemplated hereby are effectuated in accordance herewith.

 

AGREEMENT

 

In consideration of the mutual promises herein contained and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:

 

1.           Cancellation of Subject Shares . On the Effective Date, the Canceling Party will deliver to Company the necessary documentation for the cancellation of the stock certificates representing the Subject Shares, along with duly executed medallion guaranteed stock powers covering the Subject Shares (or such other documents acceptable to the Company’s transfer agent) and hereby irrevocably instructs the Company and the Company’s transfer agent to cancel the Subject Shares such that the Subject Shares will no longer be outstanding on the stock ledger of the Company and such that the Canceling Party shall no longer have any interest in the Subject Shares whatsoever. The Company shall immediately deliver to the Company’s transfer agent irrevocable instructions providing for the cancellation of the Subject Shares.

 

BHC/Bio-En - Merger Agreement – Execution Copy 22
 

 

2.         Effective Date . This Agreement shall become effective upon the execution of this Agreement. The transactions to occur at such place and time with respect to this Agreement are referred to herein as the “ Closing ”.

 

3.         Waiver . At and subsequent to the Closing, the Canceling Party hereby waives any and all rights and interests she has, had or may have with respect to the cancelled Subject Shares.

 

4.           Guaranty . To induce Bio-En to enter into the Exchange Agreement, the Canceling Party hereby absolutely, unconditionally and irrevocably guarantees to Bio-En and the Company that all obligations and liabilities have been satisfied in full and hereby agrees to be wholly responsible for any actual obligation of the Company that arises following the closing of the Exchange Agreement that was the result of an action or inaction of the Company prior to the closing of the Exchange Agreement.

 

5.           Representations by the Canceling Party . (a) The Canceling Party owns the Subject Shares of record and beneficially free and clear of all liens, claims, charges, security interests, and/or encumbrances of any kind whatsoever. The Canceling Party has sole control over the Subject Shares and/or sole discretionary authority over any account in which they are held. Except for this Agreement, no person/entity has any option or right to purchase or otherwise acquire the Subject Shares, whether by contract of sale or otherwise, nor is there a “short position” as to the Subject Shares.

 

(b) The Canceling Party has full right, power and authority to execute, deliver and perform this Agreement and to carry out the transactions contemplated hereby. This Agreement has been duly and validly executed and delivered by the Canceling Party and constitutes a valid, binding obligation of the Canceling Party, enforceable against it in accordance with its terms (except as such enforceability may be limited by laws affecting creditor's rights generally) .

 

(c) Canceling Party represents and warrants that it has the requisite authority and capacity to enter into this Agreement, as well as carry out the terms/conditions referenced herein. Additionally, Canceling Party represents and warrants that its compliance with the terms and conditions of this Agreement and will not violate any instrument relating to the conduct of its business, or any other agreement which it may be a party, or any Federal and State rules or regulations applicable to either Party.

 

6.         Further Assurances . Each Party to this Agreement will use its best efforts to take all action and to do all things necessary, proper, or advisable in order to consummate and make effective the transactions contemplated by this Agreement (including the execution and delivery of such other documents and agreements as may be necessary to effectuate the cancellation of the Subject Shares) .

 

7.         Entire Agreement; Amendments . This Agreement contains the entire understanding of the Parties with respect to the matters covered herein and therein and, except as specifically set forth herein, neither the Company nor the Canceling Party makes any representation, warranty, covenant or undertaking with respect to such matters. No amendment, modification, termination or waiver of any provision of this Agreement, and no consent to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by both Parties. Any such waiver or consent shall be effective only in the specific instance and for the specific purpose for which it was given.

 

BHC/Bio-En - Merger Agreement – Execution Copy 23
 

 

8.           Survival of Agreements, Representations and Warranties, etc . All representations and warranties contained herein shall survive the execution and delivery of this Agreement. 

 

9.         Successors and Assigns . This Agreement shall bind and inure to the benefit of and be enforceable by the Parties and their respective successors and assigns. 

 

10.        Governing Law . This Agreement and the obligations, rights and remedies of the Parties hereto are to be construed in accordance with and governed by the laws of the State of New York, with any action/dispute concerning this Agreement to be venued in the County of Rockland.

 

11.         Severability . In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof.

 

12.        Miscellaneous . This Agreement embodies the entire agreement and understanding between the Parties hereto and supersedes all prior agreements and understandings relating to the subject matter hereof. If any provision of this Agreement shall be held invalid or unenforceable for whatever reason, the remainder of this Agreement shall not be affected thereby and every remaining provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. This Agreement may be executed in any number of counterparts and by the Parties hereto on separate counterparts but all such counterparts shall together constitute but one and the same instrument.

 

IN WITNESS WHEREOF , the Parties hereto have executed this Agreement as of the date first above written.

 

  BIO-EN HOLDINGS CORP  
       
  By: /s/ Serena B. Potash  
  Name:    
  Title:    
       
  By: /s/ Serena B. Potash  
  SERENA B. POTASH , Individually  

 

BHC/Bio-En - Merger Agreement – Execution Copy 24
 

 

EXHIBIT B

 

CERTIFICATE OF MERGER

 

BHC/Bio-En - Merger Agreement – Execution Copy 25
 

 

EXHIBIT C

 

BILL OF SALE

 

Know all Men by these Present, that BIO-EN CORP . (“ Seller ”), for and in consideration of the sum of Ten dollars ($10.00) dollars, lawful money of the United States paid by BIO-EN HOLDINGS CORP. (“ Buyer ”), which receipt is hereby acknowledged, has bargained and sold, unto Buyer, his heirs, executors, administrators, successors and assigns, the following items: ‘Assets’, as described in the ‘Share Exchange/Merger Agreement’ between Seller and Buyer dated August 21, 2014 (“ Agreement ”);

 

TO HAVE AND TO HOLD the same unto the said Buyer, his heirs, executors, administrators, successors and assigns forever. AND do for his heirs, executors and administrators, covenant and agree, to and with the Buyer, to warrant and defend the sale of the aforesaid hereby sold unto the Buyer, his heirs, executors, administrators, successors and assigns, against all and every person and persons whomsoever. The warranties, covenants and promises contained in the AP Agreement between Seller and Buyer for the sale and purchase consummated by this Bill of Sale, will not merge in but will survive this Bill of Sale and become a part of this Bill of Sale and will continue in full force and effect as though set forth at length in this Bill of Sale.

 

IN WITNESS WHEREOF, the Seller has set its hand and seal or caused these presents to be signed by its proper corporate officers and caused its proper corporate seal to be hereto affixed, this 21st day of August, 2014.

 

  BIO-EN CORP.  
       
  By: /s/ Serena B. Potash  
  Name:    
  Title:    

 

BHC/Bio-En - Merger Agreement – Execution Copy 26

 

 

Exhibit 3.2

 

  State of Delaware
  Secretary of State
  Division of Corporations
  Delivered 11:02 AM 04/01/2014
  FILED 10:59 AM 04/01/2014
  SRV 140411221 - 5019291 FILE

 

CERTIFICATE OF AMENDMENT OF

CERTIFICATE OF INCORPORATION OF

BIO-EN HOLDINGS CORP.

 

Bio-En Holdings Corp., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify that:

 

FIRST:              The name of the Corporation is Bio-En Holdings Corp.

 

SECOND:         This Certificate of Amendment (this “Certificate of Amendment”) amends the provisions of the Corporation’s Certificate of Incorporation filed with the Secretary of State on August 2, 2011 (the “Certificate of Incorporation”).

 

THIRD:             The Article numbered FOURTH of the Certificate of Incorporation is hereby deleted and replaced in its entirety with the following:

 

FOURTH

 

The total number of shares of stock which the Corporation has authority to issue is Two Hundred Million (200,000,000) shares of common stock, $0.0001 par value per share.

 

Upon the date of this Certificate of Amendment to the Articles of Incorporation becomes effective in accordance with the General Corporation Law of the State of Delaware, each issued and outstanding share of the common stock of the Corporation, per share shall be automatically changed and converted into 6.3157 shares of the common stock of the Corporation, par value $0.0001 per share.

 

FOURTH:         This amendment was duly adopted in accordance with the provisions of Sections 228 and 242 of the General Corporation Law of the State of Delaware.

 

FIFTH:              This Certificate of Amendment shall be effective as of 6:01 p.m. EST on the date written below.

 

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its officer thereunto duly authorized this 1st day of April, 2014.

 

  Bio-En Holdings Corp.
     
  By: / s / Elchanan Menachem Grossbaum
    Name: Elchanan Menachem
    Grossbaum
    Title: Chief Executive Officer

 

 

 

 

 

Exhibit 3.3

 

State of Delaware  
Secretary of State  
Division of Corporations  
Delivered 01:09 PM 08/05/2014  
FILED 01:03 PM 08/05/2014  
 SRV 141036012 - 5019291 FILE  

 

CERTIFICATE OF AMENDMENT OF

CERTIFICATE OF INCORPORATION OF

BIO-EN HOLDINGS CORP.

 

BIO-EN HOLDINGS CORP., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify that:

 

FIRST:          That at a meeting of the Board of Directors of BIO-EN HOLDINGS CORP. resolutions were duly adopted setting forth a proposed amendment of the Certificate of Incorporation of said corporation, declaring said amendment to be advisable and calling a meeting of the stockholders of said corporation for consideration thereof. The resolution setting forth the proposed amendment is as follows:

 

RESOLVED, that the Certificate of Incorporation of this corporation be amended by changing the Article thereof numbered “FOURTH” so that, as amended, said Article shall be and read as follows:

 

To increase the authorized shares of capital stock, par value $0.0001 per share, from 200,000,000 to 300,000,000 shares.

 

To create 50,000,000 shares of blank check preferred stock, such that the capital stock will consist of 250,000,000 shares of common stock, par value $0.0001 per share and 50,000,000 shares of preferred stock, with such preferred shares to be issued in one or more classes or series with such designations, powers, preferences and relative participation, optional and other special rights, if any, of each such class or series, and qualifications, limitations and restrictions thereof, to be stated by a resolution adopted by the Board of Directors.

 

SECOND:     That thereafter, pursuant to resolution of its Board of Directors, a special meeting of the stockholders of said corporation was duly called and held upon notice in accordance with Section 222 of the General Corporation Law of the State of Delaware at which meeting the necessary number of shares as required by statute were voted in favor of the amendment.

 

THIRD:         That said amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

 

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its officer thereunto duly authorized this    5th      day of     August     , 2014.

 

  By: /s/Serena B. Potash
    Name: Serena B. Potash
    Title: President

 

 

 

 

 

Exhibit 3.4 

 

AMENDED BY-LAWS OF

BIO-EN HOLDINGS CORP.

 

ARTICLE I

OFFICES

 

Section 1.1.          Registered Office .  The registered office of the Corporation required by the laws of the State of Delaware to be maintained in the State of Delaware shall be the registered office named in the original Articles of Incorporation of the Corporation, or such other office as may be designated from time to time by the Board of Directors in the manner provided by law. Should the Corporation maintain a principal office or place of business within the State of Delaware, such registered office need not be identical to such principal office or place of business of the Corporation.

 

Section 1.2.           Other Offices .  The Corporation may also have offices at such other places both within and without the State of Delaware as the Board of Directors may from time to time determine or the business of the Corporation may require.

 

ARTICLE II

MEETINGS OF STOCKHOLDERS

 

Section 2.1.         Place of Meetings . All meetings of the stockholders shall be held at the principal office of the Corporation, or at such other place either within or without the State of Delaware and at such date and time as shall be designated from time to time by the Board of Directors and stated in the notice or waivers of notice of the meeting.

 

Section 2.2.          Voting List . The officer who has charge of the stock ledger of the Corporation shall prepare and make, before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting. The list shall also be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present.

 

Section 2.3.         Annual Meetings . An annual meeting of the stockholders, for the election of Directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, within or without the State of Delaware, on such date, and at such time as the Board of Directors shall fix each year and set forth in the notice of the meeting, which date shall be within 13 months subsequent to the later of the date of incorporation or the last annual meeting of stockholders.

 

Section 2.4.        Special Meeting . Special meetings of the stockholders, for any purpose or purposes, unless otherwise prescribed by statute or by the Certificate of Incorporation, may be called by the Chairman of the Board (if any), by the Chief Executive Officer, or by written order of a majority of the Directors, but such special meetings may not be called by any other person or persons. The Chairman, Chief Executive Officer, or Directors so calling any such meeting shall fix the date and time of, and the place (either within or without the State of Delaware) for, the meeting.

 

Amended and Restated By-Laws of Bio-En Holdings Corp. 1
 

 

Section 2.5.            Notice of Meeting. Written notice of the annual, and each special meeting of stockholders, stating the place, date and hour and, in the case of a special meeting, the purpose or purposes for which the meeting is called, shall be given to each stockholder entitled to vote thereat, not less than ten nor more than 60 days before the meeting. Such notice may be delivered either personally, via email or by mail. If mailed, notice is given when deposited in the United States mail, postage prepaid, and/or overnight mail directed to the stockholder at his address as it appears on the records of the Corporation.

 

Section 2.6.            Quorum. The holders of a majority of the stock issued and outstanding and entitled to vote thereat, present in person or represented by proxy, shall constitute a quorum at any meeting of stockholders for the transaction of business except as otherwise provided by statute or by the Certificate of Incorporation. The stockholders present at a duly organized meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum.

 

Notwithstanding the other provisions of the Certificate of Incorporation or these By-laws, the Chairman of the meeting or the holders of a majority of the shares of such stock, present in person or represented by proxy, although not constituting a quorum, shall have power to adjourn, postpone, or recess the meeting from time to time, without notice other than announcement at the meeting of the time and place of the adjourned, postponed, or recessed meeting. If the adjournment is for more than 30 days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. At such adjourned meeting at which a quorum shall be present or represented any business may be transacted which might have been transacted at the meeting as originally notified.

 

Section 2.7.           Voting. When a quorum is present at any meeting of the stockholders, the vote of the holders of a majority of the stock having voting power present in person or represented by proxy shall decide any question brought before such meeting, unless the question is one upon which, by express provision of the statutes, of the Certificate of Incorporation or of these By-laws, a different vote is required, in which case such express provision shall govern and control the decision of such question. Where a separate vote by class is required, the affirmative vote of the majority of shares of such class present in person or represented by proxy at the meeting shall be the act of such class. Every stockholder having the right to vote at a meeting of stockholders or to express consent or dissent to a corporate action in writing without a meeting shall be entitled to vote in person, or by proxy appointed by an instrument in writing subscribed by such stockholder, bearing a date not more than three years prior to voting, unless such instrument provides for a longer period, and filed with the Secretary of the Corporation, or such other officer as the Board of Directors may from time to time determine by resolution, before, or at the time of, the meeting.

 

All proxies shall be received and taken charge of and all ballots shall be received and canvassed by the secretary of the meeting who shall decide all questions touching upon the qualification of voters, the validity of the proxies, and the acceptance or rejection of votes, unless an inspector or inspectors shall have been appointed by the chairman of the meeting, in which event such inspector or inspectors shall decide all such questions. Each proxy shall be revocable unless expressly provided therein to be irrevocable and coupled with an interest sufficient in law to support an irrevocable power. If such instrument shall designate two or more persons to act as proxies, unless such instrument shall provide the contrary, a majority of such persons present at any meeting at which their powers thereunder are to be exercised shall have and may exercise all the powers of voting or giving consents thereby conferred, or if only one be present, then such powers may be exercised by that one, or, if an even number attend and a majority do not agree on any particular issue, each proxy so attending shall be entitled to exercise such powers in respect of the same portion of the shares as he is of the proxies representing such shares.

 

Amended and Restated By-Laws of Bio-En Holdings Corp. 2
 

 

Section 2.8.           Voting of Stock of Certain Holders; Elections; Inspectors . Shares standing in the name of another corporation, domestic or foreign, may be voted by such officer, agent or proxy as the By-laws of such corporation may prescribe, or in the absence of such provision, as the Board of Directors of such corporation may determine. Shares standing in the name of a deceased person may be voted by the executor or administrator of such deceased person, either in person or by proxy. Shares standing in the name of a guardian, conservator or trustee may be voted by such fiduciary, either in person or by proxy, but no fiduciary shall be entitled to vote shares held in such fiduciary capacity without a transfer of such shares into the name of such fiduciary. Shares standing in the name of a receiver may be voted by such receiver. A stockholder whose shares are pledged shall be entitled to vote such shares, unless in the transfer by the pledgor on the books of the Corporation, he has expressly empowered the pledgee to vote thereon, in which case only the pledgee, or his proxy, may represent the stock and vote thereon.

 

If shares or other securities having voting power stand of record in the names of two or more persons, whether fiduciaries, members of a partnership, joint tenants, tenants in common, tenants by the entirety or otherwise, or if two or more persons have the same fiduciary relationship respecting the same shares, unless the Secretary of the Corporation is given written notice to the contrary and is furnished with a copy of the instrument or order appointing them or creating the relationship wherein it is so provided, their acts with respect to voting shall have the following effect:

 

(a) If only one votes, his act binds all;

 

(b) If more than one vote, the act of the majority so voting binds all;

 

(c) If more than one vote, but the vote is evenly split on any particular matter, each fraction may vote the securities in question proportionally, or any person voting the shares, or a beneficiary, if any, may apply to the court as may have jurisdiction to appoint an additional person to act with the persons so voting the shares, which shall then be voted as determined by a majority of such persons and the person appointed by the Court. If the instrument so filed shows that any such tenancy is held in unequal interests, a majority or even-split for the purpose of this subsection shall be a majority or even-split in interest.

 

All voting of stockholders shall be taken by written ballots, each of which shall state the name of the stockholder or proxy voting and such other information as may be required under the procedure established for the meeting. At any meeting at which a vote is taken by ballots, the chairman of the meeting may appoint one or more inspectors, each of whom shall subscribe an oath or affirmation to execute faithfully the duties of inspector at such meeting with strict impartiality and according to the best of his ability. Such inspector shall receive the ballots, count the votes and make and sign a certificate of the result thereof. The chairman of the meeting may appoint any person to serve as inspector, except no candidate for the office of director shall be appointed as inspector.

 

Unless otherwise provided in the Certificate of Incorporation, cumulative voting for the election of Directors shall be prohibited.

 

Amended and Restated By-Laws of Bio-En Holdings Corp. 3
 

 

Section 2.9.           Conduct of Meeting .  The meetings of the stockholders shall be presided over by the Chairman of the Board (if any) , or if he is not present, by the Vice Chairman of the Board (if any, but if there is more than one, the Vice Chairman who is senior in terms of time as such) , or if neither the Chairman of the Board (if any) nor the Vice Chairman of the Board (if any) is present, by the President, or if neither the Chairman of the Board (if any) , the Vice Chairman of the Board (if any) nor President is present, by a chairman elected at the meeting. The Secretary of the Corporation, if present, shall act as secretary of such meetings, or if he is not present, an Assistant Secretary shall so act; if neither the Secretary nor an Assistant Secretary is present, then a secretary shall be appointed by the chairman of the meeting. The chairman of any meeting of stockholders shall determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of discussion as seem to him in order. Unless the chairman of the meeting of stockholders shall otherwise determine, the order of business shall be as follows:

 

(a) Calling of meeting to order;

 

(b) Election of a chairman and the appointment of a secretary if necessary;

 

(c) Presentation of proof of the due calling of the meeting;

 

(d) Presentation and examination of proxies and determination of a quorum;

 

(e) Reading and settlement of the minutes of the previous meeting;

 

(f) Reports of officers and committees;

 

(g) The election of Directors if an annual meeting, or a meeting called for that purpose;

 

(h) Unfinished business;

 

(i) New business; and,

 

(j) Adjournment.

 

Section 2.10.          Treasury Stock . The Corporation shall not vote, directly or indirectly, shares of its own stock owned by it; and such shares shall not be counted in determining the total number of outstanding shares.

 

Section 2.11.         Fixing Record Date .  The Board of Directors may fix in advance a date, not exceeding 60 days preceding the date of any meeting of stockholders or any adjournment thereof, or the date for payment of any dividend or distribution, or the date for the allotment of rights, or the date when any change, or conversion or exchange of capital stock shall go into effect, or a date in connection with obtaining express consent to corporate action in writing without a meeting, as a record date for the determination of the stockholders entitled to notice of or to vote at, any such meeting and any adjournment thereof, or entitled to receive payment of such dividend or distribution, or to receive any such allotment of rights, or to exercise the rights in respect of any such change, conversion or exchange of capital stock, or to give such consent, and in such case such stockholders and only such stockholders as shall be stockholders of record on the date so fixed shall be entitled to such notice of, and to vote at, any such meeting and any adjournment thereof, or to receive payment of such dividends or distribution, or to receive such allotment of rights, or to exercise such rights, or to give such consent, as the case may be, notwithstanding any transfer of any stock on the books of the corporation after any such record dated fixed as aforesaid. With respect to a meeting of stockholders, the record date shall not be less than ten days before the date of such meeting.

 

Amended and Restated By-Laws of Bio-En Holdings Corp. 4
 

 

If the Board of Directors does not fix a record date for any meeting of the stockholders, the record date for determining stockholders entitled to notice of or to vote at such meeting shall be at the close of business on the day next preceding the day on which notice is given, or, if in accordance with Section 5.2 of these By-laws notice is waived, at the close of business on the day next preceding the day on which the meeting is held. The record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.

 

Section 2.12.          Action Without a Meeting. Any action required or permitted to be taken by shareholders by vote may be taken without a meeting on written consent, setting forth the action so taken, signed by the holders of all outstanding shares entitled to vote thereon.

 

Section 2.13.         Stockholder Proposals . At an annual or special meeting of the stockholders, only such business shall be conducted as shall have been properly brought before the meeting. To be properly brought before an annual or special meeting business must be (a) specified in the notice of meeting (or any supplement thereto) given by or at the direction of the Chairman of the Board, the President, or the Board of Directors, (b) otherwise properly brought before the meeting by or at the direction of the Chairman of the Board, the President, or the Board of Directors, or (c) otherwise properly brought before the meeting by a stockholder.

 

No proposal by a stockholder shall be presented at an annual or special meeting of stockholders unless such stockholder shall provide the Board of Directors or the Secretary of the Corporation with timely written notice of intention to present a proposal for action at the forthcoming meeting of stockholders, which notice shall include (a) the name and address of such stockholder, (b) the number of voting securities he or she holds of record and which he or she holds beneficially, (c) the text of the proposal to be presented at the meeting, (d) a statement in support of the proposal, and (e) any material interest of the stockholder in such proposal. To be timely, a stockholder's notice with respect to an annual meeting of stockholders must be delivered to or mailed and received at the principal executive offices of the Corporation, not less than 120 days nor more than 150 days in advance of the date the Corporation's proxy statement was released to stockholders in connection with the previous year's annual meeting of stockholders; provided, however, that if no annual meeting was held the previous year or the date of the annual meeting has been changed by more than 30 calendar days from the date contemplated at the time of the previous year's proxy statement, notice by the stockholder to be timely must be so received at least 80 days prior to the date the Corporation intends to distribute its proxy statement with respect to such meeting. To be timely, a stockholder's notice with respect to a special meeting must be delivered to or mailed and received at the principal executive offices of the Corporation, not less than 60 days nor more than 90 days prior to the meeting; provided, however, that in the event that less than 70 days' notice or prior public disclosure of the date of the meeting is given or made to stockholders, notice by the stockholder to be timely must be so received not later than the close of business on the fifth (5th) day following the day on which such notice of the date of the special meeting was mailed or such public disclosure was made. Any stockholder may make any other proposal at an annual or special meeting of stockholders and the same may be discussed and considered, but unless stated in writing and filed with the Board of Directors or the Secretary prior to the date set forth above, no action with respect to such proposal shall be taken at such meeting and such proposal shall be laid over for action at an adjourned, special, or annual meeting of the stockholders taking place no earlier than 120 days after such meeting.

 

Amended and Restated By-Laws of Bio-En Holdings Corp. 5
 

 

This provision shall not prevent the consideration and approval or disapproval at an annual meeting of reports of officers, directors, and committees; but in connection with such reports, no new business shall be acted upon at such annual meeting unless stated and filed as provided in this Section 2.13. Notwithstanding anything in the By-laws to the contrary, no business shall be conducted at any annual or special meeting except in accordance with the procedures set forth in this Section 2.13. The chairman of the annual meeting or a special meeting shall, if the facts warrant, determine and declare to the meeting that business was not properly brought before the meeting and in accordance with the provisions of this Section 2.13, and if he should so determine, he shall so declare to the meeting and any such business not properly brought before the meeting shall not be transacted.

 

If applicable, notwithstanding any other provision of these By-laws, the Corporation shall be under no obligation to include any stockholder proposal in its proxy statement materials or otherwise present any such proposal to stockholders at a special or annual meeting of stockholders if the Board of Directors reasonably believes the proponents thereof have not complied with Sections 13 and 14 of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder, and the Corporation shall not be required to include in its proxy statement material to stockholders any stockholder proposal not required to be included in its proxy material to stockholders in accordance with such Act, rules, or regulations.

 

Section 2.14.          Nomination of Directors . Only persons who are nominated in accordance with the procedures of this Section 2.14 shall be eligible for election as Directors. Subject to the rights of holders of any class or series of stock having a preference over the common stock as to dividends or upon liquidation, nominations for the election of Directors may be made by the Board of Directors or by any stockholder entitled to vote in the election of Directors generally who complies with the notice procedures set forth in this Section 2.14. Any stockholder entitled to vote in the election of Directors generally may nominate one or more persons for election as a director at a meeting only if timely written notice of such stockholder's intent to make such nomination or nominations has been given, either by personal delivery, overnight mail or by U.S. mail, first class postage prepaid, return receipt requested, to the Secretary of the Corporation.

 

To be timely, a stockholder's notice shall be delivered to or mailed and received at the principal executive offices of the Corporation not less than ninety days nor more than one hundred twenty days in advance of the date the Corporation's proxy statement was released to stockholders in connection with the previous year's annual meeting of stockholders; provided, however, that if no annual meeting was held the previous year or the date of the annual meeting has been changed by more than thirty (30) calendar days from the date contemplated at the time of the previous year's proxy statement, notice by the stockholder to be timely must be so received at least ninety (90) days prior to the date the Corporation intends to distribute its proxy statement with respect to such meeting. Each such notice shall set forth: (a) the name and address of the stockholder who intends to make the nomination, (b) the name, age, business address, and home address of the person or persons to be nominated; (c) the principal occupation of the person or persons nominated; (d) a representation that the stockholder is a holder of record of stock of the Corporation entitled to vote at such meeting and intends to appear in person or by proxy at the meeting and intends to appear at the meeting to nominate the person or persons specified in the notice; (e) a description of all arrangements or understandings between the stockholder and each nominee and any other person or persons (naming such person or persons) pursuant to which the nomination or nominations are to be made by the stockholder; (f) such other information regarding each nominee proposed by such stockholder as would be required to be included in a proxy statement filed pursuant to the rules of the Securities and Exchange Commission, had the nominee been nominated, or intended to be nominated, by the Board of Directors; and, (g) the consent of each nominee to serve as a director of the Corporation if so elected. At the request of the Board of Directors any person nominated by the Board of Directors for election as a director shall furnish to the Secretary of the Corporation that information required to be set forth in a stockholder's notice of nomination which pertains to the nominee.

 

Amended and Restated By-Laws of Bio-En Holdings Corp. 6
 

 

No person shall be eligible for election as a director of the Corporation unless nominated in accordance with the procedures set forth in this Section 2.14. The chairman of the meeting shall, if the facts warrant, determine and declare to the meeting that a nomination was not made in accordance with the procedures prescribed by the By-laws, and if he should so determine, he shall so declare to the meeting and the defective nomination shall be disregarded.

 

ARTICLE III

BOARD OF DIRECTORS

 

Section 3.1.           Powers . The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors, which may exercise all such powers of the Corporation and do all such lawful acts and things as are not by law or by the Certificate of Incorporation or by these By-laws directed or required to be exercised or done by the stockholders.

 

Section 3.2.           Number, Election and Term .  The number of Directors of the Corporation shall initially be one (1), such number may be increased or decreased by a resolution duly adopted by the Board of Directors. Unless approved by at least two-thirds of the incumbent Directors, the number of Directors which shall constitute the whole Board of Directors shall be no fewer than two and no more than seven. Unless otherwise provided in the Articles of Incorporation, Directors need not be residents of Delaware or stockholders of the Corporation. The term for Directors shall be three (3) years.

 

Section 3.3.           Vacancies, Additional Directors and Removal From Office .  Any Director or Directors may be removed from office at any time, with cause but only by the affirmative vote, at any regular meeting or special meeting (as the case may be) of the Board of Directors or of the stockholders, of not less than two-thirds of the incumbent members of the Board of Directors (not taking into account the Directors being removed) or two-thirds of the total number of votes of the then outstanding shares of capital stock of the Corporation entitled to vote generally in the election of Directors, voting together as a single class, but only if notice of such proposal was contained in the notice of such meeting.

 

In the event of any increase or decrease in the authorized number of Directors, the newly created or eliminated Directorships resulting from such increase or decrease shall be appointed or determined by the Board of Directors. Vacancies in the Board of Directors, however caused, and newly-created Directorships shall be filled solely by a majority vote of the Directors then in office, whether or not a quorum, and any Director so chosen shall hold office for a term expiring at the annual meeting of stockholders at which the term of the class to which the Director has been chose expires and when the Director's successor is elected and qualified, subject, however, to prior death, resignation, retirement, disqualification or removal from office.

 

Amended and Restated By-Laws of Bio-En Holdings Corp. 7
 

 

No decrease in the number of Directors constituting the Board of Directors shall shorten the term of any incumbent Director.

 

Section 3.4.           Regular Meeting . A regular meeting of the Board of Directors shall be held each year, without notice other than this by-law, at the place of, and immediately following, the annual meeting of stockholders if a quorum is present; and other regular meetings of the Board of Directors shall be held each year, at such time and place as the Board of Directors may provide, by resolution, either within or without the State of Delaware, without notice other

than such resolution.

 

Section 3.5.           Special Meeting . A special meeting of the Board of Directors may be called by the Chairman of the Board (if any) or by the Chief Executive Officer and shall be called by the Secretary on the written request of any two Directors. The Chairman or Chief Executive Officer so calling, or the Directors so requesting, any such meeting shall fix the time and place, either within or without the State of Delaware, of holding such meeting.

 

Section 3.6.           Notice of Special Meeting . Personal written, email, telegraphic, cable or wireless notice of special meetings of the Board of Directors shall be given to each director at least 24 hours prior to the time of such meeting. Any Director may waive notice of any meeting. The attendance of a director at any meeting shall constitute a waiver of notice of such meeting, except where a Director attends a meeting for the purpose of objecting to the transaction of any business because the meeting is not lawfully called or convened.

 

Section 3.7.           Place of Meetings; Order of Business. The Directors may hold their meetings and may have an office and keep the books of the Corporation, except as otherwise provided by law, in such place or places, (including but not limited to telephone calls, video conference or otherwise, within or without the State of Delaware, as the Board of Directors may from time to time determine by resolution. The Chairman of the Board shall preside at all meetings of the Board of Directors. In the absence of the Chairman of the Board, a Chairman shall be elected from the Directors present. The Secretary of the Corporation shall act as Secretary of all meetings of the Directors; but in the absence of the Secretary, the Chairman may appoint any person to act as Secretary of the meeting. At all meetings of the Board of Directors business shall be transacted in such order as shall from time to time be determined by

the Chairman of the Board, or in his absence by the Director elected as chairman of the meeting.

 

Section 3.8.           Quorum and Participation . A majority of the Board of Directors shall constitute a quorum for the transaction of business at any meeting of the Board of Directors, and the act of a majority of the Directors present at any meeting at which there is a quorum shall be the act of the Board of Directors, except as may be otherwise specifically provided by statute, by the Certificate of Incorporation or by these B-laws. Members of the Board of Directors, may participate in a meeting of the Board of Directors or such committee, as the case may be, by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other and such participation shall constitute presence in person and attendance at such meeting, except where a person participates in the meeting for the express purpose of objecting to the transaction of any business on the ground that the meeting is not lawfully called or convened. If a quorum shall not be present at any meeting of the Board of Directors, the Directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum shall be present.

 

Amended and Restated By-Laws of Bio-En Holdings Corp. 8
 

 

Section 3.9.           Presumption of Assent . A Director who is present at a meeting of the Board of Directors at which action on any corporate matter is taken shall be presumed to have assented to the action unless his dissent shall be entered in the minutes of the meeting or unless he shall file his written dissent to such action with the person acting as secretary of the meeting before the adjournment thereof. Such right to dissent shall not apply to a Director who voted in favor of such action.

 

Section 3.10.          Action Without Meeting . Unless otherwise restricted by the Certificate of Incorporation or these By-laws, any action required or permitted to be taken at any meeting of the Board of Directors, or of any committee thereof as provided in Article IV of these By-laws, may be taken without a meeting, if a written consent thereto is signed by all members of the Board or of such committee, as the case may be, and such written consent is filed with the minutes of proceedings of the Board or committee. Such consent shall have the same force and effect as a unanimous vote at a meeting, and may be stated as such in any document or instrument filed with the Secretary of State of Delaware.

 

Section 3.11.          Compensation. Unless otherwise restricted by the Certificate of Incorporation, the Board of Directors shall have the authority to fix the compensation of Directors. No provision of these By-laws shall be construed to preclude any Director from serving the corporation in any other capacity and receiving compensation therefor.

 

Section 3.12.          Approval or Ratification of Acts or Contracts by Stockholders . The Board of Directors in its discretion may submit any act or contract for approval or ratification at any annual meeting of the stockholders, or at any special meeting of the stockholders called for the purpose of considering any such act or contract, and any act or contract that shall be approved or be ratified by the vote of the stockholders holding a majority of the issued and outstanding shares of stock of the Corporation entitled to vote and present in person or by proxy at such meeting (provided that a quorum is present), shall be as valid and as binding upon the Corporation and upon all the stockholders as if it has been approved or ratified by every stockholder of the Corporation. In addition, any such act or contract may be approved or ratified by the written consent of stockholders holding a majority of the issued and outstanding shares of capital stock of the Corporation entitled to vote and such consent shall be as valid and as binding upon the Corporation and upon all the stockholders as if it had been approved or ratified by every stockholder of the Corporation.

 

ARTICLE IV

COMMITTEES OF DIRECTORS

 

Section 4.1.           Designation, Powers and Name . The Board of Directors shall strive, with due speed, to designate a Nominating/Governance Committee, a Compensation Committee, and an Audit Committee and may, by resolution passed by a majority of the whole Board, designate one or more other committees, each such committee to consist of one or more of the Directors of the Corporation. Any such designated committee shall have and may exercise such of the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation as may be provided in these By-laws or such resolution. Any such designated committee may authorize the seal of the Corporation to be affixed to all papers which may require it. No such committee shall have the power or authority in reference to amending the Certificate of Incorporation (except that a committee may, to the extent authorized in the resolution or resolutions providing for the issuance of shares of stock adopted by the Board of Directors as provided by statute, fix the designation and any of the preferences or rights of such shares relating to dividends, redemption, dissolution, any distribution of assets of the Corporation or the conversion into, or the exchange of such shares for, shares of any other class or classes or any other series of the same or any other class or classes of stock of the Corporation or fix the number of shares of any series of stock or authorize the increase or decrease of the shares of any series) , adopting an agreement of merger or consolidation, recommending to the stockholders the sale, lease or exchange of all or substantially all of the Corporation's property and assets, recommending to the stockholders a dissolution of the Corporation or a revocation of a dissolution, or amending the By-laws of the Corporation; and, unless the resolution, By-laws, or Certificate of Incorporation expressly so provide, no such committee shall have the power or authority to declare a dividend, to authorize the issuance of stock, or to adopt a certificate of ownership and merger. The Board of Directors may designate one or more Directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of such committee. In the absence or disqualification of any member of such committee or committees, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member. Such committee or committees shall have such name or names and such limitations of authority as may be determined from time to time by the By-laws, by the Charter for such committee adopted by the Board of Directors, or by a resolution adopted by the Board of Directors.

 

Amended and Restated By-Laws of Bio-En Holdings Corp. 9
 

 

Section 4.2.           Procedure; Meetings; Quorum . Any committee designated pursuant to Section 4.1 shall keep regular minutes of its proceedings and report the same to the Board of Directors when requested, shall fix its own rules or procedures to the extent not otherwise set forth in the Charter or resolution with respect to such committee adopted by the Board of Directors, and shall meet at such times and at such place or places as may be provided by such rules, by the Charter for such committee adopted by the Board of Directors, or by resolution of such committee or resolution of the Board of Directors. At every meeting of any such committee, the presence of a majority of all the members thereof shall constitute a quorum and the affirmative vote of a majority of the members present shall be necessary for the adoption by it of any resolution. Unless otherwise restricted by the Certificate of Incorporation or by these By-laws, the members of any committee designated by these By-laws or the Board of Directors, may participate in a meeting of such committee by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting may hear each other, and such participation shall constitute presence in person at such meeting. Unless otherwise restricted by the Certificate of Incorporation or these By-laws, any action required or permitted to be taken at any meeting of any committee of the Board of Directors may be taken without a meeting if all members of such committee consent thereto in writing and the writing or writings are filed with the minutes of the proceedings of the committee.

 

Section 4.3.           Compensation . Members of special or standing committees may be allowed compensation for attending committee meetings, if the Board of Directors shall so determine.

 

ARTICLE V

NOTICE

 

Section 5.1.           Methods of Giving Notice . Whenever under the provisions of the statutes, the Certificate of Incorporation or these By-laws, notice is required to be given to any director, member of any committee or stockholder, such notice shall be in writing and delivered personally, email or mailed to such director, member or stockholder; provided that in the case of a director or a member of any committee such notice may be given orally or by telephone, telegram, telegraphic, cable or wireless transmission. If mailed, notice to a director, member of a committee or stockholder shall be deemed to be given when deposited in the United States mail first class in a sealed envelope, with postage therein prepaid, addressed, in the case of a stockholder, to the stockholder at the stockholder's address as it appears on the records of the corporation or, in the case of a director or a member of a committee, to such person at his business address. If sent by telegram, notice to a director or member of a committee shall be deemed to be given when the telegram, so addressed, is delivered to the telegraph company. Notice shall be deemed to have been given on the date of any telegraphic, cable or wireless transmission.

 

Amended and Restated By-Laws of Bio-En Holdings Corp. 10
 

 

Section 5.2.           Written Waiver . Whenever any notice is required to be given under the provisions of the statutes, the Certificate of Incorporation or these By-laws, a waiver thereof in writing, signed by the person or persons entitled to said notice, whether before or after the time stated therein, shall be deemed equivalent thereto. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders, directors, or members of a committee of Directors need be specified in any written waiver of notice unless so required by the Certificate of Incorporation or the By-laws.

 

ARTICLE VI

OFFICERS

 

Section 6.1.           Officers . The officers of the Corporation shall be a Chairman of the Board, one or more Vice Chairmen of the Board, a Chief Executive Officer, a President, one or more Vice Presidents, any one or more of which may be designated Executive Vice President or Senior Vice President, a Secretary, a Treasurer/Controller, and such other officers as the Board of Directors may elect or appoint. The Board of Directors may appoint such other officers and agents, including Assistant Vice Presidents, Assistant Secretaries and Assistant Controllers, as it shall deem necessary, who shall hold their offices for such terms and shall exercise such powers and perform such duties as shall be determined by the Board. Any two or more offices, may be held by the same person unless the Certificate of Incorporation provides otherwise. No officer shall execute, acknowledge, verify or countersign any instrument on behalf of the Corporation in more than one capacity, if such instrument is required by law, by these By-laws or by any act of the Corporation to be executed, acknowledged, verified or countersigned by two or more officers. The Chairman of the Board shall be elected from among the Directors. With the foregoing exceptions, none of the other officers need be a director, and none of the officers need be a stockholder of the Corporation.

 

Section 6.2.           Term of Office . Each officer shall hold office until his successor shall have been chosen and shall have qualified or until his death or the effective date of his resignation or removal, or until he shall cease to be a director in the case of the Chairman and Vice Chairman.

 

Section 6.3.           Removal and Resignation . Any officer or agent elected or appointed by the Board of Directors may be removed, with cause, by the affirmative vote of a majority of the Board of Directors whenever, in its judgment, the best interests of the Corporation shall be served thereby, but such removal shall be without prejudice to the contractual rights, if any, of the person so removed. Election or appointment of an officer or agent shall not of itself create contract rights. Any officer may resign at any time by giving written notice to the Corporation. Any such resignation shall take effect at the date of the receipt of such notice or at any later time specified therein, and unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective.

 

Amended and Restated By-Laws of Bio-En Holdings Corp. 11
 

 

Section 6.4.           Vacancies . Any vacancy occurring in any office of the Corporation by death, resignation, removal or otherwise may be filled by the Board of Directors for the unexpired portion of the term.

 

Section 6.5.           Salaries . The salaries of all officers and agents of the Corporation shall be fixed by the Board of Directors or pursuant to its direction; no officer shall be prevented from receiving such salary by reason of his also being a director.

 

Section 6.6.          Chairman of the Board . The Chairman of the Board (if such office is created by the Board) shall have all powers and shall perform all duties incident to the office of Chairman of the Board. The Chairman shall preside at all meetings of the Board of Directors or of the stockholders of the Corporation. In the Chairman's absence, such duties shall be attended to by the Vice Chairman of the Board (if any, but if there is more than one, the Vice Chairman who is senior in terms of time as such) or (if there is no Vice Chairman) by the President. The Chairman shall formulate and submit to the Board of Directors or the Executive Committee (if any) matters of general policy of the Corporation and shall have such other powers and perform such other duties as usually appertain to the office or as may be prescribed by the Board of Directors or the executive committee. The Chairman of the Board may hold such other offices as the Board of Directors may determine.

 

Section 6.7.          Vice Chairman of the Board . In the absence of the Chairman of the Board, or in the event of his inability or refusal to act, the Vice Chairman (if any, but if there is more than one, the Vice Chairman who is senior in terms of time as such) shall perform the duties and exercise the powers of the Chairman of the Board, and when acting shall have all the powers of and be subject to all the restriction upon the Chairman of the Board. In the absence of the Chairman of the Board, such Vice Chairman shall preside at all meetings of the Board of Directors or of the stockholders of the Corporation. In the Chairman's and Vice Chairmen's absence, such duties shall be attended to by the President. The Vice Chairmen shall perform such other duties, and shall have such other powers, as from time to time may be assigned to them by the Board of Directors or the Executive Committee (if any).

 

Section 6.8.          Chief Executive Officer . The Chief Executive Officer shall be the chief executive officer of the Corporation and, subject to the control of the Board of Directors, shall in general manage, supervise, and control the properties, business, and affairs of the Corporation with all such powers as may be reasonably incident to such responsibilities. Unless the Board of Directors otherwise determines, the Chief Executive Officer shall have the authority to agree upon and execute all leases, contracts, evidences of indebtedness, and other obligations in the name of the Corporation. In the absence of the Chairman of the Board, the Chief Executive Officer shall preside at all meetings of the Stockholders and (should he be a Director) of the Board of Directors. He may also preside at any such meeting attended by the Chairman of the Board if he is so designated by the Chairman. He shall have the power to appoint and remove subordinate officers, agents, and employees, except those elected or appointed by the Board of Directors. The Chief Executive Officer shall keep the Board of Directors and the Executive Committee fully informed and shall consult them concerning the business of the Corporation. He shall perform all other duties normally incident to the office of Chief Executive Officer and such other duties, and shall have such other powers, as may be prescribed by the stockholders, the Board of Directors or the Executive Committee (if any) from time to time.

 

Amended and Restated By-Laws of Bio-En Holdings Corp. 12
 

 

Section 6.9.           President . The President shall be the chief operating officer of the Corporation and, subject to the control of the Chief Executive Officer and the Board of Directors, shall in general manage, supervise and control the properties, business and day-to-day affairs of the Corporation with all such powers as may be reasonably incident to such responsibilities. In the absence of the Chief Executive Officer, or in the event of his inability or refusal to act, the President shall perform the duties and exercise the powers of the Chief Executive Officer. In the absence of the Chairman of the Board and the Chief Executive Officer, the President shall preside at all meetings of the Stockholders and (should he be a Director) of the Board of Directors. He may also preside at any such meeting attended by the Chairman of the Board if he is so designated by the Chairman. He shall have the power to appoint and remove subordinate officers, agents and employees, except those elected or appointed by the Board of Directors. Unless the Board of Directors otherwise determines, the President shall have the authority to agree upon and execute all leases, contracts, evidences of indebtedness, and other obligations in the name of the Corporation. The President shall keep the Board of Directors and the Chief Executive Officer fully informed and shall consult them concerning the business of the Corporation. He shall vote, or give a proxy to any other officer of the Corporation to vote all shares of stock of any other corporation standing in the name of the Corporation and shall exercise any and all rights and powers which this Corporation may possess by reason of its ownership of securities in such other corporation; provided that the Board of Directors may from time to time, by resolution, confer like powers upon any other person or persons. In general the President shall have all powers and shall perform all other duties normally incident to the office of President and such other duties, and shall have such other powers, as may be prescribed by these By-laws, or the Board of Directors, or the Executive Committee (if any) from time to time. In the discretion of the Board of Directors, the President may also serve as Chief Executive Officer of the Corporation.

 

Section 6.10.         Vice Presidents . The Board of Directors may appoint such Vice Presidents, including, Executive or Senior Vice Presidents, as it may determine to be in the best interests of the Corporation. In the absence of the President, or in the event of his inability or refusal to act, the Executive Vice President (or in the event there shall be no Vice President designated Executive Vice President, any Vice President designated by the Board) shall perform the duties and exercise the powers of the President, and when so acting shall have all the powers of and be subject to all the restrictions upon the President. In the absence of a designation by the Board of Directors of a Vice President to perform the duties of the President, or in the event of his absence or inability or refusal to act, the Vice President who is present and who is senior in terms of time as a Vice President of the Corporation shall so act. Any Vice President may sign, with the Secretary, certificates for shares of the Corporation. Each Vice President shall perform all duties incident to the office of Vice President and shall have such powers and perform such other duties, as from time to time may be assigned to him by these By-laws or by the Chief Executive Officer, the President, the Board of Directors, or the Executive Committee (if any).

 

Section 6.11.         Corporate Secretary . The Corporate Secretary (“ Secretary ”) shall (a) keep the minutes of the meetings of the stockholders, the Board of Directors, and committees of Directors; (b) see that all notices are duly given in accordance with the provisions of these By-laws and as required by law; (c) be custodian of the corporate records and of the seal of the Corporation, and see that the seal of the Corporation or a facsimile thereof is affixed to all certificates for shares prior to the issue thereof and to all documents, the execution of which on behalf of the Corporation under its seal is duly authorized in accordance with the provisions of these By-laws and attest the affixation of the seal of the Corporation thereto; (d) keep or cause to be kept a register of the post office address of each stockholder which shall be furnished by such stockholder; (e) sign with the President, or an Executive Vice President or Vice President, certificates for shares of the Corporation, the issue of which shall have been authorized by resolution of the Board of Directors; (f) have general charge of the stock transfer books of the Corporation; and (g) in general, shall have such other powers and shall perform all duties normally incident to the office of Secretary and such other duties, and shall have such other powers, as from time to time may be assigned to him by these By-laws, the Chief Executive Officer, the President, the Board of Directors, or the Executive Committee (if any).

 

Amended and Restated By-Laws of Bio-En Holdings Corp. 13
 

 

Section 6.12.          Treasurer/Controller .  The Treasurer/Controller (“ Controller ’) shall (a) have charge and custody of and be responsible for all funds and securities of the Corporation; receive and give receipts for moneys due and payable to the Corporation from any source whatsoever and deposit all such moneys in the name of the Corporation in such banks, trust companies, or other depositories as shall be selected in accordance with the provisions of Section 7.3 of these By-laws; (b) prepare, or cause to be prepared, for submission at each regular meeting of the Board of Directors, at each annual meeting of the stockholders, and at such other times as may be required by the Board of Directors, the President or the executive committee (if any), a statement of financial condition of the Corporation in such detail as may be required; and (c) in general, shall have all powers and shall perform all the duties incident to the office of Controller and such other duties, and shall have such other powers, as from time to time may be assigned to him by these By-laws, the Chief Executive Officer, the President, the Board of Directors, or the Executive Committee (if any). If required by the Board of Directors, the Controller shall give a bond for the faithful discharge of his duties in such sum and with such surety or sureties as the Board of Directors shall determine.

 

ARTICLE VII

CONTRACTS, CHECKS AND DEPOSITS

 

Section 7.1.           Contracts . Except as otherwise provided in these By-laws or by law or as otherwise directed by the Board of Directors, the Chairman of the Board, the Chief Executive Officer, the President, and Vice President, and/or the Secretary shall be authorized to execute and deliver, in the and on behalf of the Corporation, all agreements, bonds, contracts, deeds, mortgages, and other instruments, either for the Corporation's own account or in a fiduciary or other capacity, and the seal of the Corporation, if appropriate shall be affixed thereto by any such officer or the Secretary. The Board of Directors, the Chairman of the Board, the Chief Executive Officer, or the President or, if designated by the Board of Directors, the Chairman of the Board, the Chief Executive Officer, or the President, any Vice President or the Secretary, may authorize any other officer, employee, or agent to execute and deliver, in the name and on behalf of the Corporation, agreements, bonds, contracts, deeds, mortgages, and other instruments, either for the Corporation's own account or in a fiduciary or other capacity, and, if appropriate, to affix the seal of the Corporation thereto. The grant of such authority by the Board of Directors or any such officer may be general or confined to specific conditions. Subject to the foregoing provisions, the Board of Directors may authorize any officer, officers, agent or agents, to enter into any contract or execute and deliver any instrument in the name of and on behalf of the Corporation, and such authority may be general or confined to specific instances.

 

Section 7.2.           Checks, Etc .   All checks, demands, drafts or other orders for the payment of money, notes or other evidences of indebtedness issued in the name of the Corporation, shall be signed and, if so required by the Board of Directors, shall be countersigned by such officer or officers or such agent or agents of the Corporation, and in such manner, as shall be determined by the Board of Directors.

 

Section 7.3.          Deposits . All funds of the Corporation not otherwise employed shall be deposited from time to time to the credit of the Corporation in such banks, trust companies or other depositories as the Board of Directors may select. Checks, drafts, bills of exchange, acceptances, notes, obligations, and orders for payment of money made payable to the Corporation may be endorsed for deposit to the credit of the Corporation with a duly authorized depositary by the Controller and/or such other officers or persons as the Board of Directors from time to time may designate.

 

Amended and Restated By-Laws of Bio-En Holdings Corp. 14
 

  

Section 7.4.           Loans.   No loans and no renewals of any loans shall be contracted on behalf of the Corporation except as authorized by the Board of Directors. When authorized so to do, any officer or agent of the Corporation may effect loans and advances for the Corporation from any bank, trust company, or other institution or from any individual, corporation, or firm, and for such loans and advances may make, execute, and deliver promissory notes, bonds, or other evidences of indebtedness of the Corporation. When authorized so to do, any officer or agent of the Corporation may pledge, hypothecate, or transfer as security for the payment of any and all loans, advances, indebtedness, and liabilities of the Corporation, any and all stocks, securities, and other real or personal property at any time held by the Corporation and to that end may endorse, assign, and deliver same. Such authority may be general or confined to specific instances.

 

ARTICLE VIII

CERTIFICATES OF STOCK

 

Section 8.1.           Issuance. The shares of the Corporation shall be represented by certificates, provided that the Board of Directors may provide by resolution that some or all classes or series of the Corporation's stock may be uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered. Notwithstanding the adoption of such a resolution by the Board of Directors, every holder of stock represented by certificates and upon request every holder of uncertificated shares shall be entitled to a certificate or certificates showing the number of shares of stock registered in his name on the books of the Corporation. The certificates shall be in such form as may be determined by the Board of Directors, shall be issued in numerical order and shall be entered in the books of the Corporation as they are issued. They shall exhibit the holder's name and number of shares (and if the stock of the Corporation shall be divided into classes or series, the class or series of such shares) and shall be signed by the Chairman of the Board, the Chief Executive Officer, the President or a Vice President and by the Secretary or the Controller. Any of or all of the signatures on the certificate may be facsimiles. The stock record books and the blank stock certificate books shall be kept by the Secretary, or at the office of such transfer agent or transfer agents as the Board of Directors may from time to time by resolution determine. In case any officer, transfer agent or registrar who shall have signed or whose facsimile signature or signatures shall have been placed upon any such certificate or certificates shall have ceased to be such officer, transfer agent or registrar before such certificate is issued by the Corporation, such certificate may nevertheless be issued by the Corporation with the same effect as if such person were such officer, transfer agent or registrar at the date of issue.

 

If the Corporation shall be authorized to issue more than one class of stock or more than one series of any class, the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights shall be set forth in full or summarized on the face or back of the certificate which the Corporation shall issue to represent such class of stock; provided that, except as otherwise provided by statute, in lieu of the foregoing requirements there may be set forth on the face or back of the certificate which the Corporation shall issue to represent such class or series of stock, a statement that the Corporation will furnish to each stockholder who so requests the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Within a reasonable time after the issuance of transfer of uncertificated stock, the Corporation shall send to the registered owner thereof a written notice containing the information required to be set forth or stated on certificates pursuant to this Section 8.1 or otherwise required by statute or with respect to this Section 8.1 a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Except as otherwise expressly provided by law, the rights and obligations of the holders of uncertificated stock and the rights and obligations of the holders of certificates representing stock of the same class and series shall be identical.

 

Amended and Restated By-Laws of Bio-En Holdings Corp. 15
 

 

All certificates surrendered to the corporation for transfer shall be cancelled and no new certificate shall be issued until the former certificate for a like number of shares shall have been surrendered and cancelled, except that in the case of a lost, stolen, destroyed or mutilated certificate a new one may be issued therefor upon such terms and with such indemnity, if any, to the Corporation as the Board of Directors may prescribe. Certificates shall not be issued representing fractional shares of stock.

 

Section 8.2.           Lost Certificates . The Board of Directors may direct a new certificate of stock or uncertificated shares to be issued in place of any certificate theretofore issued by the Corporation alleged to have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen or destroyed. When authorizing such issue of a new certificate or certificates, the Board of Directors may, in its discretion and as a condition precedent to the issuance thereof, require the owner of such lost, stolen or destroyed certificate, or his legal representative, to advertise the same in such manner as it shall require or to give the Corporation a bond in such sum as it may deem sufficient to indemnify it against any claim that may be made against the Corporation on account of the alleged loss, theft or destructions of any such certificate or the issuance of such new certificate or uncertificated shares, or both.

 

Section 8.3.          Transfers . Upon surrender to the Corporation or the transfer agent of the Corporation of a certificate for shares duly endorsed or accompanied by proper evidence of succession, assignment or authority to transfer, it shall be the duty of the Corporation to issue a new certificate to the person entitled thereto, cancel the old certificate and register the transaction upon its books. Upon presentation to the Corporation or the transfer agent of the Corporation of an instruction with a request to transfer, pledge or release an uncertificated share or shares, it shall be the duty of the Corporation to register the transfer, pledge or release upon its books, and shall provide the registered owner with such notices as may be required by law. Transfers of shares shall be made only on the books of the Corporation by the registered holder thereof, or by his attorney thereunto authorized by power of attorney and filed with the Secretary of the Corporation or the transfer agent.

 

Section 8.4.          Registered Stockholders . The Corporation shall be entitled to treat the registered owner of any share or shares of stock whether certificated or uncertificated as the holder in fact thereof and, accordingly, shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of the State of Delaware.

 

Section 8.5.          Regulations Regarding Certificates .  The Board of Directors shall have the power and authority to make all such rules and regulations as they may deem expedient concerning the issue, transfer and registration or the replacement of certificates for shares of capital stock of the Corporation.

 

Amended and Restated By-Laws of Bio-En Holdings Corp. 16
 

 

ARTICLE IX

DIVIDENDS

 

Section 9.1.           Declaration .  Dividends upon the capital stock of the Corporation, subject to the provisions of the Certificate of Incorporation, if any, may be declared by the Board of Directors at any regular or special meeting, pursuant to law. Dividends may be paid in cash, in property or in shares of capital stock, subject to the provisions of the Certificate of Incorporation.

 

Section 9.2.           Reserve . Before payment of any dividend, there may be set aside out of any funds of the Corporation available for dividends such sum or sums as the Board of Directors from time to time, in its absolute discretion, shall think proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or maintaining any property of the Corporation, or for such other purpose as the Board of Directors shall think conducive to the interest of the Corporation, and the Directors may modify or abolish any such reserve in the manner in which it was created.

 

ARTICLE X

INDEMNIFICATION

 

Section 10.1.          Third Party Actions . This Corporation shall, to the maximum extent permitted from time to time under the law of the State of Delaware, indemnify and upon request shall advance expenses to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit, proceeding or claim, whether civil, criminal, administrative or investigative (other than an action by or in the name of the Corporation) by reason of the fact that such person is or was or has agreed to be a director, officer, employee, or agent of this Corporation or any of its direct or indirect subsidiaries or while such person is or was serving at the request of this Corporation as a director, officer, partner, trustee, employee or agent of any corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorney's fees and expenses), judgments, fines, penalties and amounts paid in settlement actually and reasonably incurred in connection with the investigation, preparation to defend or defense of such action, suit, proceeding or claim if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interest of the Corporation, and with respect to any criminal action or proceeding, had no reasonable cause to believe such person's conduct was unlawful; provided, however, that the foregoing shall not require this Corporation to indemnify or advance expenses to any person in connection with any action, suit, proceeding, claim or counterclaim initiated by or on behalf of such person. Such indemnification shall not be exclusive of other indemnification rights arising under any By-laws, agreement, vote of Directors or stockholders, or otherwise and shall inure to the benefit of the heirs and legal representatives of such person. Any person seeking indemnification under this Section 10.1 shall be deemed to have met the standard of conduct required for such indemnification unless the contrary shall be established.

 

Amended and Restated By-Laws of Bio-En Holdings Corp. 17
 

 

Section 10.2.          Actions By or in the Right of the Corporation .  This Corporation shall, to the maximum extent permitted from time to time under the law of the State of Delaware, indemnify and upon request shall advance expenses to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit, proceeding or claim by or on the right of the Corporation to procure a judgment in its favor by reason of the fact that such person is or was or has agreed to be a director, officer, employee, or agent of this Corporation or any of its direct or indirect subsidiaries or while such person is or was serving at the request of this Corporation as a director, officer, partner, trustee, employee or agent of any corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorney's fees and expenses), judgments, fines, penalties and amounts paid in settlement actually and reasonably incurred in connection with the investigation, preparation to defend or defense of such action, suit, proceeding or claim if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interest of the Corporation, and except that no indemnification shall be made with respect to any claim, issue, or matter as to which such person shall have been adjudged to be liable to the Corporation unless and only to the extent that the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the relevant court shall deem proper. Such indemnification shall not be exclusive of other indemnification rights arising under any By-laws, agreement, vote of Directors or stockholders or otherwise and shall inure to the benefit of the heirs and legal representatives of such person. Any person seeking indemnification under this Section 10.2 shall be deemed to have met the standard of conduct required for such indemnification unless the contrary shall be established.

 

Section 10.3.           Successful Defense .  To the extent that a director, officer, employee, or agent of the Corporation has been successful on the merits or otherwise in defense of any action, suit, or proceeding referred to in Sections 10.1 or 10.2 or in defense of any claim, issue, or matter therein, he shall be indemnified against expenses (including attorneys' fees) actually and reasonable incurred by him in connection therewith.

 

Section 10.4.          Insurance . The Corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person's status as such, whether or not the Corporation would have the power to indemnify such person against such liability under the provisions of this Article X of the By-laws.

 

Section 10.5.           Definitions . For purposes of this Article X, reference to the "Corporation" shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence has continued, would have had power and authority to indemnify its Directors, officers and employees or agents, so that any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under the provisions of this Article X with respect to the resulting or surviving corporation as such person would have with respect to such constituent corporation if its separate existence had continued.

 

For purposes of this Article X, references to "other enterprises" shall include employee benefit plans; references to "fines" shall include any excise taxes assessed on a person with respect to any employee benefit plan; and references to "serving at the request of the Corporation" shall include any service as a director, officer, employee or agent of the Corporation which imposes duties on, or involves services by, such director, officer, employee, or agent with respect to an employee benefit plan, its participants, or beneficiaries; and a person who acted in good faith and in a manner he reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner "not opposed to the best interests of the Corporation" as referred to in this Article X.

 

Amended and Restated By-Laws of Bio-En Holdings Corp. 18
 

 

Section 10.6.           Survival; Preservation of Other Rights. The foregoing indemnification provisions shall be deemed to be a contract between the Corporation and each director, officer, employee, and agent who serves in any such capacity at any time while these provisions as well as relevant provisions of the Business Corporation Law are in effect and any repeal or modification thereof shall not affect any right or obligation then existing with respect to any state of facts then or previously existing or any action, suit, or proceeding previously or thereafter brought or threatened based in whole or in part upon any such state of facts. Such a contract right may not be modified retroactively without the consent of such director, officer, employee, or agent.

 

The indemnification provided by this Article X shall not be deemed exclusive of any other rights to which those indemnified may be entitled under any by-law, agreement, vote of stockholders or disinterested Directors or otherwise, both as to action in his official capacity and as to action in another capacity while holding officer, and shall continue as to a person who has ceased to be a director, officer, employee, or agent and shall inure to the benefit of the heirs, executors, and administrators of such a person.

 

ARTICLE XI

MISCELLANEOUS

 

Section 11.1.          Seal .  The Board of Directors may provide a suitable seal, containing the name of the corporation. The seal may be used by causing it or a facsimile thereof to be impressed or affixed or otherwise reproduced.

 

Section 11.2.          Books .  The books of the corporation may be kept (subject to any provision contained in the statutes) outside the State of Delaware at such place or places as may be designated from time to time by the Board of Directors.

 

Section 11.3.          Fiscal Year . The fiscal year of the Corporation shall be the calendar year, or as such as established from time to time by the Board of Directors.

 

Section 11.4.         Resignations.   Any director, member of a committee, or officer may resign at any time. Such resignation shall be made in writing and shall take effect at the time specified therein, or if no time be specified, at the time of its receipt by the President or Secretary. The acceptance of a resignation shall not be necessary to make it effective, unless expressly so provided in the resignation.

 

Section 11.5.          Facsimile Signatures . In addition to the provisions for the use of facsimile signatures elsewhere specifically authorized in these By-laws, facsimile signatures and counterparts of any officer or officers of the Corporation may be used whenever and as authorized by the Board of Directors.

 

Section 11.6.          Reliance upon Books, Reports and Records . Each Director and each member of any committee designated by the Board of Directors shall, in the performance of his duties, be fully protected in relying in good faith upon the books of account or reports made to the Corporation by any of its officers, or by an independent certified public accountant, or by an appraiser selected with reasonable care by the Board of Directors or by any such committee, or in relying in good faith upon other records of the Corporation.

 

Amended and Restated By-Laws of Bio-En Holdings Corp. 19
 

 

ARTICLE XII

AMENDMENT

 

The Board of Directors shall have the power to adopt, amend and repeal from time to time these By-laws of the Corporation and the Certificate of Incorporation.

 

The rest of this page is left intentionally blank.

 

Amended and Restated By-Laws of Bio-En Holdings Corp. 20

 

 

Exhibit 10.1

 

Execution Copy

 

CANCELLATION AGREEMENT

 

This CANCELLATION AGREEMENT (this “ Agreemen t”), dated August 20, 2014 ( the “ Effective Date ”), by and between BIO-EN HOLDINGS CORP. (the “ Company ”), a Delaware corporation, and SERENA B. POTASH , individually (the “ Canceling Party ”). Company and Cancelling Party are also hereinafter individually and jointly referred to as “ P(p)arty ” and/or “ P(p)arties ”.

 

RECITALS

 

WHEREAS , as of the date hereof, the Canceling Party is the owner of 7,894,625 shares of the Company’s commons stock, par value $0.0001 per share (“ Potash Shares ”); and

 

WHEREAS , concurrently herewith, Company and the Canceling Party are entering into an ‘Share Exchange/Merger Agreement’ (“ Exchange Agreement ”) with Bio-En Corp., a Delaware corporation (“ Bio-En ”), pursuant to which Company and the Canceling Party will cancel 6,024,625 shares of the Potash Shares (“ Subject Shares ”) in exchange for the consummation of the Exchange Agreement (“ Cancellation Payment ”); and

 

WHEREAS , after the cancellation of the Subject Shares, the Canceling Party will own 1,870,000 Potash Shares (“ Remaining Shares ”); and

 

WHEREAS , it is a condition precedent to the consummation of the Exchange Agreement that the Canceling Party will enter into this Agreement, which will effectuate the cancellation of the Subject Shares; and

 

WHEREAS , the Canceling Party is entering into this Agreement to, amongst other things, induce Bio-En to enter into the Exchange Agreement and the Canceling Party acknowledges that Bio-En would not consummate the transactions contemplated by the Exchange Agreement unless the transactions contemplated hereby are effectuated in accordance herewith.

 

AGREEMENT

 

In consideration of the mutual promises herein contained and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:

 

1.           Cancellation of Subject Shares . On the Effective Date, the Canceling Party will deliver to Company the necessary documentation for the cancellation of the stock certificates representing the Subject Shares, along with duly executed medallion guaranteed stock powers covering the Subject Shares (or such other documents acceptable to the Company’s transfer agent) and hereby irrevocably instructs the Company and the Company’s transfer agent to cancel the Subject Shares such that the Subject Shares will no longer be outstanding on the stock ledger of the Company and such that the Canceling Party shall no longer have any interest in the Subject Shares whatsoever. The Company shall immediately deliver to the Company’s transfer agent irrevocable instructions providing for the cancellation of the Subject Shares.

 

1
 

 

Execution Copy

 

2.            Effective Date . This Agreement shall become effective upon the execution of this Agreement. The transactions to occur at such place and time with respect to this Agreement are referred to herein as the “ Closing ”.

 

3.            Waiver . At and subsequent to the Closing, the Canceling Party hereby waives any and all rights and interests she has, had or may have with respect to the cancelled Subject Shares.

 

4.           Guaranty . To induce Bio-En to enter into the Exchange Agreement, the Canceling Party hereby absolutely, unconditionally and irrevocably guarantees to Bio-En and the Company that all obligations and liabilities have been satisfied in full and hereby agrees to be wholly responsible for any actual obligation of the Company that arises following the closing of the Exchange Agreement that was the result of an action or inaction of the Company prior to the closing of the Exchange Agreement.

 

5.            Representations by the Canceling Party . (a) The Canceling Party owns the Subject Shares of record and beneficially free and clear of all liens, claims, charges, security interests, and/or encumbrances of any kind whatsoever. The Canceling Party has sole control over the Subject Shares and/or sole discretionary authority over any account in which they are held. Except for this Agreement, no person/entity has any option or right to purchase or otherwise acquire the Subject Shares, whether by contract of sale or otherwise, nor is there a “short position” as to the Subject Shares.

 

(b)            The Canceling Party has full right, power and authority to execute, deliver and perform this Agreement and to carry out the transactions contemplated hereby. This Agreement has been duly and validly executed and delivered by the Canceling Party and constitutes a valid, binding obligation of the Canceling Party, enforceable against it in accordance with its terms (except as such enforceability may be limited by laws affecting creditor's rights generally) .

 

(c)            Canceling Party represents and warrants that it has the requisite authority and capacity to enter into this Agreement, as well as carry out the terms/conditions referenced herein. Additionally, Canceling Party represents and warrants that its compliance with the terms and conditions of this Agreement and will not violate any instrument relating to the conduct of its business, or any other agreement which it may be a party, or any Federal and State rules or regulations applicable to either Party.

 

6.            Further Assurances . Each Party to this Agreement will use its best efforts to take all action and to do all things necessary, proper, or advisable in order to consummate and make effective the transactions contemplated by this Agreement (including the execution and delivery of such other documents and agreements as may be necessary to effectuate the cancellation of the Subject Shares) .

 

7.            Entire Agreement; Amendments . This Agreement contains the entire understanding of the Parties with respect to the matters covered herein and therein and, except as specifically set forth herein, neither the Company nor the Canceling Party makes any representation, warranty, covenant or undertaking with respect to such matters. No amendment, modification, termination or waiver of any provision of this Agreement, and no consent to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by both Parties. Any such waiver or consent shall be effective only in the specific instance and for the specific purpose for which it was given.

 

2
 

 

Execution Copy

 

8.           Survival of Agreements, Representations and Warranties, etc . All representations and warranties contained herein shall survive the execution and delivery of this Agreement. 

 

9.           Successors and Assigns . This Agreement shall bind and inure to the benefit of and be enforceable by the Parties and their respective successors and assigns. 

 

10.         Governing Law . This Agreement and the obligations, rights and remedies of the Parties hereto are to be construed in accordance with and governed by the laws of the State of New York, with any action/dispute concerning this Agreement to be venued in the County of Rockland.

 

11.         Severability . In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof.

 

12.         Miscellaneous . This Agreement embodies the entire agreement and understanding between the Parties hereto and supersedes all prior agreements and understandings relating to the subject matter hereof. If any provision of this Agreement shall be held invalid or unenforceable for whatever reason, the remainder of this Agreement shall not be affected thereby and every remaining provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. This Agreement may be executed in any number of counterparts and by the Parties hereto on separate counterparts but all such counterparts shall together constitute but one and the same instrument.

 

IN WITNESS WHEREOF , the Parties hereto have executed this Agreement as of the date first above written.

 

  BIO-EN HOLDINGS CORP
   
  By: /s/ Serena B. Potash
  Name: Serena B. Potash
  Title: President
   
  By: /s/ Serena B. Potash
  SERENA B. POTASH , Individually

 

3

 

Exhibit 10.2

 

EXCLUSIVE LICENSE AGREEMENT

 

THIS EXCLUSIVE LICENSE AGREEMENT (hereinafter the “LA”) is made this 23rd day of March, 2014 (hereinafter the “Effective Date”) by and between GeneSyst International, Inc., a Delaware Corporation, with an address at 1737 Georgetown Road, Suite J, Hudson, Ohio 44236-5013 (hereinafter the "LICENSOR") and Bio-En Corp. , a Delaware Corporation, with a Registered Address: Bio-En Corp. 56 Main street Monsey, NY 10592 (hereinafter the "LICENSEE").

 

RECITALS

 

WHEREAS , LICENSOR has the exclusive right to license the Patents, (as defined in Section 1 (F)) hereto, pursuant to the terms and conditions of the Right to License Agreement dated December 31, 2012, by and between LICENSOR and Eau-Viron, Inc.;

 

WHEREAS , LICENSEE desires to obtain certain rights to the Patent Rights (as defined in Section 1(G)) and LICENSOR agrees to grant such rights to LICENSEE and its AFFILIATE(S) (as defined in Section 1(A)) pursuant to the terms and conditions of this LA;

 

WHEREAS , LICENSOR intends to extend the rights granted herein to the LICENSEE’s AFFILIATES, such that each Project [as defined in Section 1(J)] incorporating the Patent Rights may be performed by LICENSEE’s AFFILIATES;

 

WHEREAS , as partial consideration for this LA, LICENSEE shall, by separate instrument executed contemporaneously with this LA, issue to LICENSOR common stock of LICENSEE in an amount such that, after issuance, LICENSOR’s common stock shall be equal to TEN percent (10%) of LICENSEE’s issued and outstanding common stock; as of the effective date of signatures hereto;

 

WHEREAS , LICENSEE acknowledges that (1) the Patent Rights do not include Technical Support Services (as defined in Section 1(K)) of LICENSOR; (2) Technical Support Services requirements with respect to the Patented Technology (as defined in Section 1(H) hereof) may be unique to the Territory (as defined in Section 1(L)); and (3) LICENSEE will be responsible for securing or self-performing the necessary Technical Support Services with respect to the Patented Technology.

 

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, and for other good and valuable consideration, the receipt, invoice arrangements and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:

 

1. DEFINED TERMS . For purposes of this LA, the following terms will be defined as follows:

 

A. “AFFILIATE” means a business entity in the Market Territory which is registered in The Market Territory in which LICENSEE holds an ownership interest acceptable to LICENSOR which approval shall not be unreasonably withheld.

 

B. "Apparatus" means those gravity pressure vessels and related equipment, systems and/or methods, provided that the use of such technology would infringe a Valid Claim (as defined in Section 1 (M)) in the absence of this LA.

 

1
 

 

C. "GAAP" means generally accepted accounting principles as used in the United States of America applied on a consistent basis.

 

D. “Independent Consulting Services” means consultation and Technical Support Services provided by LICENSOR to LICENSEE or an AFFILIATE under the Independent Contractor Consulting Agreement (hereinafter the “ICCA”) of Exhibit D attached to and made a part of this LA.

 

E. “Initial Project” means the first Project (as defined in Section 1(J)) under this LA with the first AFFILIATE.

 

F. “Patents” means the patents and pending patent applications listed in Exhibit A attached to and made a part of this LA; and all continuations, continuations-in-part, divisions, extensions, reexaminations and reissues of the patents and pending patent applications listed in Exhibit A , whether filed on before or after the Effective Date of this LA, which trace their earliest priority filing date by unbroken lineage to a patent or patent application listed in Exhibit A .

 

G. “Patent Rights” mean the rights secured by the Patents.

 

H. “Patented Technology” means the technology claimed in the Patents.

 

I. “Parties” means the LICENSOR, LICENSEE and each AFFILIATE, as applicable.

 

J. “Project” means each commercial operation within the Territory (as defined in Section 1(L)) at which any of the Patented Technology is used.

 

K. “Technical Support Services” mean assistance in effecting the commercialization of any of the Patented Technology, including but not limited to assistance with raw material characterization, process laboratory simulation, chemical analysis, staff training, engineering design, construction, operation and maintenance process design and application matters, marketing, applicability, limitation analysis, business profitability, contractual limitation, presentation and seminars, contract documents, graphics, construction or materials management, construction inspection, market projections, cost estimating, specifications, operations, maintenance, employee training and quality control.

 

L. “Territory” means The Nation of Malta.

 

M. “Valid Claim” shall mean (a) a claim of a pending patent application that has not been pending for longer than seven years (or such longer time period as may be permitted under applicable law), or (b) a claim of an issued and unexpired Patent that has not been held invalid or unenforceable by a court or other governmental agency of competent jurisdiction in a decision or order.

 

2. INCORPORATION OF RECITALS . The parties acknowledge that the Recitals are true and correct in all respects and are incorporated herein by reference.

 

2
 

 

3. LICENSE GRANT .

 

A. Upon payment of the Initial License Fee (as defined in Section 4(A)), LICENSOR hereby grants to LICENSEE an exclusive license (without the right to sublicense) to make, use, have made, sell, market, and develop the Patented Technology in the Territory.

 

B. This LA is not restricted as to application as presented in the teachings and preferred embodiments of the Patents, and permit any use within the capability of the method or apparatus Patents, except as pertains to methods involving exceptional safety and technical qualifications in management, engineering and employee training. Examples of such special requirements include low level and or mixed and transuranic radioactive wastes, the demilitarization of chemical, biological and radiological weapons, pharmaceutical and carcinogenic wastes, and any such marketing or contracting efforts must be approved by LICENSOR on a case by case basis according to the qualifications of the participants applicable to Projects within the Territory.

 

C. LICENSEE will not associate the Patented Technology with any other technology that may have a material adverse effect on the integrity or reputation of the Patented Technology without the prior written consent of LICENSOR, which consent shall not be unreasonably withheld, conditioned or delayed.

 

D. LICENSEE will not enter into any agreement, or nondisclosure or non-circumvention agreement limitation, with any third party that would prevent such third party from entering into an agreement concerning the Patents with LICENSOR outside of the Territory.

 

E. LICENSEE will be responsible for providing LICENSOR with a timely report each time LICENSOR’S Patented Technology is disclosed or represented to any third party or client, including the well-known journalistic who, where, when, what and why, with outline of future actions, schedules and requirements and any representations made in regard to the Patented Technology.

 

F. LICENSOR acknowledges and agrees that the licenses granted hereunder will extend to LICENSEE’S AFFILIATES after each such AFFILIATE agrees to be bound by the terms and conditions of the agreement attached hereto as Exhibit B (“EXCLUSIVE AFFILIATE LICENSE Agreement”). The obligations and liabilities of each AFFILIATE and the LICENSEE shall be several and not joint, and independent from any other obligations and liabilities of any other AFFIIATE such that a default by one of them shall not be a default by another.

 

4. COMPENSATION.

 

A. With signature hereto, LICENSEE, shall pay to LICENSOR an initial license fee equal to THREE HUNDRED THIRTY THOUSAND US DOLLARS ($330,000.00) in an amount in Euros as of the date of agreement (the “Initial License Fee”) net after any applicable Value Added Tax fees, or equivalent payment requirements.

 

B. LICENSEE will, as well as on behalf of each Affiliate(s) hereto as applicable, agrees that it shall pay to LICENSOR a royalty equal to three percent (3%) of gross revenues, as defined under GAAP in the Territory, actually received by LICENSEE (the “Royalties”), but in no event less than US $330,000.00 in an amount in Euros as of the date of agreement net after any applicable Value Added Tax or equivalent payment requirements, per calendar year per Project (the “Minimum Royalty”). LICENSEE shall pay the Royalties due within thirty (30) days after the end of each calendar quarter, such payments to begin within thirty (30) days after the first full calendar quarter after the Effective Date. The first Minimum Royalty shall be due thirty (30) days after the anniversary of the first of the following events, LICENSEE’S procurement of initial project development funding, client contract or initiation of engineering, and shall be due annually thereafter.

 

3
 

 

C. The LICENSEE, as well as on behalf of each Affiliate(s) hereto as applicable, shall provide to the LICENSOR at its offices on or before the last working day of February of each year a written report for each Project for the previous year, or portion thereof, that will include a detailed report of the Royalties or credits due (“Annual Report”). Any credit(s) shall be applied to the next Royalties payment(s) due. On ten (10) days written notice, the LICENSOR shall have the right at its expense to perform diligence and/or audit the records of the LICENSEE and/or each AFFILIATE relating to the payments due to LICENSOR hereunder. Said audit shall be conducted in a timely fashion in the offices of the LICENSEE or AFFILIATE in a semi-private office provided and furnished by the LICENSEE or AFFILIATE. In the event irregularities that exceed ten percent (10%) of the actual Royalties paid are discovered in any audit, the LICENSEE or AFFILIATE shall have thirty (30) business days from written formal notice from LICENSOR to remedy the irregularity.

 

D. As an alternative to the payment of Royalties, in the event no performance price for services producing an ongoing gross income to LICENSEE, and on behalf of each Affiliate(s) hereto, is involved and the Vessel is sold or built for the use of a client, a fixed fee shall be paid by AFFILIATE to LICENSOR in an amount equal to 9.0% of the construction price of each gravity pressure vessel, appurtenances, and supporting improvements directly relating thereto (hereinafter “Fixed Fee”). The construction price shall include the sum of all construction contracts, design and contract document fees, and contract revisions. The construction price does not include monies for land, legal fees, finance fees and/or points, insurance, interest, or bonding requirements. The Fixed Fee shall be paid to LICENSOR on a pro rata basis with the construction monthly draws for progress payments against the construction account and reconciled with the final payment with National Society of Professional Engineers "Certificate of Substantial Completion" form 1910-8-D, latest edition. The Initial License Fee and the Independent Contractor Consulting Services Fee (as defined in Section 5(F)) shall apply should this alternative be selected.

 

E. Upon prior notification to LICENSOR, as an alternative to the payment of Royalties, LICENSEE or its AFFILIATE(S), and on behalf of each Affiliate(s) hereto, may as an alternative and upon notification of election of this alternative, and LICENSEE or its AFFILIATE(S) may elect to tender a purchase order to LICENSOR for a LICENSOR supplied Vessel, supported by a dedicated payment assurance or guarantee from a banking institution approved by the LICENSOR, for the specific facility for which the purchase order is applicable, as of the date of the purchase order, with the cost of the license rights for the remaining life of the patent covering said Vessel included in the purchase price of the Vessel from the LICENSOR. The Initial License Fee and the Independent Contractor Consulting Services Fee (as defined in Section 5(F)) shall apply should this alternative be selected.

 

4
 

 

F. LICENSEE, and on behalf of each Affiliate(s) hereto, shall also enter into the ICCA of Exhibit D and provide to LICENSOR an independent contractor consulting services fee of not less than US $150,000.00 per year in an amount in Euros as of the date of agreement (the “Independent Contractor Consulting Services Fee”) to cover the costs of consultation and Technical Support Services. Any portion of the annual Independent Contractor Consulting Services Fee not used within the given year shall not be refundable, but will be applied against the subsequent year’s fee. This payment obligation will be that of the AFFILIATE operating each separate Project, but payments shall be remitted by and through LICENSEE.

 

G. Any payment amounts in this LA refer to U.S. currency unless partial exception is made in advance of the payment due date.

 

H. In the event an AFFILIATE signs the AFFILIATE LICENSE AGREEMENT, EXHIBIT B, in the form attached hereto the AFFILIATE, through the LICENSEE, shall be obligated to pay or perform the obligations to LICENSEE under this Section 4 with respect to the Project or Projects undertaken by such AFFILIATE. The obligations and liabilities of each AFFILIATE and the LICENSEE under this LA shall be several and not joint and independent from the obligations and liabilities of any other AFFILIATE so that a default by one of them under this LA shall not be a default by the others. In the event of the termination of cessation or suspension of operations by the LICENSEE, the agreements with the Licensee of each AFFILIATE hereunder shall transfer directly to the LICENSOR.

 

5. TERRITORY . For purposes of determining whether the rights granted hereunder are being used by LICENSEE in the Territory, the physical location of LICENSEE’S use of the Patents, Patent Rights, or Patented Technology shall control.

 

6. TERM . Unless otherwise terminated in accordance with Section 7 hereof, the term of this LA shall continue from the Effective Date until the date of expiration of the last to expire of the Patents. The term of the LA for each Project shall be for the earlier of: (i) the cessation of all activities with respect to the active use of the Patented Technology at any plant/facility located the Project site(s) by LICENSEE or any AFFILIATE; or (ii) the life of the last to expire of the Patents used by LICENSEE or any AFFILIATE at any plant/facility located the Project site(s).

 

7. TERMINATION.

 

A. LICENSOR may terminate this LA upon a breach by LICENSEE or an AFFILIATE, only with respect to the defaulting LICENSEE or defaulting AFFILIATE, if LICENSEE or such AFFILIATE fails to cure the breach within thirty (30) days of such LICENSEE’S or AFFILIATE’S receipt of notice of default. The following events will be considered defaults:

 

1) LICENSEE or AFFILIATE has not made one of the payments or scheduled fees duly required by this LA as of the due date;

 

2) LICENSEE or AFFILIATE has voluntarily or involuntarily become bankrupt as determined or accepted in a Court of Law having such jurisdiction, entered into the protection of the Bankruptcy Courts, or a receiver has been appointed, and the payments required under this LA have not been made within thirty (30) days of the due date;

 

5
 

 

3) LICENSEE or AFFILIATE, or any officers or board directors of LICENSEE or AFFILIATE, have been determined by a mutually agreed arbitrator, negotiator or officer of a Court of Law to have been involved in matters of willful malfeasance, gross negligence or felonious actions with respect to this LA which has substantially harmed LICENSOR, provided LICENSOR is not in default of this LA;

 

4) LICENSEE or AFFILIATE materially breaches the listed obligations of this LA and has not timely cured such breaches; or

 

5) LICENSEE or AFFILIATE fails to use its good faith efforts to comply with the Territorial Market Development and Business Operations and Financing Plan as approved by the LICENSOR.

 

B. A default by LICENSEE will not permit LICENSOR to terminate the rights of any AFFILIATE that is not in default. In such event that LICENSEE’s rights under this LA have been terminated, any AFFILIATE of an existing Project may continue to operate the Project and shall thereafter remit all payments due on account of such Project directly to LICENSOR. LICENSOR and any such AFFILIATE shall execute mutually acceptable estoppel agreements, and other reasonably requested documentation, from time to time, in order to assure such AFFILIATE and any lenders to a Project that the rights of the AFFILIATE will not be adversely affected upon a default of the LICENSEE or any other AFFILIATE.

 

C. LICENSOR expressly agrees that LICENSEE shall not be liable for any damages that may be incurred by LICENSOR as a result of the failure of an AFFILIATE to pay any scheduled fee or Royalties, resulting in the termination of the LA as defined in this Section 7. LICENSOR also expressly agrees that AFFILIATE(S) shall not be liable for any damages that may be incurred by LICENSOR as a result of the failure of LICENSEE or another AFFILIATE to pay any scheduled fee or Royalties, resulting in the termination of the LA as defined in this Section 7.

 

8. PATENT FEES; MAINTENANCE AND PROTECTIONS.

 

A. Patent Fees. LICENSOR shall be responsible for all annuity and/or maintenance fees due and payable to the United States Patent and Trademark Office with respect to Patents. LICENSOR represents and warrants that it will not allow any patent to lapse during the Term of this LA without (i) giving LICENSEE sixty (60) days written notice of LICENSOR’s intent to allow such patent to lapse; and (ii) the prior written consent of LICENSEE, provided the LICENSEE is current on any and all payments to LICENSOR.

 

B. Patent Application Fees. With respect the pending Patents, LICENSOR shall use its best efforts to prosecute such applications. LICENSOR shall be responsible for all costs (including attorneys' fees and filings fees) associated with the prosecution of said applications.

 

9. LITIGATION CONDITION SUBSEQUENT. In the event any litigation is asserted against LICENSEE of such a nature as to substantially harm LICENSEE’S ability to market or fund the Patented Technology, LICENSEE shall, in good faith, diligently prosecute or defend any such claim. Notwithstanding the foregoing, this provision shall not mitigate LICENSOR’S duty to defend patent infringements and the like, at its cost, as otherwise provided in this LA.

 

6
 

 

10. PLANNING. As a requirement to qualify to enter into this LA, the LICENSEE shall provide to LICENSOR for the LICENSOR’S approval, a "Plan for the Territory Market Development and Business Operations and Financing." The scope of these plans sponsored by the LICENSEE would include evaluation, market and organizational tasks leading up to and including Product Enhancement Training (PET) operations and staff training as well as scheduling and confirmed costs to design, build and operate a commercial gravity pressure vessel process, “Proof of LICENSEE qualification.” This Plan for Territory Market Development and Business Operations and Financing shall be CONFIDENTIAL and shall not be disclosed by LICENSOR to any other person or entity, and shall only be reviewed by the executive officers and Directors of LICENSOR on a need to know basis. On notification by the LICENSOR, the LICENSEE may be required to document to the LICENSOR fiscal capability to execute the plans described herein. The actual source of LICENSEE'S funding shall be of good public reputation, and shall be subject to the approval of the LICENSOR, which approval shall not be unreasonably denied.

 

11. CONTROLLED INFORMATION. The provisions of the "Bilateral Nondisclosure Agreement" Exhibit C shall be applicable herein.

 

12. INFORMATION EXCHANGE. The lateral exchange of information is in three categories. The first is that information that is advantageous to have in the public domain. That will include University studies, papers, thesis presentations, grant results, and laboratory simulations. The second is the intermediate grade work of common benefit to the Patented Technology, but to be kept within the circle or family of companies holding license under the subject Patents, including vendor data, published costs, permit requirements, public contracts, RFP notifications, or information about the competition. The third is that level of technical knowhow defined by the source to be "Confidential" in nature and not to be traded or revealed without the written consent of the author or sponsor. This category might include patent applications, litigation details, contracts under negotiation, client lists, and so forth. The LICENSOR shall maintain a library listing items under each of these categories by title and abstract for the consideration of participants in the patent license, as revealed by the participants to the LICENSOR. Materials obtained from this database will be provided at the nominal fee of reproduction, handling and mailing.

 

13. OWNERSHIP OF INFORMATION. The parties hereto acknowledge and agree that any results, data and information that is derived from the use of the Patented Technology by LICENSEE and/or its AFFILIATES in connection with the operation of its respective business shall be solely owned by LICENSEE and/or its AFFILIATES. Notwithstanding, LICENSOR will be given access to all such results, data and information. All such results, data and information shall be subject to the terms of the Bilateral Nondisclosure Agreement of Exhibit C.

 

14. TECHNICAL SUPPORT SERVICES. LICENSEE acknowledges and agrees that (i) the Patents, Patent Rights and Patented Technology include no Technical Support Services; (ii) Technical Support Services requirements with respect to the Patented Technology may be unique to the Territory; and (iii) LICENSEE will be responsible for securing or self-performing necessary Technical Support Services with respect to the Patents, Patent Rights and Patented Technology. The provisions of the ICCA of Exhibit D shall be considered to be applicable to LICENSOR’S provision of Technical Support Services and the tasks separately identified therein shall be performed by LICENSOR by mutual agreement of the Parties for the applicable fees to be paid to LICENSOR for such services.

 

7
 

 

15. QUALITY CONTROL. For quality control the AFFILIATE for each Project, by or through LICENSEE, shall provide to the LICENSOR one set of construction documents and one set of permit applications in their last proposed form. The LICENSOR shall provide one set of non-binding comments to the LICENSEE for the subject AFFILIATE within two (2) weeks of receipt thereof. Said review or any additional reviews prior to design and/or permit completion or subsequent to the non-binding review hereinabove shall be subject to the terms of the ICCA and applicable fees to be paid to LICENSOR for such services.

 

16. PUBLIC INFORMATION. LICENSEE and each AFFILIATE shall conform to the trademarks and nomenclature as defined by LICENSOR, and GeneSyst International, Inc. and the inventor, James A. Titmas, shall be identified and credited in each news release, public presentation, funding promotion, or release of technical data involving the Patented Technology which is in the control of LICENSEE. The use of the terms, the “Gravity Pressure Vessel™,” or the “GPV™,” reaction method or apparatus, or the “Titmas Process™,” or the “GeneSyst Process™,” conversion system are to be utilized as applicable. LICENSOR shall be permitted to review news releases, public presentations, and funding promotion prior to release by LICENSEE for compliance with this provision.

 

17. REPRESENTATIONS AND WARRANTIES.

 

A. Each party represents and warrants to the other party that (i) it is a legal entity duly organized, validly existing and in good standing; (ii) it has all requisite corporate power and authority to execute, deliver and perform its obligations hereunder; (iii) it will comply with all laws and regulations applicable to the performance of its obligations hereunder and will obtain all applicable permits and licenses required of it in connection with its obligations hereunder; (iv) it will avoid deceptive, misleading or unethical practices that could adversely affect the performance of the other party’s obligations under this LA or damage the reputation of the other party; (v) it is not a party to any agreement with a third party, the performance of which is reasonably likely to affect adversely its ability or the ability of the other party to perform fully its respective obligations hereunder; and (vi) its performance of its obligations under this LA will not violate any other agreement between such party and any third party.

 

B. LICENSOR represents and warrants to LICENSEE that (i) as of the Effective Date of this LA, LICENSOR has no knowledge or information that would lead LICENSOR to conclude that the Patents, Patent Rights, or Patented Technology infringe or violate the patent, copyright, trademark, trade secret or other intellectual property rights of any third party; (ii) the Patents, Patent Rights, and Patented Technology as licensed to LICENSEE by LICENSOR under the terms and conditions of this LA are free from any encumbrance, liens, obligations or any other such restrictions; and (iii) LICENSOR has all rights necessary to provide the licenses granted hereunder.

 

18. INFRINGEMENT MATTERS.

 

A. Each Party will notify the other Party promptly in writing when any infringement is uncovered or suspected, including but not limited to (a) any known or suspected infringement of the Patented Technology by a third party, and (b) any claim that a Project infringes the intellectual property rights of a third party.

 

8
 

 

B. In the event that any information is brought to the attention of LICENSOR or LICENSEE that others are infringing on the Patent Rights granted pursuant to this LA, LICENSOR shall, at its own expense prosecute all such infringement. The control of the litigation, including settlement, shall be by the LICENSOR. LICENSEE shall have the right, at its expense, to be represented by counsel of its own choice and to prosecute and/or join in all such litigation. Should LICENSEE elect not to join in any such litigation, LICENSOR will keep LICENSEE reasonably informed as to the status of any such enforcement. The final disposition of any and all litigation affecting the interests of LICENSOR in the patents shall be by the LICENSOR. LICENSOR shall control and settle any such suit in a manner consistent with the terms and provisions of this LA.

 

C. LICENSOR shall defend, at its own expense, all infringement suits that may be brought against LICENSEE or any AFFILIATE based on or related to manufacture, use, or other exploitation of the Patented Technology, or devices based upon the Patented Technology. Provided, however, if said suit is directly attributable to actions or inactions by LICENSEE or any AFFILIATE that are substantially inconsistent with the rights granted to LICENSEE or AFFILIATE in the Patented Technology, the costs of defense shall be borne by the LICENSEE or the applicable AFFILIATE. Each Party hereto shall have the right to pursue the defense of the Patents independently or in a joint action. The control of the litigation, including settlement, in all cases shall be by the LICENSOR.

 

19. REMEDY FOR DEFAULT. If LICENSEE or any AFFILIATE is in default of the terms of this LA, and has not cured said default within thirty (30) days of written notification by LICENSOR and receipt of the notice of default by LICENSEE and defaulting AFFILIATE, if any, LICENSOR shall have the right, but not obligation, to void the rights of the defaulting Party, in whole or in part and/or pursue any other remedies under this LA or permitted by law or equity.

 

20. PATENT IMPROVEMENTS; FUTURE DEVELOPMENTS. In the event an improvement patent is licensed or granted to the LICENSOR bearing the same expiration date as a patent listed in Exhibit A, the LICENSEE shall benefit from the Exclusive License rights under said improvement under the terms defined herein. If a new patent is co-authored with the LICENSEE by any officer or employee of the LICENSOR, then the LICENSOR and the LICENSEE shall, jointly, have the right to license said patent outside of the Territory and shall share in the economic benefits thereof. The LICENSOR shall be the managing partner in all matters involving said co-authored Patent.

 

A. Joint Ownership . Except as set forth in the ICCA, any inventions which are jointly invented by an officer or employee of LICENSEE and/or an AFFILIATE, and an officer or employee of the LICENSOR, and LICENSEE and/or such AFFILIATE and LICENSOR are joint owners of the invention as a result thereof, then LICENSOR and LICENSEE and/or such AFFILIATE shall be joint owners of any patent issuing from the joint invention. LICENSOR shall be the managing partner with respect to any joint inventions and shall have the exclusive right to market any such jointly owned patent outside the Territory and the right to license said patent outside of the Territory, but LICENSOR and LICENSEE shall share equally in the economic benefits thereof.

 

B. Valuation Process . In order to determine the value of the economic benefit of the jointly owned patent under subsection (A) above, for a period of twenty (20) days after notice from one Party to another Party, each of the Parties shall use good faith efforts to undertake to mutually agree upon the value of the economic benefit of the jointly owned patent. If the Parties are unable to mutually agree upon the value of the economic benefit of the jointly owned patent during such 20-day time period, then within ten (10) days after the expiration of such 20-day period, the Parties shall use good faith efforts to select an independent valuation expert (the " Selected Valuation Expert ") with experience in LICENSEE'S industry to perform an independent valuation of the economic benefits of the jointly owned patent and such independent valuation shall be binding on the Parties hereto. If the Parties are unable to agree upon the Selected Valuation Expert within such 10-day period, then within ten (10) days after the expiration of such 10-day time period, each Party shall select one (1) independent valuation expert (collectively, the " Initial Experts ") and the Initial Experts shall mutually select one (1) independent valuation expert (the “ Valuation Expert ”) within ten (10) days of such request who shall independently perform the valuation of the economic benefit of the jointly owned patent within thirty (30) days after the date of selection by the Initial Experts and such determination of the value of the economic benefit of the jointly owned patent shall be final and binding on the Parties. The costs and expenses incurred in connection with the independent valuations performed by the Selected Valuation Expert, the Initial Experts and the Valuation Expert, if required, shall be borne equally by the Parties. If a Party fails to select an Initial Expert during such 10-day time period and the other Party has selected an Initial Expert within such 10-day time period, then the Initial Expert selected within such 10-day time period shall be deemed to be the Valuation Expert and shall perform the independent valuation of the economic benefit of the jointly owned patent within thirty (30) days after his or her selection and such independent valuation shall be valid and binding upon on the Parties for the purposes of this Section 20.

 

9
 

 

21. OTHER FUTURE PATENTS. Any future patents directly related to gravity pressure vessels and related or supporting technology and procedures in which LICENSOR or James A. Titmas (“Titmas”) may have or acquire rights, or which Titmas has either: (i) invented or (ii) been instrumental in inventing and has patent right thereto, shall be considered to be added to Exhibit A. Any future patents not exclusively related to gravity pressure vessels and related or supporting technology and procedures in which James A. Titmas (“Titmas”) may have or acquire rights, or which Titmas has either: (i) invented or (ii) been instrumental in inventing, shall be exempt from the terms of this LA.

 

22. DISPUTE RESOLUTION PROCESS.

A. Except as set forth in Section 7, LICENSOR and LICENSEE agree that any and all claims, counterclaims, disputes, and other matters in question between them arising out of or relating to this LA or the breach thereof (“Disputes”) shall be resolved in the manner set forth below.

 

1) Negotiation.  LICENSOR and LICENSEE shall endeavor to settle and resolve any Disputes between them, excluding validity or enforceability of the Patents, by direct good faith discussions and negotiations conducted by and between the officers of LICENSEE and LICENSOR, as soon as practicable after the Dispute arises and before initiating any litigation, arbitration or other adversarial dispute resolution procedures. Any Dispute not resolved within thirty (30) days after written notice by one party to the other of its existence will be referred to mediation in accordance with Section 22(A).

 

2) Mediation.  LICENSOR and LICENSEE agree that they shall first submit any and all unsettled Disputes, excluding validity or enforceability of the Patents, to mediation with a neutral mediator, without using a dispute resolution organization or administrative service. The mediator will be selected within fifteen (15) days of the end of negotiations between the parties. Within thirty (30) days after the mediator is selected, both parties and their respective attorneys will meet with the mediator for one mediation session of at least four (4) hours. If such mediation is unsuccessful in resolving a Dispute, then (1) the parties may mutually agree to a dispute resolution of their choice, or (2) either party may seek to have the Dispute resolved by a court of competent jurisdiction.

 

10
 

 

23. GENERAL PROVISIONS.

 

A. LICENSEE shall not have the right to sublicense.

 

B. Neither Party may assign this LA to any third party without the prior written consent of the other Party, provided that either Party may assign this LA upon a merger or sale of substantially all of such Party’s capital stock or assets. This LA shall be binding upon and inure to the benefit of each of the Parties, their respective heirs, legal representatives, successors, and assigns.

 

C. The laws of the State of Delaware shall govern the validity, performance, and enforcement of this LA.

 

D. Should LICENSOR enter into a license agreement to make, use, have made, sell or develop the Patented Technology with a third party on more favorable terms to the licensee than this LA, LICENSEE shall have the option for thirty (30) days after such terms are brought to its attention to elect to avail itself of such license agreement and
substitute it for this LA.

 

E. This LA and all Exhibits attached hereto contain the entire agreement between the Parties as to the matters contained herein, and supersedes any and all other agreements, contracts, promises, or representations, whether written or oral between the Parties with respect to the subject matter hereof. No subsequent agreements, contracts, promises or representations shall be binding and effective between the parties, unless set forth in writing and signed by authorized representatives of the Parties.

 

F. Any forbearance or failure or delay by any of the Parties to exercise any right, power, or remedy hereunder shall not be deemed to be a waiver of such right, power, or remedy, and any single or partial exercise of any such right, power, or remedy hereunder shall not preclude the further exercise thereof; and every right, power, or remedy of any Party shall continue in full force and effect until such right, power, or remedy is waived specifically by an instrument in writing executed by such Party.

 

G. In addition to the agreements and notices to be delivered as herein provided, each of the Parties hereto shall, from time to time upon the reasonable request of the other Party, execute and deliver such additional certificates, notices or instruments and shall take such other action as may reasonably be required to more effectively carry out the terms of this LA, and consummate the transactions contemplated hereby.

 

11
 

 

H. All entities signing this LA represent and warrant that their execution, delivery and performance of this LA has been duly authorized by all necessary corporate and other action and is valid and binding upon such entities. All individuals signing this LA hereby confirm that they have carefully reviewed all the terms and conditions set forth in this LA; they understand these terms and conditions; and they knowingly execute this LA with the understanding they will be bound by these terms and conditions.

 

I. This LA shall be construed without regard to the identity of the person who drafted the various provisions and the rule of construction shall not apply. Each and every provision of this LA with its Exhibits and such other documents and instruments, shall be construed as though all of the Parties participated equally in the drafting process.

 

J. If any provision of this LA or the application of the same shall be deemed to be illegal or unenforceable, then to the extent that such provision is severable under the laws of the state of Delaware, the remainder of this LA shall continue in full force and effect.

 

K. The paragraph headings contained in this LA are for conveniences only and shall not affect, or be used in connection with, the interpretation of this LA.

 

L. This LA may be executed in any number of copies, each of which shall be deemed an original.

 

24. NOTICES

 

A. Any notice required to be given under this LA shall be given by certified or registered mail, return receipt requested, or by standard US mail and shall be effective as of the date of mailing or transmission, directed to the parties to the following addresses or such or other place as either Party may direct in writing:

 

 

(the remainder of this page left blank)

 

12
 

 

13
 

 

EXHIBIT A

PATENTS AND PATENT APPLICATIONS

  

 

5,711,817 APPARATUS AND METHOD FOR THE CONTINUOUS CONVERSION OF CELLULOSIC MATERIAL TO ETHANOL, JAMES A. TITMAS, 27 JANUARY 1998.

 

6,716,360 B2 “METHOD AND APPARATUS FOR TREATING WASTE STREAMS,” A.K.A. UREA PRODUCTION FROM WET OXIDATION, JAMES A TITMAS, ISSUED 16 APRIL 2004 EXPIRATION 16 APR 2022.

 

6,746,516 B2 "METHOD AND APPARATUS FOR TREATING AIR EMISSIONS AND RECOVERING PRODUCTS THEREFROM" JAMES A. TITMAS, ISSUED 8 JUN 2004 EXPIRATION 10 JUN 2022.

 

7,188,791 "GRAVITY PRESSURE VESSEL AND METHOD FOR TREATING VULCANIZED RUBBER" JAMES A. TITMAS, ISSUED 13 MAR 2007. EXPIRATION 7 JAN 2025.

 

7,189,328 B1 “METHOD FOR EXTRACTION OF DISSOLVED TRACE MATERIALS FROM SOLUTION AND RELATED APPARATUS” JAMES A TITMAS, ISSUED 13 MARCH 2007, EXPIRATION 25 JUN 2024.

 

7,211,194 “GRAVITY PRESSURE VESSEL AND RELATED APPARATUS AND METHODS, A.K.A. SELF HEATING HYDROLYSIS GRAVITY PRESSURE VESSEL” JAMES A. TITMAS. ISSUED 1 MAY 2007, EXPIRATION OCT 2024.

 

8,168,043 “RETORT APPARATUS AND A METHOD FOR CONTINUOUSLY PROCESSING LIQUID AND SOLID MIXTURES AND FOR RECOVERING PRODUCTS THEREFROM,” JAMES A. TITMAS. ISSUED 1 MAY 2012, EXPIRATION 29 AUG 2028.

 

8,173,024 "APPARATUS FOR CONDUCTING SUPERCRITICAL WET OXIDATION CONTAINED WITHIN A FLUID ENVELOPE" JAMES A. TITMAS, APPLICATION DATE 25 JULY 2008, EXPIRATION 25 July 2028

 

Note: No assurance is given or implied that the following Patents Pending will be awarded.

 

 

SN 12/452,605 “METHOD AND APPARATUS FOR HYDROLIZING CELLULOSIC MATERIAL,” JAMES A. TITMAS A.K.A. HOLOCELLULOSE ISOLATION IN A GRAVITY PRESSURE VESSEL." (selected foreign patents having been awarded – US patent has been approved, publishing pending)

 

14
 

 

EXHIBIT B

EXCLUSIVE AFFILIATE LICENSE AGREEMENT

 

The below party (the “AFFILIATE”) is an AFFILIATE of ____________________________, a company duly organized under the laws of ________________, the “LICENSEE” under a certain “Exclusive License Agreement” (the “LA”) between GeneSyst International, Inc., a Delaware corporation, the “LICENSOR,” and LICENSEE, executed by them on _________, 201_.

 

AFFILIATE, for good and valuable consideration the receipt and sufficiency of which is acknowledged, agrees to be bound by all of the terms and conditions of the LA applicable to an AFFILIATE of LICENSEE. If at any time LICENSEE should fail to pay or perform any of the obligations set forth in the LA with respect to the Project or Projects under taken by AFFILIATE, AFFILIATE shall assume that obligation within thirty (30) days of receipt of written notice of LICENCEE’S default.

 

IN WITNESS WHEREOF, LICENSOR, LICENSEE and AFFILIATE have through their duly authorized representatives executed this Exhibit B that shall form an integral part of the LA as of this _______ day of _____________, .

 

GeneSyst International, Inc.

By:

Print Name: James A. Titmas

Title: CEO

 

 

 

 

 

AFFILIATE

By:                                                                                                         

Print Name:                                                                    

Title:                                                                                                      

 

15
 

 

EXHIBIT C

BILATERAL NONDISCLOSURE AGREEMENT

 

GENESYST INTERNATIONAL, INC., a Delaware corporation, referred to herein as the "LICENSOR" and Bio-En Corp. , , referred to herein as the “LICENSEE” (together referred to as the "Parties") agree pursuant to the terms of this Bilateral Nondisclosure Agreement (the “BNA”) to the exchange of confidential information solely for the purpose of evaluation, on the condition that the Parties will not discuss or make use in any manner of the information supplied by the LICENSOR or the LICENSEE except under the conditions set forth below:

 

BE IT RESOLVED that in consideration of the recitals contained hereinafter, including the mutual promises herein contained, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned Parties do hereby certify that:

 

1. Each of the Parties hereto agrees that the information which it intends to impart to the other subsequent to the execution hereof will lead to disclosure of intellectual property, clients, intermediaries, contacts, and identification of lending institutions, borrowers, corporations, individuals, shareholders and/or Trusts and shall remain confidential for the term of this BNA.

 

2. The Parties agree for a period equal to the term of the Exclusive Licensing Agreement (the “LA”) not to divulge any confidential information which has heretofore or may hereafter be disclosed to the other orally or in writing, and not to make further use of the same without written permission of Party disclosing such confidential information.

 

3. The above obligation shall not apply to:

A. Information that at the time of disclosure is in the public domain;

B. Information which after disclosure by the Parties to each other becomes part of the public domain by publication or otherwise through no act or failure of the Party;
C. Information, which the Party can show, was in its possession at the time of disclosure and was not acquired directly or indirectly from either Party;
D. Information which is rightfully disclosed to the other by a third party who did not acquire the information directly or indirectly from the other.
E. Information ordered to be made public through and by court rulings or procedures;

 

4. Nothing contained in these BNA, terms shall be construed as a restraint, shop right, or license, for any intellectual property, or impede the marketing thereof by the owner or designated representative.

 

5. Nothing herein shall prohibit the disclosure of such information required to be disclosed in the normal course of business dealings of the Parties hereto.

 

16
 

 

EXHIBIT D

INDEPENDENT CONTRACTOR CONSULTING AGREEMENT

 

WHEREAS, GeneSyst International, Inc. , a Delaware Corporation (“LICENSOR”) and Bio-En Corp. , (“LICENSEE”). (LICENSOR and LICENSEE sometimes referred to as the “Parties”), desire to enter into an Independent Contractor Consulting Agreement (the “ICCA”) for the LICENSOR to provide expertise and Technical Support Services in the field of gravity pressure vessel applications and related matters as set forth in the terms and conditions contained below:

 

NOW, THEREFORE, in consideration of the respective agreements and commitments set forth below, and other good and valuable consideration, the receipt and sufficiency of which is acknowledged by each of the Parties, the Parties agree as follows:

 

1. Engagement of LICENSOR . Upon the execution of this ICCA, the LICENSEE hereby agrees to retain the LICENSOR to work as an independent contractor, and not as an employee. The required retainer fee shall be not less than $150,000.00 in an amount in Euros as of the date of agreement payable by invoice on the execution of the LA and maintained at said level during project execution and invoicing. The LICENSOR will consult with and advise LICENSEE, as requested by LICENSEE, on an hourly charge basis. It is agreed and understood that the LICENSOR has other service contracts, but will devote sufficient time and attention to meet the reasonable consulting needs of the LICENSEE.

 

2. Economics .

 

A. Consulting fees . In addition to any Royalties or Licensing fees, the LICENSEE shall pay the LICENSOR consulting fees for services requested by the LICENSEE. The LICENSOR shall provide LICENSEE with detailed written invoices specifying the hours worked and describing the work performed and the person or persons performing the work; crediting and pro-rating a portion of the fee over the engineering, design and construction aspects of the project. The LICENSOR will forward these statements to LICENSEE on a monthly basis. If in the estimation of the LICENSOR the consulting fee for a single identified task shall exceed $5,000.00, unless previously approved as an integral part of a LICENSEE approved Task. in an amount in Euros as of the date of agreement on any request for services, LICENSOR shall notify LICENSEE prior to providing said services, unless otherwise defined or approved by the LICENSEE.

 

B. Hourly charges . (effective 1/Jan/2013) shall be as listed hereinafter and a part of this agreement, unless an alternative payment program is established by mutual agreement. All time work sheets and receipts applicable to the project will be kept for a minimum of two years and will be available for the LICENSEE's inspections or attached to the invoice if requested.

 

C. Terms . Upon the initial request for services under this ICCA, LICENSEE shall pay to LICENSOR a retainer in the amount to be determined based on the authorized tasks requested by the LICENSEE as estimated and outlined by the LICENSOR subject to direction as described under paragraph 5 below. Invoices are "Net due", and all payments are due within 30 days of the date of the invoice.

 

3. Capacity and Good Character . The LICENSOR covenants and agrees that any dealings it may have with any suppliers, consultants, or other third parties, will be conducted according to the highest ethical standards and the highest standards of integrity. The LICENSOR further agrees that it will not issue any press releases, or make any statements to the press, or communicate in any way with the news media, to respond to questions from the news media without the approval of the LICENSEE in matters related to this Agreement.

 

17
 

 

4. Authority . The LICENSOR shall have no authority to directly or indirectly bind the LICENSEE, its parties, affiliates, consultants, and/or employees in any manner whatsoever, without specific, prior written direction from the LICENSEE, except as provided for in this Agreement.

 

5. Independent Contractor . The LICENSOR's relationship to the LICENSEE shall be that of an independent contractor. The LICENSOR further acknowledges and agrees that he shall not be entitled to participate in any health insurance, pension plan, profit sharing plan or any other benefits the LICENSEE may provide to its own employees. The LICENSEE is interested only in the results achieved by the LICENSOR. The LICENSOR shall be responsible as to the manner and means of accomplishing the work requested by the LICENSEE but is subject to the direction of LICENSEE as to the authorization of tasks and the delineation of task objectives.

 

6. No-Representation . All "tools," i.e., software, programs and electronic versions of drawings, specifications, reports, photographs, data, formulae, estimates, schedules or other and drawing masters or tracings or laboratory notes, will remain the property of LICENSOR. Printed hard copies turned over to the client as "product" including drawings, specifications, pictures, reports, calculations, etc., shall become the property of the LICENSEE, subject to payment therefore, and the appropriate limitations of the confidentiality agreement.

 

A. Equipment and Design Development . The Parties shall not except as allowed by the Exclusive License Agreement (the “LA”), without the prior written consent of the other, manufacture, use or sell any equipment, apparatus, method, process or product designed or fabricated, using or employing any Confidential and Proprietary Information.

 

B. No Claim . NOTHING contained in the Independent Contractor Consulting terms or any disclosure hereunder shall be construed as granting to the LICENSOR or the LICENSEE any claim to the Confidential and Proprietary Information other than provided for in the LA. Nor shall anything in these terms be construed as granting to the LICENSOR or the LICENSEE any other right in any patent or patent application relating to the Confidential and/or Proprietary Information except as agreed under the LA. For the record, a list of patents in various stages of award or development authored or co-authored by James A. Titmas prior to this date is available for inspection.

 

B. Designate "Confidential" . The Parties agree to make reasonable efforts to mark "CONFIDENTIAL", if so requested by the other, any written or graphic information in its possession which discloses Confidential and Proprietary Information, whether such written or graphic information is generated by the other, or by the LICENSOR for the LICENSEE, and to hold same confidential pursuant to the provisions of these terms.

 

C. Limit Access to Information . The Parties agree to permit access to such information only to that limited number of the others key personnel and consultants as shall be necessary to permit the utilization of such information for the purposes stated above. The Parties further agree to notify each person who has access to such information that such information is to be maintained confidential and the parties agree to take all other reasonable action to maintain such information confidential.

 

 

18
 

 

D. Miscellaneous . The Parties acknowledge they have carefully reviewed all of these terms and conditions. The Parties further agree that this Agreement shall be binding upon and inure to the benefit of each of the Parties and their respective legal representatives, successors, and assignees. Finally, the Parties agree that the terms of the LA set forth the entire understanding between the Parties as to the matters contained herein, and supersedes and nulls any other agreements, promises or representations, whether oral or written between the Parties concerning Technical Support Services to be provided. No subsequent agreements, promises or representations shall be binding and/or effective between the Parties unless set forth in writing and signed by both Parties.

 

7. Termination . Notwithstanding any other provision in the ICCA to the contrary, this ICCA is intended to be in full force and effect for the period of the LA. Upon termination, the consultant shall promptly forward the LICENSEE its last billing, setting forth in detail the consulting work performed through the date of termination and upon payment of said billing, this ICCA shall terminate, with the sole exception of the Confidentiality provisions, which shall survive any termination according to its terms. The termination of this ICCA does not terminate the LA.

 

8. Services by LICENSOR . The specific project services shall be selected and defined by the LICENSEE prior to any services being done by the LICENSOR, or LICENSOR’S costs being obligated by the LICENSEE in an amount in Euros as of the date of agreement.

 

  Hourly Charges    
  Effective 1 January 2013    
  Patent Development................................                US $ 600.00  
  Expert Witness, Litigation, Arbitration..........            US $ 400.00  
  Principal......................................... US $ 350.00       
  Architect, Registered Engineer.................... US $ 250.00  
       
  Designer, Graduate Engineer....................... US $ 200.00  
  Senior Draftsman, Qualified Co-op Students.....        US.$ 100.00  
  AUTOCAD Operator.................................. US $  75.00  
  Lab Technicians........................ US $  60.00                      
  Travel, lodging, and approved subcontractor expenses as invoiced    

  

 

All time sheets and receipts applicable to the project will be kept for a minimum of one year after the completion of the project, and will be available for client inspection, or attached to the invoices if requested. A service charge of 1.5% per month will be added to all unpaid invoices after 30 days. Said charge is not to be construed as an acceptance of non-payment of an invoice within 30 days and non-payment shall be subject to paragraph 7. TERMINATION of the concurrent License Agreement.

 

The above rates are subject to change in the event statutory obligations for fringe benefits are imposed by the political jurisdiction’s legislation, or the “Affordable Care Act.”

 

19
 

 

20

 

Exhibit 99.1

 

BIO-EN CORP

(A DEVELOPMENT STAGE COMPANY)

 

CONTENTS

 

PAGE 1

REPORT OF INDEPENDENT REGISTERED PUBLIC

ACCOUNTING FIRM

     
PAGE 2 BALANCE SHEET - MARCH 31, 2014  
     
PAGE 3 STATEMENT OF OPERATIONS FROM JANUARY 6, 2014 (INCEPTION) TO MARCH 31, 2014
     
PAGE 4 STATEMENT OF STOCKHOLDERS’ DEFICIT FROM JANUARY 6, 2014 (INCEPTION) TO MARCH 31, 2014
     
PAGE 5 STATEMENT OF CASH FLOWS FROM JANUARY 6, 2014 (INCEPTION) TO MARCH 31, 2014
   
PAGES 6 - 11 NOTES TO THE FINANCIAL STATEMENTS

 

 
 

   

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors

Bio-En Corp

 

We have audited the accompanying balance sheet of Bio-En Corp (“the Company”) as of March 31, 2014 and the related statements of operations, stockholders’ equity and cash flows for the period from January 6, 2014 (date of inception) through March 31, 2014. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audit.  

 

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

 

In our opinion the financial statements referred to above present fairly, in all material respects, the financial position of Bio-En Corp as of March 31, 2014, and the results of their operations and cash flows for the period from January 6, 2014 (date of inception) through March 31, 2014, in conformity with U.S. generally accepted accounting principles.

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has generated no revenue to date, has an accumulated deficit and is dependent on financial support from its shareholders, which raises substantial doubt about its ability to continue as a going concern. Management’s plans concerning these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

/s/ Sadler, Gibb & Associates, LLC

 

Salt Lake City, UT

July 3, 2014

 

 

1
 

 

Bio-En Corp

(A Development Stage Company)

Balance Sheet

  

LIABILITIES STOCKHOLDERS' DEFICIT

    March 31, 2014  
       
Current Liabilities        
Accounts payable   $ 23,060  
Total Liabilities     23,060  
         
Stockholders' Deficit        
Common stock, $0.0001 par value; 200,000,000 shares authorized, 30,000,000 issued and outstanding     3,000  
Additional paid-in capital     40,922  
Deficit accumulated during the development stage     (66,982 )
Total Stockholders' Deficit     (23,060 )
         
Total Stockholders' Deficit   $ -  

 

See accompanying notes to financial statements

 

2
 

   

Bio-En Corp

(A Development Stage Company)

Statement of Operations

From January 6, 2014 (Inception) to March 31, 2014

 

Operating Expenses        
General and administrative expenses   $ 66,982  
Total Operating Expenses     66,982  
         
Net Loss   $ (66,982 )
         
Net Loss Per Share - Basic and Diluted     (0.00 )
         
Weighted average number of shares outstanding  during the period - Basic and Diluted     30,000,000  

 

See accompanying notes to financial statements

 

3
 

 

Bio-En Corp

(A Development Stage Company)

Statement of Stockholders' Deficit

From January 6, 2014 (Inception) to March 31, 2014

  

          Additional           Total  
    Common stock     paid-in     Accumulated     Stockholders'  
    Shares     Amount     capital     Deficit     Deficit  
                               
Balance, January 6, 2014     -     $ -     $ -     $ -     $ -  
                                         
Common stock issued for services ($0.0001 per share)     6,958,049       696       -       -       696  
                                         
Common stock issued for services - related parties ($0.0001 per share)     23,041,951       2,304       -       -       2,304  
                                         
Contributed capital - payment of expenses by an officer     -       -       40,922       -       40,922  
                                         
Net loss from January 6, 2014 (Inception) to March 31, 2014     -       -       -       (66,982 )     (66,982 )
                                         
Balance, March 31, 2014     30,000,000     $ 3,000     $ 40,922     $ (66,982 )   $ (23,060 )

 

See accompanying notes to financial statements

 

4
 

 

Bio-En Corp

(A Development Stage Company)

Statement of Cash Flows

From January 6, 2014 (Inception) to March 31, 2014

  

    From January 6, 2014  
    (Inception) to March 31, 2014  
       
Cash Flows From Operating Activities:        
Net Loss   $ (66,982 )
Adjustments to reconcile net loss to net cash used in operations        
Common stock issued for services     696  
Common stock issued for services - related parties     2,304  
Contributed capital - payment of expenses by an officer     40,922  
Increase in accounts payable and accrued expenses     23,060  
Net Cash Used In Operating Activities     -  
         
Cash Provided by Investing Activities     -  
         
Cash Provided by Financing Activities     -  
         
Net Decrease in Cash     -  
Cash at Beginning of Period     -  
         
Cash at End of Period   $ -  
         
Supplemental disclosure of cash flow information:        
         
Cash paid for interest   $ -  
Cash paid for taxes   $ -  

 

See accompanying notes to financial statements

 

5
 

  

Bio-En Corp

(A DEVELOPMENT STAGE COMPANY)

NOTES TO THE FINANCIAL STATEMENTS

AS OF MARCH 31, 2014

 

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION

 

Organization.

 

Bio-En Corp is a Delaware company (the “Company”), incorporated under the laws of the State of Delaware on January 6, 2014 .

 

The Company is in the development stage and is devoting substantially all of its efforts to the development of its business plan.  The Company intends to be a world leader of setting the standard for waste to bio-fuel technologies. The Company intends to plan, design and execute agreements to build, operate and maintain a bio-mass to energy facility on the Island of Malta, which is contingent on sufficient capital funding.

 

The Company’s fiscal year-end is March 31, 2014.

 

Risks and Uncertainties

 

The Company intends to operate in an industry that is subject to rapid change. The Company's operations will be subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks, including the potential risk of business failure.

 

Use of Estimates

 

In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Significant estimates include the valuation of deferred taxes assets and the valuation of stock issued for services. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At March 31, 2014, the Company had no cash or cash equivalents.

 

Share Based Payment

 

The Company recognizes all forms of share-based payments, including stock option grants, warrants, restricted stock grants, and stock appreciation rights, at their fair value on the grant date, which are based on the estimated number of awards that are ultimately expected to vest.

 

6
 

 

Bio-En Corp

(A DEVELOPMENT STAGE COMPANY)

NOTES TO THE FINANCIAL STATEMENTS

AS OF MARCH 31, 2014

 

Share based payment awards for services rendered are recorded at either the fair value of the services rendered or the fair value of the share-based payment, whichever is more readily determinable.

 

Fair Value of Financial Instruments

 

The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

 

The following are the hierarchical levels of inputs to measure fair value:

 

- Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

- Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

- Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

 

The Company's financial instruments consist of accounts payable. The carrying amount of the Company's financial instruments approximates their fair value as of March 31, 2014, due to the short-term nature of these instruments.

 

Income Taxes

 

The Company recognizes deferred tax assets and liabilities for both the expected impact of differences between the financial statements and the tax basis of assets and liabilities, and for the expected future tax benefit to be derived from tax losses and tax credit carry forwards. The Company has established a valuation allowance to reflect the likelihood of the realization of deferred tax assets.

 

7
 

 

Bio-En Corp

(A DEVELOPMENT STAGE COMPANY)

NOTES TO THE FINANCIAL STATEMENTS

AS OF MARCH 31, 2014

 

The Company has a net operating loss carry forward for tax purposes totaling approximately $23,000 at March 31, 2014, expiring through 2034. U.S. Internal Revenue Code Section 382 places a limitation on the amount of taxable income that can be offset by carry forwards after a change in control (generally greater than a 50% change in ownership).

 

Significant deferred tax assets at March 31, 2014 are approximately as follows:

 

Gross deferred tax assets:        
Net operating loss carryforwards   $ (9,000 )
Total deferred tax assets     9,000  
Less: valuation allowance     (9,000 )
Net deferred tax asset recorded   $ -  

 

The net change in the valuation allowance from January 6, 2014 (inception) to March 31, 2014 was an increase of approximately $9,000.

 

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of March 31, 2014.

 

The actual tax benefit differs from the expected tax benefit for the year ended March 31, 2014 (computed by applying the U.S. Federal Corporate tax rate of 34% to income before taxes and 8.84% for State income taxes including a blended rate of 39.83%) approximately as follows:

 

Expected tax expense (benefit) - Federal   $ (29,000 )
Expected tax expense (benefit) - State     (8,000 )
Non-deductible expenses     28,000  
Change in valuation allowance     9,000  
Actual tax expense (benefit)   $ -  

 

 

8
 

 

Bio-En Corp

(A DEVELOPMENT STAGE COMPANY)

NOTES TO THE FINANCIAL STATEMENTS

AS OF MARCH 31, 2014

 

Basic and Diluted Earnings (Loss) Per Share

 

Basic earnings (loss) per share (“EPS”) is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period, excluding the effects of any potentially dilutive securities. Diluted EPS gives effect to all dilutive potential of shares of common stock outstanding during the period including stock warrants, using the treasury stock method (by using the average stock price for the period to determine the number of shares assumed to be purchased from the exercise of warrants), and convertible debt, using the if-converted method. Diluted EPS excludes all dilutive potential of shares of common stock if their effect is anti-dilutive. The Company has had no common stock equivalents since inception.

 

Recent Accounting Pronouncements

 

There are no new accounting pronouncements that have any impact on the Company’s financial statements.

 

NOTE 2 GOING CONCERN

 

As reflected in the accompanying financial statements, the Company had a net loss of $66,982 and net cash used in operations of $-0- from January 6, 2014 (inception) to March 31, 2014, and a working capital deficit and stockholders’ deficit of $23,060 at March 31, 2014. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

The ability of the Company to continue its operations is dependent on Management's plans, which may include the raising of capital through debt and/or equity markets with some additional funding from other traditional financing sources, which may include term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The Company may need to incur liabilities with certain related parties to sustain the Company’s existence.

 

The Company will require additional funding to finance the growth of its current and expected future operations as well as to achieve its strategic objectives. There can be no assurance that financing will be available in amounts or terms acceptable to the Company, if at all.

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

 

9
 

 

Bio-En Corp

(A DEVELOPMENT STAGE COMPANY)

NOTES TO THE FINANCIAL STATEMENTS

AS OF MARCH 31, 2014

 

NOTE 3 STOCKHOLDERS’ EQUITY

 

Stock Issued for Pre-Incorporation Services

 

For the period from January 6, 2014 (inception) to March 31, 2014, the Company issued 6,958,049 shares of common stock to third parties having a fair value of $696 ($0.0001/share), based upon the fair value of pre incorporation services rendered.

 

Of the total shares issued, 2,548,853 shares, having a fair value of $255 ($0.0001/share), reflect a non-cash payment as consideration for entering into an exclusive license agreement with a 3 rd party as it pertains to the development and use of intellectual property (see Note 4).

   

Stock Issued for Services – Related Parties

 

For the period from January 6, 2014 (inception) to March 31, 2014, the Company issued 23,041,951 shares of common stock to related parties having a fair value of $2,304 ($0.0001/share), based upon the fair value of pre incorporation services rendered.

 

Contributed Capital – Payment of Expenses by an Officer

 

For the period from January 6, 2014 (inception) to March 31, 2014, an officer of the Company paid operating expenses on behalf of the Company totaling $40,922, which was treated as contributed capital.

 

NOTE 4 COMITTMENT

 

On March 23, 2014, the Company executed an agreement to be the exclusive licensee of patented intellectual property for Malta. In connection with this agreement, the following terms are noted:

 

Payment of 3% royalty of gross revenues

 

The first $330,000 is due 30 days after the Company receives initial project development funding, customer contract or initiation of engineering, and shall be due annually thereafter. The Company must pay the greater of 3% or $330,000 in future years.

 

The agreement remains in force for a period of time equivalent to the remaining life of the most current patent.

 

10
 

 

Bio-En Corp

(A DEVELOPMENT STAGE COMPANY)

NOTES TO THE FINANCIAL STATEMENTS

AS OF MARCH 31, 2014

 

NOTE 5 SUBSEQUENT EVENTS

 

Subsequent to the period ended March 31, 2014, the Company issued 600,000 shares of common stock for cash proceeds of $60 ($0.0001/share).

 

The Company has evaluated for subsequent events between the balance sheet date of March 31, 2014 and September 2, 2014, the date the financial statements were available to be issued and concluded that the events or transactions occurring during that period requiring recognition or disclosure have been made.

 

11
 

 

BIO-EN CORP

 

CONTENTS

 

PAGE 12 CONDENSED BALANCE SHEETS AS OF JUNE 30, 2014 (UNAUDITED) AND MARCH 31, 2014  
     
PAGE 13 STATEMENT OF OPERATIONS FOR THE THREE MONTHS ENDED JUNE 30, 2014 (UNAUDITED)
     
PAGE   STATEMENT OF STOCKHOLDERS’ DEFICIT FOR THE THREE MONTHS ENDED JUNE 30, 2014 (UNAUDITED)
     
PAGE 14 STATEMENT OF CASH FLOWS FOR THE THREE MONTHS ENDED JUNE 30, 2014 (UNAUDITED)
     
PAGES 15 - 20 NOTES TO THE CONDENSED FINANCIAL STATEMENTS

 

15
 

   

Bio-En Corp

Condensed Balance Sheet

 

    June 30, 2014     March 31, 2014  
    (Unaudited)        
             
ASSETS                
                 
Assets                
Cash   $ 60     $ -  
                 
Total Assets   $ 60     $ -  
                 
LIABILITIES STOCKHOLDERS' DEFICIT                
                 
Current Liabilities                
Accounts payable   $ 6,796     $ 23,060  
Total  Liabilities     6,796       23,060  
                 
                 
Stockholders' Deficit                
Common stock, $0.0001 par value; 200,000,000 shares authorized, 30,600,000 and 30,000,000 issued and outstanding, respectively     3,060       3,000  
Additional paid-in capital     103,731       40,922  
Accumulated deficit     (113,527 )     (66,982 )
Total Stockholders' Deficit     (6,736 )     (23,060 )
                 
Total Liabilities and Stockholders' Deficit   $ 60     $ -  

 

See accompanying notes to condensed financial statements

 

12
 

 

Bio-En Corp

Condensed Statement of Operations

For the Three Months Ended June 30, 2014

Unaudited

 

Operating Expenses        
General and administrative expenses   $ 46,545  
Total Operating Expenses     46,545  
         
Net Loss   $ (46,545 )
         
Net Loss Per Share  - Basic and Diluted   $ (0.00 )
         
Weighted average number of shares outstanding during the period - Basic and Diluted     30,342,857  

 

See accompanying notes to condensed financial statements

 

13
 

 

Bio-En Corp

Condensed Statement of Cash Flows

For the Three Months Ended June 30, 2014

Unaudited

 

Cash Flows From Operating Activities:        
Net Loss   $ (46,545 )
Adjustments to reconcile net loss to net cash used in operations        
Contributed capital - payment of expenses by an officer     62,809  
Decrease in accounts payable and accrued expenses     (16,264 )
Net Cash Used In Operating Activities     -  
         
Cash Provided by Investing Activities     -  
         
Cash Provided by Financing Activities        
Proceeds from issuance of common stock     60  
Net Cash Provided by Financing Activities     60  
         
Net Increase in Cash     60  
Cash at Beginning of Period     -  
         
Cash at End of Period   $ 60  
         
Supplemental disclosure of cash flow information:        
         
Cash paid for interest   $ -  
Cash paid for taxes   $ -  

 

See accompanying notes to condensed financial statements

 

14
 

 

Bio-En Corp

NOTES TO THE CONDENSED FINANCIAL STATEMENTS

AS OF JUNE 30, 2014

 

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION

 

Basis of Presentation

 

The accompanying condensed consolidated unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all the information necessary for a comprehensive presentation of financial position and results of operations.

 

It is management’s opinion however, that all material adjustments (consisting of normal recurring adjustments) have been made, which are necessary for a fair financial statements presentation.  The results for the interim period are not necessarily indicative of the results to be expected for the year.

 

Bio-En Corp is a Delaware company (the “Company”), incorporated under the laws of the State of Delaware on January 6, 2014 .

 

The Company intends to be a world leader of setting the standard for waste to bio-fuel technologies. The Company intends to plan, design and execute agreements to build, operate and maintain a bio-mass to energy facility on the Island of Malta, which is contingent on sufficient capital funding.

 

The Company’s fiscal year-end is March 31, 2015.

 

Risks and Uncertainties

 

The Company intends to operate in an industry that is subject to rapid change. The Company's operations will be subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks, including the potential risk of business failure.

 

Use of Estimates

 

In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Significant estimates include the valuation of deferred taxes assets and the valuation of stock issued for services. Actual results could differ from those estimates.

 

16
 

 

Bio-En Corp

NOTES TO THE CONDENSED FINANCIAL STATEMENTS

AS OF JUNE 30, 2014

 

Cash and Cash Equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At June 30, 2014 and March 31, 2014, the Company had no cash equivalents.

 

Share Based Payment

 

The Company recognizes all forms of share-based payments, including stock option grants, warrants, restricted stock grants, and stock appreciation rights, at their fair value on the grant date, which are based on the estimated number of awards that are ultimately expected to vest.

 

Share based payment awards for services rendered are recorded at either the fair value of the services rendered or the fair value of the share-based payment, whichever is more readily determinable.

 

Fair Value of Financial Instruments

 

The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

 

The following are the hierarchical levels of inputs to measure fair value:

 

- Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

- Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

- Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

 

17
 

 

Bio-En Corp

NOTES TO THE CONDENSED FINANCIAL STATEMENTS

AS OF JUNE 30, 2014

 

The Company's financial instruments consist of accounts payable. The carrying amount of the Company's financial instruments approximates their fair value as of June 30, 2014, due to the short-term nature of these instruments.

 

Income Taxes

 

The Company accounts for income taxes under FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

 

Basic and Diluted Earnings (Loss) Per Share

 

Basic earnings (loss) per share (“EPS”) is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period, excluding the effects of any potentially dilutive securities. Diluted EPS gives effect to all dilutive potential of shares of common stock outstanding during the period including stock warrants, using the treasury stock method (by using the average stock price for the period to determine the number of shares assumed to be purchased from the exercise of warrants), and convertible debt, using the if-converted method. Diluted EPS excludes all dilutive potential of shares of common stock if their effect is anti-dilutive. The Company has had no common stock equivalents since inception.

 

Recent Accounting Pronouncements

 

In June 2014, FASB issued Accounting Standards Update (“ASU”) No. 2014-10, “Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation”. The update removes all incremental financial reporting requirements from GAAP for development stage entities, including the removal of Topic 915 from the FASB Accounting Standards Codification. In addition, the update adds an example disclosure in Risks and Uncertainties (Topic 275) to illustrate one way that an entity that has not begun planned principal operations could provide information about the risks and uncertainties related to the company’s current activities. Furthermore, the update removes an exception provided to development stage entities in Consolidations (Topic 810) for determining whether an entity is a variable interest entity—which may change the consolidation analysis, consolidation decision, and disclosure requirements for a company that has an interest in a company in the development stage. The update is effective for the annual reporting periods beginning after December 15, 2014, including interim periods therein. Early application with the first annual reporting period or interim period for which the entity’s financial statements have not yet been issued (Public business entities) or made available for issuance (other entities). The Company adopted this pronouncement for the three months ended June 30, 2014.

 

18
 

 

Bio-En Corp

NOTES TO THE CONDENSED FINANCIAL STATEMENTS

AS OF JUNE 30, 2014

 

NOTE 2 GOING CONCERN

 

As reflected in the accompanying financial statements, the Company has minimal operations, has negative working capital and stockholders’ deficit of $6,736, used cash in operations of $0 and has a net loss of $46,545 for the three months ended June 30, 2014. This raises substantial doubt about its ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.

 

NOTE 3 STOCKHOLDERS’ EQUITY

 

Stock Issued for Cash

 

For the three months ended June 30, 2014, the Company issued 600,000 shares of common stock for $60 ($0.0001 per share).

 

Contributed Capital – Payment of Expenses by an Officer

 

For the three months ended June 30, 2104, an officer of the Company paid operating expenses on behalf of the Company totaling $62,809, which was treated as contributed capital.

 

NOTE 4 COMITTMENT

 

On March 23, 2014, the Company executed an agreement to be the exclusive licensee of patented intellectual property for Malta. In connection with this agreement, the following terms are noted:

 

Payment of 3% royalty of gross revenues

 

The first $330,000 is due 30 days after the Company receives initial project development funding, customer contract or initiation of engineering, and shall be due annually thereafter. The Company must pay the greater of 3% or $330,000 in future years.

 

The agreement remains in force for a period of time equivalent to the remaining life of the most current patent.

 

19
 

 

Bio-En Corp

NOTES TO THE CONDENSED FINANCIAL STATEMENTS

AS OF JUNE 30, 2014

 

NOTE 5 SUBSEQUENT EVENTS

 

In preparing these financial statements, the Company has evaluated events and transactions for potential recognition or disclosure through September 3, 2014, the date the financial statements were available to be issued, and concluded that events or transactions occurring during that period requiring recognition or disclosure have been made.

 

Subsequent to June 30, 2014, the Company cancelled 1,620,000 shares of common stock that was previously issued to a related party.

 

On August 21, 2014, the Company entered into a Share Exchange Agreement with Bio-En Holdings Corp, a Delaware Corporation.  This transaction closed on September 10, 2014, each issued and outstanding share of common stock of Bio En Corp will be converted into one share of Bio-En Holdings Corp.   Simultaneously, the Bio En Holdings Corp principal shareholder owning an aggregate of 7,894,625 share of Bio En Holdings Corp agrees to cancel 6,024,625 of its shares.  Bio En Corporation will be merged with and into Bio En Holdings Corp and Bio En Holdings Corp will continue as the surviving corporation in the merger. 

 

20